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PRE-CLINICAL ADVANCEMENTS IN BIOMARKERS, TOOLS, AND THERAPEUTICS FOR A 
METABOLIC NEURODEGENERATIVE DISEASE 
 
Glycogen is the storage form of glucose and a highly important substrate for cellular 
metabolism. Characterization of the enzymes and mechanisms of glycogen metabolism 
began over 70 years ago and over the last 20 years, a previously unknown protein called 
laforin has emerged as an important contributor to glycogen metabolism homeostasis. 
Multiple labs demonstrated that laforin is a glycogen phosphatase and mutations in the 
gene encoding laforin cause the formation of aberrant glycogen-like aggregates called 
Lafora bodies (LBs). LBs are cytoplasmic, water-insoluble aggregates that drive 
neurodegeneration and early death in Lafora disease (LD) patients. The direct 
relationship between mutated laforin, LB formation, and LB neurotoxicity highlights the 
importance of glycogen metabolism in the brain. To translate this knowledge into 
effective LD therapeutics, a comprehensive analysis of pre-clinical biomarkers, a new set 
of tools, and advancements in therapeutic strategies are needed. 
Consistent with the clinical phenotype, the laforin KO mouse model possesses LBs 
that drive neurodegeneration. A few studies have pointed to inflammatory responses in 
both astrocytes and microglia. However, these data need to be considered thoroughly 
to understand their relationship to LD. Two primary measures of pre-clinical LD 
therapeutic efficacy are to ablate LBs and reverse astrocyte activation. In the present 
work, we provide a longitudinal analysis of LBs and soluble glycogen and provide 
physiological evidence of the propensity of LBs to aggregate. In this same study, we 
provide evidence to suggest that microglia, not astrocytes, are drivers of an 
inflammatory response in LD.  
Another potential therapeutic target is glycogen metabolism, however, the exact 
relationship between central carbon metabolism and laforin loss-of-function has yet to 
be defined and is essential for exploring therapeutic options to target it. Herein, we 
showcase a longitudinal discovery of changes to citric acid cycle intermediates specific 
to the brain of the aging laforin KO and WT mouse model. We find that metabolite load 
in adult mice is lower in laforin KOs compared to WT, however the metabolic signatures 
of aged laforin KOs and WT mice overlap. Using a predictive biomarker analysis tool, we 
find that a recently proposed driver of metabolic dysregulation in laforin KO mice, 
     
 
glucosamine sequestration by PGBs, may also be driving aspects of metabolic disarray in 
aging. These results have generated hypotheses regarding damaged metabolic pathways 
in LD and aging that may be targeted for treatment. 
These data are yet another indicator that laforin is critical for brain glycogen 
metabolism. While laforin is known to remove phosphate from glycogen, how 
phosphate impacts normal glycogen homeostasis or how hyperphosphorylation is 
detrimental to glycogen homeostasis and LB formation remain under investigation. 
Progress in this discovery could be accelerated with additional tools. The study 
presented here showcases the generation and characterization of six laforin nanobodies 
and their epitopes and demonstrates that one inhibits laforin’s phosphatase activity. 
These laforin nanobodies could be useful tools for discovering the importance of 
glycogen phosphate and its modulation by laforin, WT laforin crystallization, laforin 
physical interactions, and laforin’s dynamic localization. Overall, these nanobodies 
represent an important set of tools that will open new avenues to illuminate the 
mechanism of laforin’s role in normal glycogen metabolism and LD. 
Other applications of the laforin nanobodies are in vitro detection assays for pre-
clinical/clinical assessment of laforin recovery treatments. Two theoretical therapeutic 
options for laforin recovery include premature termination codon (PTC) readthrough 
therapy and adeno-associated viral vector (AAV) therapy. Both these therapeutic 
strategies aim to deliver corrected genetic information for proper translation of the 
protein of interest. In the study we present here, we generate one sandwich ELISA with 
two putative functions for either PTC readthrough or AAV pre-clinical/clinical 
development using the laforin nanobodies. 
This work has advanced pre-clinical biomarkers, tools, and therapeutics for LD, a 
metabolic neurodegenerative disease. The results of which will be the basic framework 
of effective therapeutic development for several possible treatment routs and 
mechanistic insights into glycogen metabolism.  
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 The glycogen dysmetabolism hypothesis of neurodegenerative diseases: 
convergent clues from neuropathology to biochemistry 
1.1 Introduction 
 
Despite several decades of profound progress in neurology and neuroscience, many 
neurodegenerative disorders remain largely untreatable1. Considering that the primary 
risk factor for neurodegenerative disorders is age and that by 2030 all baby boomers will 
be at least 65, the proportion of people most prone to neurodegenerative diseases will 
rise from the current ~15% (2020) to ~25% by 20602–4. By 2040, deaths by these 
disorders are predicted to out-pace other prominent age-related fatalities due to lung 
cancer, colon cancer, liver cirrhosis, multiple sclerosis, female breast cancer, and 
malignant melanoma5. These statistics reflect the current and future US social and 
economic burdens with respect to age-related diseases. Recent progress has made 
significant contributions to identifying neurodegenerative hallmarks, including neuronal 
cell loss, atrophy, astrogliosis, pathological protein inclusions, inflammation, oxidative 
stress, mitochondrial dysfunction, ER stress, activation of microglia, hypoxia, and 
neuronal dysfunction3,6,7. Unfortunately, these hallmarks have not yielded disease 
altering therapies and treating neurodegeneration remains a futile battle8,9. 
One emerging theory that may offer a new set of molecular targets is that metabolic 
defects underlie many neurodegenerative pathologies1,7. Clinical investigations of 
metabolic changes in neurodegenerative disorders identified 18Fluorodeoxyglucose 
Positron Emission Tomography (18FDG PET) hypometabolism as a common, if not 
universal, characteristic of these disorders10. While dysregulated glucose metabolism is 
a clinical hallmark, the molecular underpinnings are still being defined. Additionally, 
metabolic vulnerabilities of specific neuronal clusters often accompany 
neurodegenerative disorders11. 
Systemic glucose has been considered the primary fuel for the brain, but a growing 
body of literature strongly implies that glycogen, the mammalian glucose storage cache, 
plays an indispensable role in brain function12. The underappreciation of brain glycogen 
comes from historic skepticism about its very existence that stymied advances in brain 
glycogen metabolism until very recently when methodologies were developed to detect 
it13. Earlier attempts to quantify brain glycogen were undermined by the fact that it 
quickly degrades from the hypoxic brain14. This obstacle has been surmounted by rapid 
preservation methods including either immediate flash freezing or microwave fixation 
that are required to preserve it for robust and repeated quantification15. This 
understanding led to the recent discovery that 25% of brain glycogen contains 
glucosamine, a key building block for protein glycosylation16.  
  The basic architecture of glycogen and its metabolic enzymes are well-documented. 
Glucose polymers are linked via α-1,4-glycosidic bonds via glycogen synthase (GS) that 




glycogen branching enzyme (GBE). Glycogen is degraded by glycogen debranching 
enzyme (GDE) that releases single branched glucose moieties and glycogen 
phosphorylase (GP) that catalyzes the cleavage of two subunits of glucose13. 
Glucosamine is incorporated into brain glycogen by GS and released by the concerted 
efforts of GP and GDE16. Glycogen is also degraded in the lysosome by acid α-
glucosidase (GAA)17. As glycogen is the major glucose cache, its metabolism is tightly 
regulated in a tissue-dependent manner18. Aberrant glycogen metabolism results in 
glycogen storage disorders (GSDs), wherein glycogen is synthesized and accumulates yet 
it is not broken down17. In the case of Pompe disease (GSD II), mutations in GAA result in 
normal glycogen accumulating at a far greater rate than it can be broken down. 
However, many GSDs feature an aberrant glycogen that cannot be broken down by 
GAA, GDE, and/or GP19. Thus, aberrant glycogen is a diseased form that prevents cellular 
use of the glucose that is stored in it20. 
Aberrant glycogen deposits are called polyglucosan bodies (PGBs) that were first 
identified in the aging brain by Purkinje21. The aging PGB, called corpora amylacea, 
originates from astrocytes and contains cellular debris. Corpora amylacea have been 
widely thought of as waste containers and recent work has proposed a rout of expulsion 
from the brain to the cerebral spinal fluid and lymphatic meningeal system22. Another 
subset of PGBs are intracellular PGBs that are a common feature of CNS GSDs that were 
first identified in 1911 by Gonzalo Rodríguez-Lafora, a disciple of Alzheimer, Cajal, Vogt, 
Minkowski, and Kraepelin23. Lafora’s discovery unmasked the pathophysiology of a GSD 
that produced a rare, insidious, and quickly fatal childhood dementia later named 
Lafora’s disease (LD)24. Lafora predicted that a metabolic disorder causes the formation 
of the LD PGBs that drive LD progression. Greater than 100 years since Lafora’s 
discovery, data from multiple laboratories support Lafora’s hypothesis25–28. Strikingly, 
PGBs of varied physical morphologies have been identified in many other 
neurodegenerative disorders, not currently classified as GSDs (Table 1.1A-F)29–35.  
In this chapter, recent data is highlighted that demonstrates glycogen 
dysmetabolism and PGBs as an integral factor of several neurodegenerative disorders, 
including Pompe disease, LD, aging, temporal lobe epilepsy (TLE), amyotrophic lateral 
sclerosis (ALS), and Alzheimer’s disease (AD). The differing histopathology and 
anatomical locations of PGBs is described in each of these diseases and glycogen 
dysmetabolism is a potential common metabolic phenotype. We frame the progression 
of LD as an extreme phenotype of a metabolic imbalance that is driven by aberrant 
glycogen. As such, recent success regarding LD basic research and clinical therapeutic 
translation is a potential path for new therapeutics of common neurodegenerative 










1.2 Technological advances for quantifying and analyzing glycogen 
 
Several quantitative biochemical and histological staining methods to quantify 
glycogen have made large contributions to the investigation of brain glycogen but are 
limited in specificity, spatial scale, and/or resolution13,15. Biochemical assays are 
quantitative, requiring a large volume of sample that limits their ability to assess spatial 
distribution36. Nuclear magnetic resonance spectroscopy (MRS) is quantitative and can 
be performed on live subjects but is also limited in spatial resolution37. Electron 
microscopy yields detailed observations within an area limited to several micrometers15. 
Histological examination by light microscopy using PAS has been a historically preferred 
method to determine regional, cellular, and subcellular glycogen distribution19. 
However, PAS staining is not glycogen specific as it reacts with other carbohydrate 
polymers like glycoproteins and proteoglycans38.  
A series of method and tool advancements for accurate and sensitive glycogen 
detection have recently emerged. The generation and development of two anti-
glycogen antibodies, IV58B6 and ESG1A9, have been important for mapping and 
determining brain wide spatial arrangements and morphological characteristics of 
glycogen with high specificity using immunohistochemistry (IHC) or 
immunofluorescence (IF)15. IHC studies using either of the anti-glycogen antibodies 
revealed glycogen stores in the hippocampus, cerebellum, and cortex (especially the 
molecular layers) of the mouse and rat brain39. Studies utilizing these two antibodies has 
detected a heterogeneous storage pattern of glycogen at multiple spatial scales, which 
suggests that glycogen distribution and architecture may underlie local energy 
requirements and metabolism. The addition of secondary and tertiary labeling has 
allowed for the detection of glycogen at the subcellular level and has shown that 
glycogen in mice is normally localized to the fine processes of astrocytes while trace 
amounts are found in neurons15.  
More recently, two significant advancements using mass spectrometry have been 
pioneered for accurate glycogen quantification and distribution analysis. An analytical 
method for quantifying carbohydrate polymers was developed using gas 
chromatography-coupled mass spectrometry (GCMS) that provides robust analysis of 
purified glycogen from tissue and quantification of the free glucose monomers40. 
Another novel workflow was developed to quantify and spatially visualize glycogen in 
situ using matrix-assisted laser desorption/ionization traveling-wave ion-mobility high-
resolution mass spectrometry (MALDI TW IMS)16. This novel MALDI workflow has 
allowed exploration of the relationship between PGBs, glycogen, and protein N-linked 
glycosylation in specific brain regions (see section 1.4.3 and 1.4.4).  
While these advanced glycogen analysis methods have largely been performed on 
mouse and rat samples, it is likely that the brain distribution, storage, and usage of 
glycogen differ among other species as well15. Regional glycogen storage may also 
depend on the metabolic state of the brain including the sleep cycle and circadian 




These and other integral factors on brain glycogen dynamics require more in-depth 
study especially with longitudinal dimensions to understand the extent of their influence 













































1.3 Hypothesis: Aberrant glycogen metabolism is an underlying cause of 
neurodegenerative disease  
 
Although a range of shared therapeutic targets have been identified for 
neurodegenerative disorders, current therapeutics are only symptom managing41. 
Glucose hypometabolism, mitochondrial dysfunction, oxidative stress, hypoxia, and 
glutamate dysregulation are widely correlated with neurodegeneration3,6,7. Recent 
studies hypothesized that the causative pathology is metabolic failure, as several 
neurodegenerative disorders contain metabolic defects in specific vulnerable neural 
populations7,42. Thus, rescue of ‘brain energetics’ is an emerging therapeutic concept for 
neurodegenerative disorders and aging. Tactics for ‘brain energy’ rescue in 
neurodegenerative disorders include the rescue of brain glucose metabolism that 
deteriorates in a progressive, disease and region specific manner7. Brain glucose and 
glycogen metabolism is essential to cognitive function43. Glycogenolysis is necessary for 
memory formation and retention and deficiencies in glycogen catabolism may be tied to 
memory impairment associated with neurodegenerative dementias44,45. Glycogen is also 
implicated in neural energetics as it regulates K+ and glutamate levels, which are known 
to drive action potentials46. Hyperexcitability is found in early stages of AD when mild 
cognitive impairments present and is a main feature of TLE47,48.  
The pathological condition directly relating glycogen dysmetabolism to 
neurodegeneration is LD. In LD, monogenetic linked glycogen metabolism failure is the 
cause of PGB accumulation that drives a very severe childhood dementia accompanied 
by severe epilepsy25–28. By knocking out or decreasing the activity of GS in LD mouse 
models, LD mice no longer form PGBs and there is a rescue in neurodegeneration and 
seizure susceptibility25,28,49. LD is also associated with the hallmark conditions of 
neurodegenerative diseases like glucose transport, glutamate uptake, autophagy, 
oxidative stress, and inflammation50. As such, data and conclusions from LD models 
provide key insights for investigating the hypothesis that glycogen dysmetabolism 
underlies other multifactored/sporadic neurodegenerative diseases, especially for those 
in which PGBs are found, like in AD, TLE, and ALS.  
 
1.3.1 Glycogen and cognitive function 
Supporting evidence that glycogen dysmetabolism is an underlying cause of many 
neurodegenerative diseases are the critical contributions that glycogen makes to brain 
function. Glycogen is an obligatory substrate of long-term potentiation (LTP), synaptic 
plasticity, learning, and memory51–55. This role is highlighted by the fact that CNS specific 
GSKO animals have a significant deficit in their ability to learn an instrumental 
conditioning task, a complete absence of LTP, and additional deficits in activities 




terminal55. Cognitive deficits in learning and memory are key prognostic indicators for 
many neurodegenerative diseases, including LD42,56. In LD, severity of cognitive 
symptoms at onset is the highest prognostic factor of decreased survival, where the 
average survival time is eleven years after onset. Thus, cognitive decline may be the 
most important factor associated with the fatal complications in LD that are related to 
aspiration pneumonia, status epilepticus, or other common complications of chronic 
neurodegenerative diseases50. These findings demonstrate the fundamental role of 
brain glycogen in cognition, which is a primary clinical measure of all neurodegenerative 
dementias57. Therefore, a potential avenue for discovering new molecular targets in 
neurodegenerative diseases is brain glycogen metabolism as it plays an active role in 
cognitive abilities and changes in synaptic strength underlying learning and memory 
acquisition. LD mice have severe brain PGB accumulation, increased susceptibility to 
induced seizures, and changes to synaptic transmission and LTP27. Strikingly, LD mice 
exhibit episodic memory defects with age, providing additional evidence of a causal link 
between glycogen dysmetabolism and cognitive challenges in neurodegenerative 
diseases51. Thus, the basic science of LD and corresponding mouse models can be used 
as templates to investigate the relationship of glycogen dysmetabolism and cognition in 
other neurodegenerative diseases, where the cognitive deterioration is slower, survival 
time is longer, and the driving pathology is less clearly defined. 
 
1.3.2 Glycogen and neural energetics 
The critical contribution of glycogen to neural energetics is rapidly emerging. The 
majority of brain glycogen is stored in astrocytes, thus the influence of glycogen on 
neurons is thought to be regulated through astrocytes58–60. Indeed, a well-known 
neurotrophic feature of astrocytes is their influence on ion homeostasis and glutamate 
clearance61. K+ efflux is a universally understood phenomenon of the action potential, 
first studied on squids by Hodgkin and Huxley in 1953, and in the absence of K+ ion 
clearance neuronal hypersynchronization burst firing and seizures occur62–64. Astrocytic 
Na+/K+ pumps are sensitive to increases in extracellular K+ and consume energy during 
increased axonal activity65–67. Inhibition of glycogenolysis in astrocytes, even in the 
presence of glucose, impairs K+ uptake62. Therefore, energy that fuels fundamental 
mechanisms of neural homeostasis is glycogen derived.   
Glutamate is the dominant excitatory neurotransmitter and requires rapid removal 
after synaptic transmission by cellular uptake61. Defects in glutamate transmission have 
been linked to epileptic and neurodegenerative disorders and astrocytic glycogen 
functions as a substrate for de novo synthesis of glutamate1,44,54. Conversely, glutamate 
recycling triggers glycogenolysis to produce energy for Na+ restoration and for the 
conversion of glutamate to glutamine68. As astrocytes are glycolytic, the energy required 
for glutamate-glutamine cycling comes from the conversion of glucose to lactate12. Both 
glutamine and lactate shuttle from astrocytes to neurons where glutamine is converted 
to glutamate and lactate is thought to be used as an exogenous substrate of neuronal 




the astrocyte-neuron lactate shuttle (ANLS) hypothesis postulating that lactate is the 
primary fuel of neurons and it is produced by astrocytes53. An enticing hypothesis, 
considering studies using mouse and rat olfactory neurons show that systemic glucose is 
not sufficient to sustain neuronal energy consumption12.   
The ANLS hypothesis suggests a critical utility for the metabolite mainly thought of 
as a waste product of anaerobic metabolism70. In fact, lactate has recently been 
suggested to be a major carbohydrate fuel across all cells and tissues71. The ANLS 
hypothesis is based on the observation that cells with high rates of glycolysis or 
glycogenolysis can form and shuttle lactate into diverse groups of cells whose ATP 
demands are unmet72,73. Cells receiving lactate can convert it into glucose or feed it 
directly into oxidative metabolism74. Systemic glucose or glycogen contained by neurons 
is an insufficient fuel supply to meet their ATP demands74. Extracellular lactate can 
support olfactory neuronal compound action potentials independent of glucose or other 
monosaccharide availability12. A recent in vivo study found that arousal/startle response 
in mice triggers a rapid lactate release from astrocytes that is followed by increased 
lactate levels in neurons75. Further, glucose shuttling is improbable as astrocytes lack 
glucose-6-phosphatase and they cannot release free glucose60. Therefore, oxidative 
metabolism dependent neurons may receive astrocytic glycogen derived lactate for 
direct entry into the TCA cycle. These data indicate that glycogen availability is an 
important contributor to the maintenance of proper equilibrium between excitatory 
and inhibitory neurotransmission, which is deficient in neurodegenerative diseases. 
The extent to which glycogen supports brain neural activities remains to be seen. 
Several reviews have classified glycogen as a key, even obligatory, fuel for the brain, 
though more investigation is needed to understand the extent of its role12,15,43,76–78. 
Current hypotheses based on cell culture studies pose that astrocytic glycogen is used to 
support neuronal excitation during either hypoglycemia or compounded energy 
demands76. A possible nuanced role of glycogen in neural energetics is highlighted by 
the fact that CNS glycogen synthase knockouts (GSKOs) are more susceptible to 
pharmacologically induced hippocampal seizures, but neuron specific GSKOs show less 
susceptibility55,79. This suggests cell specific regulation of glycogen metabolism. 
Interestingly, forebrain and neuron specific GSKOs do not show the same seizure 
susceptibility but do show significant deficiencies in LTP and acquisition of instrument to 
learning tasks79. These studies and brain glycogen mapping studies highlight how 
regional, cellular, and subcellular spatial arrangements of glycogen may impose regional 
and cell specific glycogen metabolism15. Moreover, glucose hypo-metabolic footprints 
seen by 18FDG PET are regionally and disease specific and metabolic imbalances are 
hypothesized to arise from specific regional and/or cellular neuronal populations1. 
Neural energetics continue to emerge as a therapeutic target to which glycogen 
metabolism is clearly linked. Further, regional and cellular locations of glycogen linked 
metabolic perturbances are likely important. As such, the location of PGBs in 
neurodegenerative diseases may provide important clues into their disease specific 






1.4 Lafora disease 
 
 
1.4.1 LD PGBs drive disease pathogenesis 
LD is an autosomal recessive childhood dementia and glycogen storage disorder that 
severely affects the CNS resulting in death before age 3080. LD patients carry autosomal 
recessive mutations in either Epm2a, which encodes the glycogen phosphatase laforin, 
or Epm2b, which encodes the E3 ubiquitin ligase malin81–87. A hallmark of LD is 
increasing numbers of cytoplasmic PGBs found throughout most tissues in LD patients 
and mouse models80 (Figure 1.1A). These PGBs drive worsening bouts of generalized 
myoclonic epilepsy and neurodegeneration25–28. Additionally, the original LB brain 
biopsy performed by Lafora reported sclerosis of medium-sized pyramidal cells, 
increased glia, and perivascular bleeding24. Laforin and malin KO mouse models have 
been generated and replicate LB formation, increased susceptibility to induced seizures, 
spontaneous myoclonus, neurodegeneration, and glial activation88,89.  
Utilizing genetic models and pre-clinical treatments, multiple labs have 
demonstrated that LD PGBs are both a diagnostic pathological feature and the drivers of 
LD25–28. Laforin KO and malin KO mice lacking the GS activator Protein Targeting to 
Glycogen (PTG) exhibit greatly reduced LB accumulation, resolved neurodegeneration, 
myoclonus, and seizure susceptibility25,26. Malin KO mice lacking at least 50% of GSY1 
activity do not exhibit LBs, neurodegeneration, or abnormal electrophysiological 
properties27,28. Conversely, constitutively active GS in genetically modified mouse and fly 
models results in neurodegeneration, as shown by progressive death of cerebellar 
Purkinje neurons90. These results indicate that genetically decreasing glycogen load 
results in disease rescue, while overaccumulation of glycogen can drive neuronal death.  
The LD mouse models have also been key to defining additional pathways that are 
perturbed, many being common to other neurodegenerative diseases, apoptotic 
dysfunction, endoplasmic reticulum stress, reduced clearance of misfolded toxic 
proteins through the ubiquitin proteasome system, and astrogliosis91–94. Multiple 
genetic manipulations have been performed to establish that these effects are 
important features of LD pathophysiology, though secondary to LD PGB accumulation. 
For example, LD mouse models have an impairment of autophagy as measured by an 
increase in p62. Rescue of p62 levels, as well as LTP, kainate induced seizures, and 
neuroinflammation is genetically achieved by crossing a malin KO mice with mice lacking 
one copy of GYS1, thereby decreasing GS activity by 50%. Moreover, mice with a 
constitutively active brain specific GS or overexpressing PTG accumulate PGBs and 
exhibit increased p62 levels, which are further increased when crossed with an LD 
mouse. These results indicate that LB accumulation drives the autophagy and 
neurological impairments in LD. Furthermore, they demonstrate that decreasing GS 
activity to 50% ablates many of the clinical issues. In further support of these data, 
administration of an inducer of autophagy partially restores autophagy defects, 




absence of LB reduction95. Collectively, these data demonstrate that autophagy, seizure 
activity, cognitive defects, endoplasmic reticulum stress, neurodegeneration, and 













































1.4.2 Lafora body localization 
LD PGBs were first described in a 1911 report on LD patient brain biopsies, where 
Lafora observed them virtually exclusive to neurons in the cortical and spinal tissue24. 
Patient biopsies reported PGBs in the ganglion cells of the second, third, and fourth 
layers of the cerebral cortex, and in the cells of the quadrigeminal, visual, oblongata, 
and posterior horns of the spinal cord. In LD mouse models, LBs are prevalent in 
the hippocampus, cerebellum, cortex, and brainstem (Figure 1.2A)80. Since Lafora’s 
initial sighting, LD PGBs were historically thought to mainly exist in neurons. Within the 
last three years however, two independent investigations using a combination of 
immunofluorescent techniques published the same conclusion that astrocytes harbor 
the vast majority of PGBs in the brains of LD mouse models96,97. Only 4% of neurons 
contained LD PGBs while they were found in 99% of astrocytes96. Further, astrocytic 
PGBs have been described as more abundant in the astrocytic processes rather than the 
soma96,97. Trace quantities of LD PGBs have been recently sighted in microglia, which is 
consistent with the original work of Lafora24,97. Whether the microglia containing LD 
PGBs had engulfed them or if the aggregates form inside them is not yet known.  
Interestingly, microglia activation, a neuroinflammation marker of LD measured by 
Iba1, is rescued in a malin KO model crossed with a mouse model unable to accumulate 
glycogen in astrocytes98. In this double KO model, the LD PGBs are greatly diminished in 
contrast to the malin KO model. These results further support the data indicating that 
neuronal LBs represent a very small fraction of total LBs96,97. However, rescue of 
astrocytic LBs do not rescue susceptibility to kainate-induced seizures, indicating that 
LBs may drive secondary pathophysiology in a cell specific manner98. Interestingly, 
astrocytic LD PGBs are less similar to neuronal LBs than they are to corpora amylacea in 
terms of their distribution in the brain, size, clustering, and presence of neo-epitopes 
recognized by IgMs96. Further, p62, a scaffold protein that can be bound by ubiquitin 
and guide its binding partners to autophagosomes and autophagic processes, is 
indicated to be a main feature of astrocytic, but not neuronal LD PGBs, and is also found 
in corpora amylacea96,99,100. Further study is needed to determine if, like corpora 
amylacea, astrocytic PGBs are being expelled to the CSF. If so, perhaps astrocytic PGBs 
traversing the perivascular space promotes perivascular bleeding, as documented in 













1.4.3 Lafora body architecture  
By electron microscopy (EM) native LD PGBs range from 2-10+ μm and are formed 
of clusters of ‘glycogen-like’ particles and fibrillar material (Figure 1.1A)80,101. LD PGBs, 
like glycogen and starch, can be digested with -amylase that hydrolyzes -1-4-
glycosidic linkages102–104. Like brain glycogen, LD PGBs contain ~75% glucose and ~25% 
glucosamine16. Multiple groups identified that LD PGBs stain similarly to plant starch 
with iodine, Best’s carmine, methenamine-silver nitrate, and PAS-dimedone. However, 
LD PGBs were metachromatically different than starch by Alcan and Toluidine blue 
methods102,104. If native LD PGBs are boiled, mechanically agitated, or lintnerized and 
viewed by light microscopy the polysaccharide forms into a network assembly in the 
same way that starch disassembles with the same methods20. Since mammalian glucose 
polymerization is performed exclusively by glycogen synthase, LD PGBs are aberrant 
glycogen whose structural features are more comparable to starch105. 
LD PGBs purified from brain and muscle have glucose chains dramatically longer 
than normal glycogen that allows the chains to form helical structures making them 
more resistant to degradation36,106,107. Long glucose polymers of starch, generally longer 
than normal glycogen, form a clustered arrangement of branch points giving rise to 
helical structures that expel water105,108. A confounding factor of LD PGBs is their 
elevated phosphate content in comparison to starch and glycogen89. In starch, the role 
of phosphate is to break up the tight helical associations. Therefore, the 
phosphorylation and dephosphorylation of starch is a tightly regulated process critical 
for controlled access of β-amylases and dispersal of glucose109,110. By keeping to the 
starch analogy, the LD PGB hyperphosphorylation should increase the solubility of LD 
PGBs, not decrease it. Thus, phosphorylation has been suggested to have little to do 
with glycogen solubility and its role is poorly understood105,107. The normal biochemical 
role of glycogen phosphate and the relationship of LD PGB hyperaccumulated 
phosphate to LD is still unclear and continued investigation in this area will be highly 
informative.  
 
1.4.4 Aberrant glycogen metabolism in Lafora disease 
LD PGBs form due to glycogen dysmetabolism caused by loss of function to the E3-
ubiquitin ligase malin or the glycogen phosphatase laforin with mutations in either gene 
resulting in a similar histological phenotype25–28. While mutations in either gene result in 
PGBs, the exact mechanism leading to PGBs has not been defined. Malin is an E3-
ubiquitin ligase that ubiquitinates several enzymes involved in glycogen metabolism, 
glycogen debranching enzyme (AGL/GDE), protein targeting to glycogen (PTG/R5), a 
regulatory subunit of protein phosphatase 1 (PP1), laforin, and glycogen 
phosphorylase49,84,111–114. Malin-dependent ubiquitination of glycogen phosphorylase 
results in nuclear localization of glycogen phosphorylase that impacts nuclear glycogen 
metabolism and histone acetylation114. Laforin is the only human glycogen phosphatase 




However, the exact mechanism(s) by which the loss of function of either laforin or malin 
create aberrant hyperphosphorylated glycogen still needs to be resolved. Additionally, 
many unanswered questions about the role of nuclear glycogen metabolism and how 
brain glycogen metabolism is regulated remain.  
This is of clinical interest considering that LD patients die of neurological 
complications although PGBs are also abundant in the skeletal muscle and heart82. 
Tissue specific regulation of glycogen metabolism is well studied105. Interestingly, the LD 
PGBs architecture is also tissue specific, showing the longest and most starch-like chain 
length distribution in the brain, followed by those from heart, and then skeletal 
muscle20. A positive correlation between PGB chain length and degree of tissue 
deterioration has been suggested as neuronal tissue is the first to degenerate in LD20. 
Therefore, tissue regulated glycogen metabolism may influence the pathogenic features 
of LD PGBs that promote more mild or severe cellular dysregulation.  
Cellular metabolism is rescued by LD PGB breakdown using an amylase fusion 
protein that can enter mouse brain tissue and break up LD PGBs118. Moreover, depletion 
of astrocytic LBs, which are the predominant form of LBs, in a malin KO mouse results in 
the partial rescue of central carbon, amino acid, and lipid metabolic pathways98. In many 
nervous system diseases, glycosylation is severely depleted119. In laforin KO mice and 
GSD III mouse models, glycogen derived glucosamine were determined to be higher 
than age matched controls16. Further, N-linked glycosylation defects were linked to 
brain regions where PGBs are most abundant. Impressively, the aberrant glycosylation 
footprint of LD mice resemble normal conditions after treatment with the amylase 
fusion protein16,118. These data suggest that PGB formation likely sequesters 
glucosamine, leading to metabolic disarray in the mouse. Furthermore, they emphasize 
that glycogen is needed to support the brains normal metabolic functions. 
 
1.4.5 Clinical evidence of brain metabolic defects in LD  
A recent retrospective study and review focused on eight Italian patients genetically 
confirmed for LD that underwent 18F-FDG-PET120. Though the patient ages, genders, 
genotypes, and disease severity were mixed in this analysis, a bilateral hypometabolic 
phenotype was observed in all patients that was more pronounced in advanced disease 
states. Interestingly, regions with high PGB loads, brainstem, cerebellum, hippocampus, 
and cerebral cortex, did not directly overlap with the hypometabolic regions that were 
the temporal (8/8), parietal (7/8), and frontal lobes (7/8), as well as the thalamus (6/8) 
(Figure 1.2A). Further, temporoparietal hypometabolism in patients was worsened in 
correlation to impaired visual symptoms. In nine additional cases identified from eight 
publications, 18F-FDG-PET showed heterogeneous findings, ranging from diffusely 
decreased cerebral glucose metabolism to unremarkable examinations in two cases. 
Prospective longitudinal studies are needed to clarify these data, but a regionally 
specific hypometabolism hallmark is emerging. While these studies are difficult for rare 




at four clinical sites121. This study, and others like it, will provide key clinical baselines to 







































1.5 Pompe disease - glycogen storage disease type II 
 
1.5.1 Aberrant glycogen in Pompe disease - glycogen storage disease type II (GSD II) 
Pompe disease (GSD II) is a lysosomal storage disorder caused by deficiency of the 
lysosomal enzyme acid alpha-glucosidase (GAA, alglucosidase alpha). Mutations in the 
GAA gene lead to excessive accumulation of lysosomal glycogen primarily in the cardiac, 
skeletal, and smooth muscles. The availability of enzyme replacement therapies (ERTs) 
for Pompe patients are increasing their lifespans, revealing neurological components 
initially overshadowed by myopathies. Thus, a CNS phenotype is emerging in Pompe 
disease provoking a reclassification of the GSD to be attributed to both muscle and 
nervous system122.  
The ultimate involvement of the CNS in Pompe disease is not yet clear. However, 
several observations by EM and PAS indicate that full characterization of Pompe 
neuropathology is critical to understanding and treating this disease. In the infantile 
form, glycogen accumulation is seen in neurons of the cortex, midbrain, pons, medulla, 
and cranial nerve nuclei (Figure 1.1B)123. Glycogen accumulation is also detected 
throughout nuclei of the brainstem and cerebellum (Figure 1.2B)124. Neuronal swelling, 
or ballooning, is observed in the substantia nigra, dorsal raphae nuclei, pontine nuclei, 
inferior olivary nuclei, and dentate nucleus122. Additionally, Schwann cells of nerve 
sheaths in the cortex, glial cells and astrocytes of white matter, but rarely Purkinje cells, 
all accumulate glycogen. Failure to meet myelination milestones at a median age of 6 
months in Pompe patients has been suggested to be related to the involvement 
glycogen accumulation in the CNS125. Some studies have indicated that glycogen 
accumulation in the cerebral cortex is associated with learning difficulties and 
intellectual disability in type II glycogen storage diseases126–129. 
Interestingly, glycogen accumulation is more prominent in the infantile onset 
version of Pompe disease, while late onset Pompe disease glycogen accumulation is 
observed more rarely122. In late onset, the CNS involvement of glycogen has been 
observed in Schwann cells of the nerve sheaths in the cerebral cortex and spinal cord. 
Lysosomal glycogen as also been detected in neuronal cell bodies spheroid-shaped 
structures resembling corpora amylacea are reported in the spinal cord130. In large 
Pompe diseased mammals and birds including cattle, dogs, quails, sheep, and cats, 
glycogen deposits are shown within brain and spinal cord accumulating in neurons and 
glial cells131. The extent of the CNS involvement in Pompe disease may be elucidated 
using Pompe disease mouse models with targeted disruption of GAA. Three mouse 
models with targeted disruption to GAA provide evidence of PAS positive glycogen 
accumulation in the brain and spinal cord including the cerebral cortex, olfactory bulb, 
thalamus, hippocampus, hindbrain, cerebellum, and medulla132. AAV-mediated gene 
therapy in GAAKO mice improves neurological defects, but additional research is 





1.5.2 Aberrant metabolism in Pompe disease 
Mutations in the gene encoding the lysosomal enzyme GAA prevent Pompe patients 
from breaking down lysosomal glycogen in the muscle, heart, and CNS131. Glycogen 
accumulates initially in the lysosome and then in the cytoplasm and becomes 
pathogenic134. Subsequently, swelling and rupture of lysosomal membranes releases 
hydrolytic material causing cellular damage17. Clinical severity is predicted based on 
residual activity of GAA135. In the most severe cases, patients undergo progressive 
myopathy and hypertrophic cardiomyopathy with the main cause of fatality being 
respiratory failure131. 
GAA replacement therapy has been useful as both a proof-of-concept for ERTs and 
in the clinic with two that are currently approved. The current standard ERT (Myozyme 
and Lumizyme) utilizes a recombinant human GAA (rhGAA) analog that enters cells and 
lysosomes by the mannose-6-phosphate (M6P) receptor135. Both ERTs are created using 
recombinant DNA technology to produce the human GAA enzyme in Chinese hamster 
ovary (CHO) cells and are biologically comparable. Myozyme and Lumizyme have been 
shown to improve patient survival rates, however, manufacturing differences result in 
differing clinical attributes. Therefore, Myozyme is indicated for infantile-onset Pompe 
disease while Lumizyme is indicated for patients aged ≥8 years136.  
Unfortunately, because rhGAA is exclusively targeted to the lysosome, cytoplasmic 
glycogen is left to accumulate135,137. A newer delivery platform, tested in Pompe mouse 
models, utilizes an antibody fragment (Fab) fused to GAA called VAL-1221 that allows 
entry into the lysosome and cytoplasm137. This antibody-enzyme fusion (AEF) protein is 
comprised of the Fab fused to GAA and gains entrance into cells by either the M6P 
receptor the equilibrative nucleoside transporter 2 (ENT2) receptor and allows for 
clearance of lysosomal and cytoplasmic glycogen. VAL-1221 completed a Phase I/II 
clinical trial with promising safety profiles and offers greater potential for clearing both 
cytoplasmic and lysosomal glycogen.  
A pre-clinical study on LD mice has tested an AEF platform, VAL-0417, to deliver 
amylase to cells in order to degrade pathogenic LBs, rather than replacing an enzyme118. 
The AEF is comprised of the humanized 3E10 Fab fragment and pancreatic α-amylase. 
VAL-0417 degrades LBs and reduces LB load in vitro and degrades glycogen and 
polyglucosan in vivo. Using VAL-1221 to test LD PGB clearance from the brains of LD 
mouse models would be useful for discovering if the AEF could enter cells of the CNS as 
well as fibroblasts. If so, VAL-1221 may have the potential therapeutic application for 
any of the 17 GSDs (Table 1.1). Further, the utility of VAL-1221 within the CNS of Pompe 
patients would be a useful investigation to further understand the involvement of the 








1.6.1 Aberrant glycogen in aging 
Age-dependent brain PGBs called corpora amylacea were first described in 1837 yet 
they are an understudied aggregate21. Corpora amylacea are PAS+ aggregates that were 
historically defined as histological features that increased in abundance with age and 
even more with neurological disease29. Corpora amylacea are found largely in glia 
throughout the brain (Figure 2C)19. Neurodegenerative diseases in which 
hyperabundant corpora amylacea have been described include Parkinson’s disease, 
diabetes, vascular dementia, multiple sclerosis, Huntington’s disease, Pick’s disease, 
diabetic neuropathy, peripheral neuropathy, motor neuron disease19,138. Thus, as aging 
is inextricably linked with neurodegeneration there is also increased corpora amylacea 
accumulation. While corpora amylacea are increased in some diseases, it is currently 
unclear how similar or different diseased corpora amylacea are from disease specific 
PGBs. 
The age-dependent existence of corpora amylacea has been re-confirmed recently in 
fly models and multiple mouse models, including wildtype C57BL/J6 and the accelerated 
aging mouse model, senescence accelerated mouse prone 8 (SAMP8)99. SAMP8 mice 
also exhibit reduced lifespan, lordosis, hair loss, and reduced physical activity, similar to 
human aging139,140. Like LD PGBs, corpora amylacea are observed widely in astrocytes 
and less often in neurons29. Corpora amylacea ultrastructure is a spherical body ranging 
from 2-30 m that appears as clustered 8-12 nm fibrils that are aggregated or tangled 
and can be decorated with cell debris29,100,141. The fibrils are comprised of glucose 
polymers as are PAS+ and diastase-resistant and are dependent on the activity of GS in 
fly and mouse models99. Corpora amylacea appear to contain a dense core ranging 50-
100 nm in diameter surrounded by concentric rings (Figure 1C)29.  
For nearly 180 years, corpora amylacea were largely ignored and considered benign 
and/or innocuous aging aggregates31. Yet repeated findings by electron microscopy 
depicted cellular debris, including organelles from neurons, astrocytes, and 
oligodendrocytes, to be harbored within corpora amylacea29,100. Additionally, the 
presence of the proteasome targeting protein ubiquitin has been an identifying feature 
of corpora amylacea100. Together, these studies implicated corpora amylacea in cellular 
waste removal and suggested that corpora amylacea may be a vessel in which cell 
debris could be removed from the cell and eventually degraded. Recent reports 
corroborate the hypothesis that corpora amylacea may be an integral component of 
brain waste disposal with corpora amylacea acting as waste containers to protect the 
cell from damaging residual products21,31,142. Naturally occurring IgM antibodies were 




direct macrophages to phagocytize them21,31. Further, data indicating that corpora 
amylacea exist predominantly in periventricular and subpial regions were intriguing, but 
no reports identified their existence in the CNS, suggesting that they simply 
accumulated and remained trapped19. Improved methods, which had previously failed 
to identify corpora amylacea in the cerebral spinal fluid (CSF), were elegantly employed 
to discover that corpora amylacea are transported through the blood brain barrier, 
entering the CSF, and are present in lymph nodes22. Moreover, these data demonstrate 
that corpora amylacea can be phagocytosed by macrophages22. Thus, corpora amylacea 
are likely involved in a cellular clearance mechanism. 
 
1.6.2 Aberrant metabolism in aging 
Aging is intimately associated with neurological deterioration and is the greatest risk 
factor for it143. There are multiple biomarkers that overlap between aging and 
neurodegenerative diseases, including the production of cognitive defects like memory 
loss and learning impairments along with molecular perturbations like reactive oxygen 
species and mitochondrial defects3. 18F-FDG-PET imaging of age-influenced brain 
metabolism indicates that the frontal lobes as well as regions within the default mode 
network, including the temporal and parietal lobes, and prefrontal and posterior 
cingulate cortex show a strong age-related glucose hypometabolism trend144. These 
data suggest that aging alone could cause a widespread reduction in brain matter and 
glucose metabolism.   
Only a few studies have begun to examine brain metabolism to characterize the role 
it plays in the CNS during aging. One 2016 study examined the aging metabolic profile of 
the cortex, hippocampus, and caudoputamen at 12-, 18-, and 24-months of age for 
normal male C57BL/6 mice using HILIC ESI-Q-TOF/MS145. This global-untargeted 
metabolomics study suggested aging is associated with a significant imbalance of core 
metabolite levels. Specifically, NAD levels decline, AMP/ATP levels increase, 
purine/pyrimidine accumulate and there are significantly altered oxidative 
phosphorylation and nucleotide biosynthesis and degradation. A more recent study 
determined metabolic fingerprints of brain samples in young (~2-months) and aged 
(~24-months) normal female C57BL/6J mice using 1H-NMR spectroscopy146. The NMR 
spectra showed age-dependent changes revealed decreased concentrations of lactate, 
methionine, N-acetylaspartate, uridine, and inosine. In contrast, concentrations of 
leucine, isoleucine, valine, glutamine, allantoin, uracil, tyrosine, and phenylalanine were 
increased in the aged mice. These untargeted global analyses of wildtype aged mice 
demonstrate that aging is associated with increased metabolite diversity. Several 
pathways may be involved in these changes as aging metabolic signatures have been 




analyses, especially on a longitudinal time frame, is needed to understand the 
mechanisms that drive metabolic defects in aging.  
Understanding the mechanism by which metabolites are dysregulated in the aging 
brain may uncover the inextricable link between aging and neurodegeneration. A 
potential link between aging and aberrant brain metabolism are the aging corpora 
amylacea, which are even more abundant in neurodegenerative diseases148. Similarly, 
the abundance of other neurodegenerative markers like Heat Shock Protein 70 (HSP70), 
advanced glycation end products (AGEP), and alpha-synuclein increase with age149–152. 
Strikingly, mice lacking GS also lack these markers in all brain regions99. While corpora 
amylacea accumulation disrupts neurological function in aged mice, mice lacking GS 
exhibit decreased corpora amylacea and increased maximum climbing speeds99. 
Conversely, increased GS activity promotes increased corpora amylacea and progressive 
degeneration of Purkinje neurons in mice and flies99. Thus, neuronal glycogen synthesis 
contributes to age-related functional decline. These data provide a direct link between 
glycogen synthesis and the formation of corpora amylacea to age-dependent protein-
based aggregates that are well known hallmarks of many neurodegenerative diseases of 
aging. Furthermore, they indicate that the equilibrium of brain glycogen is critical, and 
imbalance creates neurodegeneration. 
Unfortunately, a direct physiological relationship of glycogen and corpora amylacea 
to the aging metabolome is not well-defined at this time. The historical assumptions 
that corpora amylacea are innocuous resulted in limited examination of the relationship 
between aberrant glycogen metabolism in aging. Data from the recent resurgence in 
corpora amylacea suggests that progressive accumulation of aberrant glycogen in the 
brain may contribute to aging-based neurological decline. If so, then interventions that 
slow this process could be protective against neurological deficits of aging. Glycogen 

















1.7 Temporal lobe epilepsy 
 
1.7.1 Aberrant glycogen in temporal lobe epilepsy 
Greater than 3 million in the US and over 70 million globally suffer from 
epilepsy153,154. Several factors can cause epilepsy including stroke, prenatal damage, CNS 
infection, head injury, genetics, and brain tumors155. For most epileptic patients, the 
cause is unknown. Seizures are typically diagnosed with electroencephalography (EEG) 
where “spike and wave” formations coming from specific electrodes map seizure 
activity to the surface of the brain156. These signals can discriminate a focal epilepsy 
from a generalized one. The chaotic neuronal discharge that defines epilepsy can be 
dampened with anti-seizure medications, and cocktails of these medications yield 
diminishing returns with the addition of each one157. Available epilepsy medications fail 
to control seizures in one third of patients including those with the most common focal 
refractory epilepsy, temporal lobe epilepsy (TLE)157,158. Although use of many new 
antiepileptic drugs with new mechanisms of action has increased, the ability to achieve 
seizure freedom has not157. Therefore, a paradigm shift in research strategies and 
therapeutic avenues is needed.  
For TLE, several different neurological phenotypes are identified, which divide the 
disease into pathological subgroups. About 30% of TLE patients have identifiable MRI 
lesions such as tumor, cortical dysplasia, or cavernous hemangioma159. Approximately 
50% of TLE patients, fall into a pathological subgroup called mesial temporal lobe 
epilepsy (MTLE) that is classically characterized by hippocampal sclerosis (HS positive) by 
MRI. Patients with MTLE can suffer from spontaneous recurrent seizures and neuronal 
loss that originate from mesial temporal lobe structures, such as the hippocampus, 
parahippocampus, amygdala, entorhinal cortex temporal pole, and the 2 rostral thirds 
of the superior middle and inferior temporal gyri of the right hemisphere160–162. For the 
remaining portion of TLE patients, MRI cannot identify the brain pathology. 
MTLE is particularly interesting with respect to PGBs as they are observed in the 
temporal regions that are commonly biopsied, and these surgical resections create 
dramatic reduction in seizure activity (Figures 1.1D and 1.2D)163. Clinical reports of PGBs 
in biopsied temporal lobes from patients with TLE began to appear in the early 1990’s 
and have now become a marker for MTLE34,163,164. For MTLE patients, temporal 
lobectomies are frequently performed for those with partial complex intractable 
seizures163. In most of these resections, the hippocampus reveals neuronal loss 
especially of the CA1, CA3, and endofolium sectors161. These findings overlap with 
electron microscopy images, as well as PAS+ staining that show a strong presence of 
PGBs in the pyramidal layer of the hippocampus, primarily the CA1, CA3, CA4, 
endofolium, and fascia dentata sectors165,166. Interestingly, PGBs also appear in the 




PGBs appear filamentous and amorphous, dominating the white matter and 
perivascular area, and showing up inside astrocytes and axons34. The localized nature of 
MTLE PGBs has provoked the intriguing possibility that MTLE may be a localized form of 
a glycogen storage disorder. Now, this concept is gaining traction as studies are 
demonstrating metabolic links between aberrant glycogen and MTLE167–169. 
 
1.7.2 Aberrant metabolism in temporal lobe epilepsy 
Epileptic foci in TLE have been correlated with hypometabolic activity using 18F-FDG-
PET.  TLE hypometabolic zones include the contralateral temporal lobe, ipsilateral 
temporal neocortex, the ipsilateral basal ganglia and thalamus159. Interictal glucose 
hypometabolism is reported in 80% of patients with mesial TLE. Interestingly, even in 
patients without evidence of hippocampal sclerosis on MRI, the localization of 18F-FDG 
PET hypometabolism corresponds to the ictal EEG region. 18F-FDG-PET can also provide 
prognostic data based on the extent of initial hypometabolism present167,170. A more 
extensive hypometabolic region can indicate a poor prognosis and a longer duration of 
epilepsy. Therefore, hypo-glucose metabolism is a clinical biomarker for TLE that is used 
to determine patient management and surgical decisions. A recent study demonstrated 
the utility of 18F-FDG PET in localizing an ictal focus in TLE patients even in those with 
normal MRI159. This study demonstrated that moderate to severe temporal lobe 
hypometabolism was noted in cases of lesional MRI. Thalamic hypometabolism was 
associated with moderate to severe rather than mild temporal lobe hypometabolism, 
suggesting that a hypometabolic thalamus is a marker of temporal dysfunction. 
Extratemporal hypometabolism was a predictor of poor postsurgical seizure outcome 
while localized temporal hypometabolism predicted a good outcome170. Thus, a 
hypometabolic assessment is a clinically useful diagnostic and prognostic indicator of 
TLE. 
A hypothesis is emerging that neuronal action potentials are supported by systemic 
glucose and brain glycogen. Glucose alone is insufficient to support compound action 
potentials and is supplemented by glycogen12. The ANLS hypothesis (see section 1.3.2) 
suggests that lactate derived from astrocytic glycogen is a major carbohydrate fuel 
supporting neuronal energetics. Depleting glycogen or interfering with lactate transport 
results in the loss of the compound action potential171. Moreover, glycogen homeostasis 
is required to control hyperexcitability and seizures68,79.  
In TLE, K+ buffering is clearly dysregulated in specimens from TLE patients172. One 
study found that astrocytic K[ir] channels are dysfunctional in sclerotic CA1 hippocampal 
regions of MTS patients173. Using patch clamp, a reduction in astroglial K[ir] currents was 
observed in sclerotic compared with nonsclerotic hippocampi. These data indicate that 




contribute to hyperexcitability in epileptic tissue. When and how this dysfunction 
develops during epileptogenesis is not yet clear. Considering the critical role of 
astrocytes to maintain interstitial K+ homeostasis and the connections between 
astrocytic K+ buffering and astrocytic glycogen, impairment of astrocyte K+ uptake 
should be proconvulsant. Thus, PGB laden sclerotic tissue may be connected to a 
dysfunction of astrocytic K+ transporters and K+ buffering.   
Astrocytic K+ homeostasis and glycogen metabolism are also coupled to glutamate 
uptake (see section 1.3.2), which is dysregulated in TLE. In TLE patients and in rodent 
epilepsy models, regions of the hippocampus affected by cell death exhibit a 
downregulation of glutamine synthetase and an increase in extracellular glutamate 
concentration, ultimately resulting in neural hyperexcitability, excitotoxicity, and 
neurodegeneration168,174. While glutamate levels are increased, glutamine levels are 
decreased, and the process of cycling is slower as observed my magnetic resonance 
spectroscopy169. These data pose another rout by which the glycogen dysmetabolism 
and PGBs could upend the foundations of neural homeostasis promoting seizure 
activity. Glycogenolysis is suggested to yield the ATP supply that maintains the Na+ 
gradient that drives glutamate transport172. Inhibition of glycogenolysis can rase 
extracellular glutamate levels79. Glutamate transport requires the cotransport of Na+ 
and H+ and the counter transport of K+. While, glutamate transporters are expressed on 
multiple cell types, astrocytes are primarily responsible for glutamate uptake175. Thus, 
suppression of glycogenolysis by PGB accumulation could disrupt the ion gradients 
required for glutamate uptake by astrocytes. Future studies are needed to clarify the 





















1.8 Amyotrophic lateral sclerosis  
 
1.8.1 Aberrant glycogen in amyotrophic lateral sclerosis  
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disorder176. 
Motor neurons of the corticospinal tract, motor cortex, and motor neurons of the lower 
brainstem and spinal cord are affected. ALS onset occurs around age 50 with a fatal 
prognosis in only 3-5 years. Several mechanisms are correlated to ALS onset and 
progression, including excitotoxicity, oxidative stress, mitochondrial dysfunction, protein 
aggregation, diminishment in axonal transport, defects in RNA metabolism, and 
neuroinflammation. Mutant forms of more than 40 genes have been clinically 
implicated in ALS, including superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 
(TDP-43), and fused in sarcoma (FUS), although most cases are sporadic177. Without 
effective treatment, ALS remains a fatal diagnosis and new hypotheses regarding 
therapeutic targets are focused on glucose metabolism.  
CNS protein misfolding and aggregation is commonly associated with 
neurodegeneration in ALS. For example, inclusions of human mutant or wild type SOD1 
are found at autopsy and in SOD1 overexpressing transgenic mouse models. Recently, 
glycogen accumulations in ALS and ALS SOD1G93A transgenic mice were detected. 
Strikingly, large PAS+ PGB-like aggregates were observed in cervical spinal cord sections 
from ALS patients that were absent in age and gender matched donors (Figure 1.1E and 
1.2E)32. ALS PGBs occupied both neurons and glia in the gray matter and only astrocytes 
in white matter. Biochemical analysis of tissue homogenates confirmed the elevated 
glycogen in both gray and white matter, yet glucose was only elevated in the gray 
matter. Glycogen levels were also higher in the brainstem and lumbar spinal cord as well 
as in the liver and skeletal muscle prior to disease symptom onset.  
 
1.8.2 Aberrant glycogen metabolism in amyotrophic lateral sclerosis  
 Altered energy metabolism in ALS correlates to disease progression, suggesting a 
pathogenic role for energy metabolism in ALS178. Nearly two dozen studies have 
examined ALS patients using 18F-FDG-PET that has uncovered a diffuse cortical 
hypometabolic phenotype179–181. Therefore, reduced cortical glucose uptake has 
become a robust early indicator of ALS. Recent studies have described a regional 
hypermetabolic phenotype localized to the brainstem and both the cortical and dorsal 
spinal cord. In SOD1G93A mice, spinal cord glucose uptake initially increased before 
symptom onset and subsequently declined during disease progression182. Additionally, 
proteins involved in glycolysis, β-oxidation, and mitochondrial metabolism are altered 




have displayed increased survival and decreased life-threatening events and 
hospitalization184. Additionally, an ALS fruit fly model overexpressing TDP-43 and 
phosphofructokinase (PFK), the rate limiting enzyme of glycolysis, in the CNS displayed 
increased locomotor activity and lifespan185. Thus, increased glucose availability may be 
protective, and the early hypermetabolic activity may be an initial mechanism to 
compensate for metabolic perturbations.  
Recent metabolic observations suggest links between glycogen accumulation and 
metabolic deficiencies in ALS. In the spinal cords of ALS patients, alpha-glucosidase, the 
deficient enzyme in Pompe disease, is decreased at the mRNA and protein levels32,186. 
ALS SOD1G93A transgenic mice also show a reduction in alpha-glucosidase in the spinal 
cord, as well as liver and skeletal muscle32. In several neuromuscular diseases including 
ALS, genetic evidence suggests that aberrant metabolism of glycosphingolipids, a 
subgroup of glycolipids, plays an important role. Glycolipids are lipids attached to a 
carbohydrate polymer by a glycosidic bond. They are found on the surface of all 
eukaryotic membranes extending from the cell membrane to the extracellular 
environment. Glycosphingolipids are formed through the covalent linkage of a glycan 
moiety to ceramide, a lipid prominently found in the myelin sheath that surrounds 
axons. In the SOD1G93A mouse model, inhibition of glycosphingolipid synthesis 
exacerbated disease progression, whereas administration of GM3, a subtype of 
glycosphingolipids, slowed it187. Thus, glycosphingolipids may be important players in 
ALS and their aberrant metabolism may be related to glycogen accumulation. Further 
investigations are needed to discern the type of glycogen or PGBs that were observed in 
ALS patients and mice. Crossing ALS mice with a GSKO line would aid in defining the 
relationship of glycogen accumulation to pathogenesis in ALS.  
To further understand the underpinnings of glucose hypometabolism in ALS, polar 
metabolite changes in ALS in important field of investigation, yet largely 
unstudied178. Though clinical meta-analysis suggests that metabolism does impact ALS, 
there is not an assertive study to establish any direct link between changes in metabolic 
parameters and the progression and survival of ALS176. Therefore, some pathways may 
be affected and modulate ALS outcome, but they are not defined. One study has 
analyzed FUS mutated human derived ALS motor neurons in vitro and did not identify 
alterations to glycolysis or TCA cycle intermediates188. Given the recent discovery of 
glycogen accumulation in the spinal cord, further investigation into the neural and/or 
glial cell origins may elucidate cell specific metabolic deficiencies. Interestingly, the 
lactate shuttle has been shown to exist beyond axons and astrocytes in 
oligodendrocytes and their myelinated axons. Oligodendrocytes have been proposed to 
perform aerobic glycolysis and give lactate to the myelinated compartments. Though 
glycogen’s role in this process has not been defined, alterations in metabolic support by 
oligodendrocytes is now expected to underlie various diseases that are psychiatric or 




understanding of how different cell types in the CNS contribute to reduced 
carbohydrate catabolism and new therapeutic opportunities for ALS. 
1.9 Alzheimer’s disease 
 
1.9.1 Aberrant glycogen in Alzheimer’s disease 
Alzheimer’s disease (AD) is the leading cause of dementia. In 2021, 6.2 million 
Americans (11.3%) 65 and older are living with AD189. Adults younger than 65 can also 
develop AD, but this prevalence is rarer and number less certain. Like many chronic 
diseases, AD develops from multiple factors. The greatest risk factor for AD is age and 
genetics, especially the E4 APOE variant, and having a family history of AD190. Hallmark 
clinical symptoms of memory loss and brain atrophy are believed to be driven by senile 
plaques of β-amyloid and neurofibrillary tangles of hyperphosphorylated-tau191. Due to 
these misfolded aggregates, AD is a proteinopathy192. In both sporadic and familial AD, 
amyloid-β oligomers are observed in the cerebral cortex and hippocampus and 
neurofibrillary tangles of hyperphosphorylated-tau are deposited in soma and processes 
of neurons193,194. Neurofibrillary tangles first develop in the transentorhinal cortex and 
spread to the entorhinal cortex and hippocampus prior before showing in neocortical 
regions193. A cascade of other symptoms that define AD include, innate immune 
activation and inflammation, ER stress, ROS, mitochondrial dysfunction, synaptic 
toxicity, and cell death192. Ultimately a combination of some or all of these 
perturbations cascade to drive neurodegeneration that leads to atrophy of the 
neocortex, hippocampus, amygdala, basal forebrain, and brainstem. Clearing the 
plaques or tangles do not prevent or rescue the disease, and the cascade of effects are 
still undefined as cause or consequence of the proteinopathy. Thus, a new framing of 
the underlying mechanisms or causes of AD is welcomed195.  
  AD glycogen-like aggregates were first described using light and electron 
microscopy in 1985 from post-mortem brain and called granular glycogen bodies (Figure 
1.1F)148. While termed granular glycogen bodies, the exact composition and architecture 
of these aggregates are unknown. EM observations distinguish these glycogen bodies 
from PGBs in that their ultrastructure appears granular rather than fibrillar as seen in LD 
and aging (Figure 1.1A, C, F). Further, toluidine blue stains these deposits an even dark 
blue, as opposed to the light blue periphery of CA. Thus, the AD granular glycogen 
bodies were distinct from visible corpora amylacea yet also observed in proximity to 
corpora amylacea in AD brains. The AD granular glycogen bodies range 5-50 m and are 
found non-membrane bound in the cytoplasm of cellular processes in both gray and 
white brain matter. While primary neuronal atrophy is observed in the hippocampal and 
cortical regions, AD glycogen-like aggregates are found more broadly throughout the 




lateral occipital gyri (Figure 1.2F). Further investigation of the structure of AD granular 
glycogen and cellular origins is needed. 
1.9.2 Glycogen metabolism in Alzheimer’s disease 
Though direct links between glycogen and AD are currently under investigation, 
glucose hypometabolism is an established clinical AD hallmark that is especially 
prominent in E4 APOE carriers196–199. Another emerging metabolic connection is that 
astrocyte energetics and metabolism may be a critical factor200. In healthy aging, 
astrocytes support neurons by maintaining neuron homeostasis, maintaining ion 
gradients and removing excess extracellular glutamate as well as Aβ, the main 
component of the amyloid plaques found in AD brains201. 
In the diseased stage, astrocytes show decreased glycolysis202,203. The resulting 
glucose hypometabolism represents a misregulation of nutrient transporters, metabolic 
enzymes and mitochondrial complexes200. This is connected to levels of 
hyperphosphorylated tau in cerebrospinal fluid (CSF) and impaired cerebral 
metabolism204. The metabolic changes create a cascade of pathological events, leading 
to oxidative stress and astrogliosis. Reactive astrocytes produce proinflammatory 
cytokines that activate microglia and amplify neuroinflammation in the brain205,206. They 
produce more reactive oxygen species and their support functions decline200. There is a 
reduction in glutathione, which prevents damage by reactive oxygen species, glutamate 
uptake, and Aβ clearance, with a concomitant increase in Aβ production. This ultimately 
results in Aβ deposition in the brain and synaptic dysfunction, causing dementia. 
What promotes abnormal glucose metabolism in AD is not known. One hypothesis is 
that the observed overactivity of glycogen synthase kinase 3 beta (GSK3B) could have 
the effect of inhibiting GS and starving the cell of glycogen207. Another is that soluble 
glycogen is in limited supply due to the progressive formation of AD granular glycogen. 
Glycogen breakdown is key to many aspects of brain function, and its tie to learning and 
memory formation as well as long term memory consolidation (see section 3.1) are 
particularly interesting in the case of AD. Genetically engineered mice that cannot form 
glycogen in the brain (GSKO) have defects in long-term potentiation (LTP), which is 
consistent with their deficits in short-term memory formation and long-term memory 
consolidation27. Also consistent with this hypothesis, feeding AD mice a diet 
supplemented with pyruvate facilitates increased soluble glycogen stores and improves 
spatial learning208.  
Interestingly, cerebral glucose hypometabolism as measured by 18F-FDG-PET has 
emerged as a clinical hallmark for AD196–199. The degree of glucose hypometabolism has 
an intimate relationship with AD clinical symptoms and severity. There are multiple 
clinical and animal studies focused on whether AD cerebral hypometabolism implies 
general impairment of glucose utilization, i.e., transport deficiencies, or another 




of cerebral hypometabolism, especially in carriers of E4 APOE, has raised a “chicken-or-
egg” narrative with respect to impaired glucose utilization causing neurodegenerative 
processes and vice versa10.  
Cerebral hypometabolism could be part of a vicious cycle, both cause and 
consequence of AD neurodegeneration10. A glycogen dysmetabolism centric view poses 
the concept that glucose sequestration is a function of glycogen dysmetabolism yielding 
AD granular glycogen and consequently brain hypometabolism. The creation of AD 
granular glycogen likely precedes neurodegeneration, however that does not preclude 
the possibility that it ignites a positive feedback loop wherein the neurodegenerative 
processes further impose glycogen and/or glucose dysmetabolism.  
 
1.10 Conclusions and future directions 
 
Searching for effective treatments of neurodegenerative diseases is one of the more 
challenging aspects of neuroscience. Scientists have made significant advancements 
understanding the range of molecular and cellular pathologies that contribute to 
neurodegeneration, including protein aggregation, mitochondrial dysfunction, 
glutamate toxicity, calcium load, proteolytic stress, oxidative stress, neuroinflammation, 
and aging. Efforts to treat neurodegenerative diseases are often limited by the fact that 
they tend to address any one of the above pathological changes while ignoring 
others. Lack of clarity regarding a possible root cause that underlies all the above 
pathologies poses a significant challenge to the crusade of curing neurodegenerative 
disease.  
Glucose hypometabolism underlies virtually all neurodegenerative diseases. 
Evidence of glycogen metabolism disruption is a striking similarity between LD and 
Pompe disease, aging, TLE, AD, and ALS. In this respect, Lafora’s disease offers a helpful 
model. LD is a fatal neurodegenerative disease, with traditional neurodegenerative 
disease biomarkers of ROS, inflammation, astrogliosis, hypoxia, and neuronal 
dysfunction, exacerbated by defined metabolic targets involved in glycogen metabolism. 
LD is a glycogen storage disorder, defined by PGB aggregation all over the body, driving 
metabolic defects, CNS deterioration, and fatality. While similar aberrant glycogen 
accumulation is found in the CNS of Pompe, aging, TLE, AD, and ALS patients, it has not 
been as well characterized as in LD.  
A standard approach to classifying the structure and identity of PGBs will be useful 
to determine the classifications of these PGBs. Using a published pipeline of methods 
used to examine the structure and localization of LD PGBs, similar experiments should 
be performed to understand structural aspects in Pompe disease, aging, TLE, AD, and 




the classification of neurodegenerative diseases that are not traditionally defined GSDs 
but diagnosable by glycogen deposits/PGB accumulation. Moreover, due to increased 
technological advances in glycogen detection, many classical GSDs where a neurological 
component may be missed should be re-investigated for the influence of CNS PGBs.  
There are other neurodegenerative diseases in which to our current understanding, 
do not develop disease specific PGBs but are afflicted with a gross accumulation of the 
aging PGB, CA. Exact differences between corpora amylacea and disease PGBs have yet 
to be extracted beyond aspects observable by microscopy. Astrocytic LD PGBs for 
example, appear immunologically like corpora amylacea. Molecular and structural 
differences between corpora amylacea that hyperaccumulates with neurological disease 
and aging PGBs need to be examined.  
Ultimately, the relationship of glycogen deposits/PGBs to upstream and downstream 
metabolic defects is of interest. Current advances in metabolomics and MALDI to 
measure glycogen and related metabolic changes may facilitate an understanding of the 
dysregulated brain energy metabolism underlying neurodegenerative diseases. The 
possibility of using newly developed methods and technologies to find translational 
molecular targets is exciting. Given the importance of glycogen synthesis to brain 
energetics and the succession of multifaceted events detrimental to health that follow 
its dysmetabolism, glycogen in disease research will be a critical area neuroscience in 















Disease Name(s) Gene Affected enzyme OMIM  
GSD 0a GYS2 Liver glycogen synthase 240600 
GSD 0b GYS1 Muscle glycogen synthase 611556 
GSD 1a, von Gierke G6PC Glucose-6-phosphatase α 232200 




GSD 2, Pompe disease GAA Alpha α-glucosidase 232300 
GSD 3, Cori/Forbes AGL Glycogen debranching enzyme 232400 
GSD 4, Anderson, 
Adult polyglucosan body 
disease (ABPD) 
GBE1 Glycogen branching enzyme 232500 
GSD 5, McArdle PYGM Muscle phosphorylase 232600 
GSD 6, Hers PYGL Liver phosphorylase kinase 232700 
GSD 7, Tauri PFKM Muscle phosphofructokinase 232800 
GSD 9a PHKA2 
Phosphorylase b kinase (α2 
subunit) 
236000 
GSD 9b PHKB 
Phosphorylase b kinase (β 
subunit) 
261750 
GSD 9c PHKG2 
Phosphorylase b kinase (𝛾 
subunit) 
613027 
GSD 9d PHKA1 
Phosphorylase b kinase (α1 
subunit) 
300559 




GSD 11, Fanconi-Bickel SLC2A2 Glucose transporter 2* 277810 
GSD 12 ALDOA Aldolase A 611881 
GSD 13 ENO3 β-Enolase 612932 
GSD 14 PGM1 Phosphoglucomutase 1 614921 
GSD 15 GYG1 Glycogenin-1 603942 
Danon disease LAMP2 
Lysosomal-associated 
membrane protein 2 
300257 
Lafora disease, 2A EPM2A Laforin 254780 







Figure 1.1 Electron microscopy (EM) and Periodic Acid Schiff stain (PAS) of glycogen 
deposits/PGBs. 
A) Lafora disease (LD) B) Pompe disease – glycogen storage disorder type II (GSD II) C) 
Aging D) Temporal lobe epilepsy (TLE) E) Amyotrophic lateral sclerosis F) Alzheimer’s 
disease (AD)  





Figure 1.2 Diagram of glycogen deposits/PGBs in neurodegenerative diseases. 
Black dots/circles represent aberrant glycogen accumulations. A) Lafora disease (LD) B) 
Pompe disease – glycogen storage disorder type II (GSD II). Black dots represent PGB 
accumulation in EOPD and black circles represent PGB accumulation in LOPD. C) Aging 






 Pathological biomarkers of a glycogen metabolism disorder in the aging 
brain 
2.1 Introduction 
Brain metabolism is the biochemical engine of cognition, memory, and behavior and 
is ignited and fueled by glucose. The brain accounts for 2% of body mass and 25-40% of 
total glucose utilization in the resting state and glucose is the pivotal molecule driving 
brain central carbon metabolism210–212. Glucose not only provides bioenergetics for ATP, 
but also supports nucleotide and neurotransmitter biosynthesis that is important for 
synaptic communications and normal brain homeostasis. Glucose is stored as the 
macro-biomolecule glycogen, the majority of which is found in the liver and skeletal 
muscle. Until recently, glycogen could not be detected in the brain because previous 
methods were not sensitive enough and failed to preserve glycogen from degradation 
after euthanasia. Recently improved detection methods and rapid preservation 
methods have proven successful at preventing glycogen degradation post-euthanasia. 
These advances led to discoveries of an emerging role for glycogen in synaptic plasticity 
and memory consolidation45,52,54.  
Glycogen is comprised of glucose monomers that are linked by -1,4-glycosidic 
linkages into polymers by glycogen synthase (GS). These glycose polymers are branched 
every ~13 glucose residues by glycogen branching enzyme that generates -1,6-
glycosidic linkages. Glucose-1-phosphate is released by degrading cytoplasmic glycogen 
by glycogen debranching enzyme and glycogen phosphorylase. Static analysis of brain 
glycogen using immunohistochemistry (IHC) reveals region specific and heterogeneous 
storage patterns39,213. However, a dynamic analysis of glycogen in aging and disease is 
lacking. Mutations in genes encoding glycogen metabolism enzymes cause glycogen 
storage diseases (GSDs) with severe tissue specific pathogenesis214. A hallmark of most 
GSDs are insoluble glycogen-like aggregates called polyglucosan bodies (PGBs), which 
vary in cellular location and morphology depending on the molecular defect.  
The pathogenicity of brain PGBs is highlighted by the GSD Lafora disease (LD) that 
also presents as a fatal childhood dementia and progressive myoclonus epilepsy, where 
LBs are known drivers of the severe disease course. Multiple laboratories using 
numerous pre-clinical models have demonstrated that LBs drive LD inflammation, 
neurodegeneration, and epilepsy25,27,51,92,215–221. LD patients develop seemingly normal 
during their first decade of life with epilepsy and myoclonus emerging during 
adolescence80. Patients then experience rapid neurodegeneration, ataxia, dysarthria, 
and amaurosis that leads to a vegetative state prior death typically within 10 years of 
onset. LD is an autosomal recessive childhood dementia caused by mutations in either 
the Epilepsy Progressive Myoclonus type 2a or 2b (Epm2a or Epm2bB) gene each 
accounting for ~50% of cases46,81–83. The proteins encoded by Epm2a and Epm2b are the 
glycogen phosphatase laforin and the E3 ubiquitin ligase malin, respectively. Loss of 
function of either protein promotes the generation of aberrantly branched, hyper-
phosphorylated, cytoplasmic PGBs called Lafora bodies (LBs) throughout the body and 




neurotoxic78,222. In the brain, LBs are found in 99% of astrocytes, and <10% of neurons96. 
Multiple independent studies have established that decreasing LB formation or ablating 
previously established LBs prevents neurodegeneration and epilepsy in LD mouse 
models while restoring normal brain metabolism25–28,118,223. Conversely, overexpression 
of constitutively active glycogen synthase promotes the accumulation of a PGB that 
drives neurodegeneration in flies and mice90. These studies have elucidated the 
molecular etiology of LD and established the importance of proper glycogen metabolism 
in the brain.  
Visualizing glycogen is often achieved by using Periodic Acid Shiff staining that was 
developed in the 1940’s224. PAS reacts with 1,2-glycol linkages and stains multiple 
carbohydrate polymers, including glycogen, PGBs, glycoproteins, and proteoglycans38. 
PAS stain is a standard technique for identifying glucose polymers in paraffin embedded 
tissue, but PAS is limited in both specificity and sensitivity. A more accurate method for 
quantitation of glucose polymers has been recently established using gas-
chromatography coupled mass spectrometry (GCMS)40. There are many sources of 
glucose polymers in tissues beyond glycogen like glycoproteins and proteoglycans, 
which PAS and GCMS can detect. 
LBs can also be detected by an IgM antibody purified from the antisera of rabbits 
inoculated with the myocardium of a LD patient, designated KM279217,225,226. KM279 
detects LBs from human brain, skeletal muscle, heart, and liver as well as LBs from other 
mammals like dogs and mice225–231. KM279 also detects other PGBs like those found in 
GSD IV, hepatocyte “ground-glass” inclusions in livers of alcohol abuse patients, 
aggregates in a patient with alpha-thalassemia major receiving iron chelation therapy, 
and aggregates in a patient with trisomy 21 who had undergone a bone marrow 
transplant for acute myeloid leukemia232,233. Importantly, KM279 also detects a PGB 
found in the aging brain called corpora amylacea, a polyglucosan structure catalyzed by 
glycogen synthase that accumulates with advancing age90,225,226,234. A recent detailed 
analysis defined that KM279 recognizes aberrant PGBs but does not detect normal 
glycogen225. 
An additional anti-carbohydrate antibody is IV58B6. IV58B6 is a robust anti-glycogen 
antibody that was raised against the mandibular cartilage of a rat38,225,235,236. IV58B6 can 
detect both soluble and insoluble glycogen molecules, like PGBs, as well as 
mycobacterial polysaccharides and α-glucans39,213,226,237–245. Interestingly, glycogen 
synthesized in vitro either enzymatically or synthetically is not detected by IV58B6 but 
can be detected by the anti-glycogen antibody ESG1A9, providing a clue that the 
epitope may be related to branching structure39. Several groups have reported that 
IV58B6 and ESG1A9 have different affinities for varied sizes of glycogen particles39. 
Although the exact epitopes of KM279, IV58B6, and ESG1A9 still need to be defined, 
these antibodies are powerful tools to visualize and quantify glycogen and glycogen-like 
aggregates while maintaining spatial information that is lost when glycogen is purified, 
hydrolyzed, and quantified. The IV58B6 and KM279 antibodies have been used to study 
healthy and diseased glycogen in the WT and Epm2a-/- (LKO) mouse brain15,217.  
In this study, four methods were applied to define the longitudinal patterns of 




IV58B6 IHC analysis of WT mouse brains, skeletal muscle, and hearts are supported by a 
recently established and highly robust method for quantifying hydrolyzed glycogen 
using GCMS. These methods were also used to examine laforin heterozygote mice, a 
model of healthy carries of an LD locus.  
These methods were used to define a longitudinal analysis of glycogen dynamics in 
mice with healthy and diseased glycogen metabolism. In doing so, this study contributes 
to the characterization of the detection specificity of PAS and the glucose polymer 
detection method by GCMS and the epitopes of IV58B6 and KM279. For sake of clarity, 
we discuss these techniques with respect to their known specificities for soluble 
glycogen and/or PGBs. Thus, this longitudinal study is a comprehensive biomarker 
analysis of the dynamics of glycogen and PGBs. Brain glycogen and LBs are largely found 
in astrocytes, and glia have been proposed to be involved in an inflammatory response 
in LD25,27,118,215,221,223. Using traditional markers of astrogliosis, Gfap, and microgliosis, 
Iba1, we also include analyses of glial activation over time. Our analyses collectively 
describe a plateau effect of total LB accumulation and provide physiological evidence to 
strongly suggest their propensity to aggregate. We further show that microglia are 
significantly activated in LKOs compared to laforin heterozygotes, whose microglia 
activation is the same as in WT mice. These main findings act as a particularly important 




























2.2.1 Mouse models and tissue preparation 
Laforin KO (LKO) mice have been described previously and were generated 
by removing the DSPD exon of Epm2a, producing an Epm2a-null mutant217. Male 
C57BL/6J LKO, and WT mice were bred to create laforin heterozygotes. The mice were 
housed in a climate-controlled environment with a 14/10 h light/dark cycle (lights on at 
0600 h) with water and solid diet provided ad libitum throughout the study. The animal 
procedures used in this study were approved by the Institutional Animal Care and Use 
Committee (IACUC) at as specified by the 1985 revision of the Animal Welfare Act. WT, 
LKO, or laforin heterozygous mice were sacrificed at 1-, 3-, 6-, 9-, 12-months. WT and 
LKO mice were also sacrificed at 24-months. Mice were sacrificed by cervical dislocation, 
and decapitation, and tissues were rapidly dissected. One half of the heart, half the 
quantity of dissected skeletal muscle, and one hemisphere of the brain was fixed with 
formalin (10% formaldehyde in PBS) for 24 h and exchanged for 70% ethanol after 24 h 
for immunohistochemistry. The remaining tissue was flash-frozen in liquid nitrogen. 
 
2.2.2 Histology 
Periodic Acid Schiff (PAS) staining was performed per standard protocol on 4 m 
sections of formalin fixed brain, skeletal muscle, or heart embedded in paraffin234.  
IHC was performed on 4 m sections of brain, heart, or skeletal muscle using 
IV58B6, Gfap, or Iba1 were de-waxed, rehydrated, and warmed to 37˚C for 1 h in 
Ventana CC2 Standard buffer for antigen retrieval. The antigen retrieval method specific 
to sections receiving KM279 were [Dako Low pH, 110C, 20', 1 h RT]. The generation of 
KM279 and IV58B6 primary antibodies has been previously described225,226,235. 
Concentrations of antibodies were as follows: KM279 1:50, IV58B6 1:50, Gfap (Ab7260) 
1:2000, Iba1 (ab5076) 1:300. Detection kits used: KM279 Vector MOM (MP-2400), 
IV58B6 Vector MOM (MP-2400), Gfap Ventana OmniMap Rabbit-HRP (760-4311), Iba1 
Ventana OmniMap Goat-HRP (760-182). 
 
2.2.3 Gas-chromatography mass spectrometry (GCMS) analysis of glycogen 
One hemisphere of the brain, half the quantity of dissected skeletal muscle, and one 
half of the heart was flash-frozen in liquid nitrogen and pulverized into powder (5 m 
particles) using a liquid nitrogen Freezer/Mill Cryogenic Grinder (SPEX SamplePrep). 
Glycogen purification, hydrolysis, derivatization, and quantitation of glycogen by GCMS 
was performed as described previously40. 20 mg of each pulverized tissue was extracted 
in 1 mL of 50% methanol and separated into polar (aqueous layer) and insoluble 




10 min. The pellet was subsequently washed three times with 50% methanol and once 
with 100% methanol to remove polar contaminants. The polar fraction was saved for 
future experiments. The pellet was hydrolyzed by resuspension in 100 μL of deionized 
water followed by addition of an equal part of 6 N HCl. The samples were vortexed 
thoroughly and incubated at 95 °C for 2 h. The hydrolysis was quenched by adding 100% 
methanol after which, the samples were incubated on ice for 30 min. The supernatant 
was collected after centrifugation at 15,000 rpm at 4°C for 10 min and subsequently 
dried by SpeedVac (Thermo). Derivatization of dried polar samples began with the 
addition of 70 μL of 20 mg/mL methoxylamine hydrochloride in pyridine followed by a 
30 oC incubation for 1.5 hr. Then, 50 μL was transferred to a V-shaped amber glass 
chromatography vial and 80 μL of trimethylsilylating agent N-methyl-N-trimethylsilyl-
trifluoroacetamide (MSTFA) was added. This step was followed by a 30 min incubation 
at 37 oC. After cooling, the derivatized mixture was analyzed by GCMS. An Agilent 7800B 
GC coupled to a 5977B MS detector was used in this study. GCMS protocols were similar 
to those described previously except for a modified source temperature of 280 °C209. 
MassHunter Unknowns Analysis (B.09.00, Agilent Technologies, Santa Clara, CA, USA) 
software matched to the FiehnLib metabolomics library was utilized for curation of the 
MS data set with retention time and fragmentation pattern matching. Mass spectra 
were translated to relative metabolite abundance using MassHunter Quantitative 
Analysis (TOF) (B08, Agilent Technologies, Santa Clara, CA, USA). Relative abundances 
were adjusted to protein input. 
 
2.2.4 Quantification and statistical analysis 
PAS staining and IHC quantitation was achieved using HALO analysis software by 
Indica Labs. PAS, KM279, and IV58B6 analysis (total glycogen) were based on the “Area 
Quantification” v2.1.11 algorithm. Analysis of IV58B6 regarding nuclear and cytoplasmic 
glycogen, Gfap, and Iba1 were based on the Multiplex IHC v2.3.4 algorithm. Activated 
microglia analysis was based on the “Microglial Activation” v1.4 algorithm. Multiple 
comparison two-way Anova and descriptive statistics were performed using GraphPad 















2.3.1 Longitudinal analysis of glycogen and PGBs in the brain, skeletal muscle, and 
heart 
PAS stain is a historically standard technique for identifying PGBs and glycogen in 
paraffin embedded tissue38,142. A more accurate method for quantitation of glucose 
polymers has been recently established using GCMS40. Using both methods, we 
analyzed whole brains of 1-, 3-, 6-, 9-, 12-, and 24-month-old WT and laforin knockout 
(LKO) male mice. To achieve minimal glycogen degradation post-mortem, mice were 
euthanized by cervical dislocation followed by decapitation and rapid dissected with 
tissues submerged in liquid nitrogen or formalin. PAS-stained slides were digitally 
captured using a ZEISS Axio Scan.Z1 slide scanner and analyzed using the HALO image 
analysis platform. PAS staining (Figures 2.1 and 2.2) and respective area quantitation 
(Figure 2.1B) revealed that the quantity of PAS+ signals in the brain of LKO mice sharply 
increases between the ages of 1- and 6-months and then plateaus 8-fold higher than 
WT. Conversely, WT PGBs steadily increased over time though at a dramatically lower 
level than LKO mice (Figure 2.1B).  
While PAS reacts with glycogen, glycoproteins and proteoglycans, the GCMS-based 
method specifically quantifies glucose. Therefore, the GCMS method was utilized to test 
if the PAS+ quantification was reporting levels of glucose-based polymers. Tissues frozen 
in liquid nitrogen were pulverized to 5 μm particles using a magnetic assisted tissue-
grinding mill while submerged in liquid nitrogen. The free lipids and polar metabolites 
were removed by the addition of 50% methanol:chloroform (1:1). Glycogen and PGBs 
were extracted with subsequent methanol and trichloroacetic acid treatment and, 
resuspended in H2O, hydrolyzed to glucose monomers by HCl, derivatized, and analyzed 
by GCMS40. LKO GCMS quantitation revealed a dramatic increase between 1- and 3-
months that plateaus after 6-months and is 5-fold higher than WT (Figure 2.1C).  
Adjacent slices from the same animals were analyzed by immunohistochemistry 
(IHC) using the IV58B6 antibody that has been demonstrated to detect both glycogen 
and PGBs and the KM279 antibody that detects PGBs (Figure 2.3A)225,226,235. By 12-
months, LKO whole brain KM279 detection signals reached an amplitude that is higher 
than WT by 15-fold (Figures 2.3B-C and 2.4). Importantly, WT whole brain KM279 
detection is identical to that seen in laforin heterozygotes suggesting that healthy LD 
carriers do not accumulate LBs (Figures 2.27A-B and 2.4). Analysis and quantitation of 
IV58B6 detection closely match the total glucose polymers detected by GCMS (Figures 
2.3D-E, 2.5 and 2.1B). IV58B6 detection signals dramatically increased between 1- and 
3-months and plateaued after 6-months 2-fold higher than WT. Conversely, there is no 
statistical difference in IV58B6 glycogen levels in aged WT mice. Interestingly, a study 
examining glycogen in young versus old mice using IV58B6 IHC demonstrated patchy 
glycogen that diminished over time as corpora amylacea accumulate, resulting in 




morphology is observed and quantified by IV58B6 and GCMS in the WT and laforin 
heterozygous mice (Figures 2.3D-E and 2.28A-C).  
On the corresponding WT and LKO skeletal muscle and heart tissues, we performed 
a similar longitudinal PAS stain, KM279 IHC, and GCMS analysis. Unlike the rapid 
accumulation and plateau with PAS+ and KM279 staining observed in the LKO brain, a 
continuous increase was observed from 1-month to 24-months for both signals in the 
LKO skeletal muscle and heart (Figures 2.6A-F, 2.7, 2.8, 2.9, and 2.10). WT KM279 
signals increased in skeletal muscle and heart tissues over time, but the increase was 
dramatically more blunted than in the age-matched LKO tissues (Figures 2.6A-C, 2.7, 
2.8, 2.9, and 2.10). These data illustrate that the rate of LB accumulation in skeletal 
muscle and heart is constant and is not like the rapid and then plateaued accumulation 
in the brain. GCMS analysis on LKO skeletal muscle supported the KM279 detection 
findings exhibiting an increase in glucose polymers over time and reaching a level 5-fold 
higher than WT by 12-months (Figure 2.29A). The same analyses performed on LKO 
hearts indicates that glucose polymers are 8-fold higher than WT by 12-months (Figure 
2.29B). GCMS analysis of WT and laforin heterozygous skeletal muscle shows that 
glycogen levels remain constant between 1- and 12-months while increasing in heart 
(Figure 2.29C-D). Interestingly, KM279 detection is also observed to increase in the 
heart of laforin heterozygotes but not in WT (Figure 2.10). These results contribute to 



























2.3.2 Longitudinal analysis of glycogen and PGBs in the hippocampus, cerebellum, 
and brainstem  
In LD patients and mice, PGBs are predominately observed in the hippocampus, 
brainstem, and cerebellum218. Therefore, we defined these regions-of-interest (ROIs) 
and performed regional “Area Quantification” analysis of the KM279 detection signal by 
using the HALO image analysis platform. In each of the ROIs, the LKO KM279 detection 
signal increases rapidly before 6-months and plateaus after 6-months of age (Figures 
2.11A-C, 2.12, 2.13, and 2.14), which is the same pattern observed in whole brain 
analysis (Figure 2.3B-C). During the plateau, hippocampus and cerebellum LKO KM279 
detection signals are each 30-times higher than WT (Figure 2.11A, C). The brainstem 
LKO KM279 detection signal is 15-times higher than WT (Figure 2.11B). Therefore, LBs 
are highest in the hippocampus and cerebellum. The WT KM279 detection signal shows 
an expected age dependent upward trend that is matched by laforin heterozygotes, 
suggesting that healthy carriers of an LD locus do not have LBs (Figures 2.11A-C, 2.12, 
2.13, 2.14, and 2.27C).  
Between 1- and 6-months, the rate of KM279 detection signal increases most rapidly 
in the cerebellum, with a rate of increase that is 10-times faster than in the 
hippocampus and 5-times faster than in the brainstem (Figure 2.11A-C). Within this 
same time frame, KM279 detection in the brainstem increases 2-times faster than in the 
hippocampus (Figure 2.11A, C). Taken together, these results suggest that LB onset and 
accumulation rate is highest in the cerebellum, followed by brainstem, and lastly in the 
hippocampus.  
A similar ROI analysis was performed to quantitate the IV58B6 detection signal. Like 
whole brain analysis, regional IV58B6 detection on LKO mice indicates that the IV58B6 
detection signal increases steeply between 1- and 6-months and then plateaus (Figures 
2.11D-F, 2.15, 2.16, 2.17). The LKO IV58B6 detection signal is highest in the 
hippocampus followed by the cerebellum and the brainstem, where total glycogen is 5-
times, 3-times, and 2-2.5-times higher, respectively, than in WT mice (Figure 2.11D-F). 
The WT IV58B6 detection signal is approximately equal between the hippocampus and 
cerebellum and does not increase with age, which agrees with previous reports (Figure 
2.11D, F)15. The IV58B6 detection signal in the brainstem is less than in the hippocampus 
or cerebellum and shows an increasing trend over time (Figure 2.11E). The laforin 
heterozygote hippocampus IV58B6 detection signal is almost 2-times as much as WT 
and decreases overtime (Figure 2.12D-F). This finding may be suggestive of a region 
dependent regulation of laforin expression. Observational analysis of the WT and laforin 
heterozygote hippocampus exhibits a morphological change in IV58B6 detection 
patterns between the two genotypes over time, moving from a disperse to clustered 
arrangement (Figure 2.12A). These data emphasize results from the whole brain 
analysis in which IV58B6 detection and GCMS detection of carbohydrate polymers 
remains constant over time while changes in IV58B6 detection patterns are observed 





2.3.3 Average size and size variation of LD and aging PGBs in the hippocampus 
Both PAS staining and KM279 IHC detect PGBs. Interestingly, PAS staining yields 
uniform signals while KM279 IHC yields light and dark staining as well as uniform versus 
punctate patterns. Therefore, we studied these signal attributes to characterize LBs and 
corpora amylacea. We first measured the diameters and calculated descriptive statistics 
of PAS+ signals from the hippocampus of WT and LKO mice during 6-, 9-, 12-, and 24-
months, i.e., the age range where the PAS+ signal “Area Quantification” plateaus. The 
PAS+ signal coefficient of variation increases in LKO mice from 42% to 61% between 6- 
and 12-months, while in WT mice it does not change over time and is on average 43% 
(Table 2.1). These statistical measures indicate that PAS+ signal diameters vary 
significantly in both LKO and WT and that the variation increases with age in LKO mice. 
The average diameters of LKO PAS+ signals increase from 1.4-3.2 μm, and range from 
4.5-14.6 μm, while neither the average diameter nor range of WT PAS+ signals change 
with age (Figure 2.1D and Table 2.1). Importantly, the LKO PAS+ signals described in the 
75th percentile increase more dramatically over time than those within the 25th 
percentile, while neither value changes over time in WT mice (Table 2.1). These data 
indicate that the size of PAS+ signals become larger with time while PAS+ “Area 
Quantification” stays the same. Furthermore, the increase in LB size variation is driven 
by the higher abundance of larger signals. Collectively, these data strongly suggest that 
LBs aggregate.  
A similar analysis was performed on KM279 detection signals using adjacent brain 
slices. The KM279 detection signal reveals two structures in the brains of WT and LKO 
mice. One structure appears uniform, looking dense, dark brown, and circular (Figure 
2.30A, B). The other is a non-uniform structure, appearing uncondensed and light brown 
and encircling the uniform structure (Figure 2.30A-D). These structures were separately 
quantified using the “Area Quantification” analysis tool (Figure 2.30C, D). Between 1- 
and 24-months, the accumulation of the “uncondensed” material paralleled the 
accumulation of the uniform dark brown circular aggregates with almost 2-times the 
abundance (Figure 2.30C). To measure the diameters of KM279 detection signals we 
measured the uniformly detected structures because the boundaries are clearly defined 
and excluded the non-uniform appearing material (Figure 2.30A-B). The calculated 
coefficient of variation of the of WT uniform KM279 detection signals does not change 
over time and is on average 52%. In LKO mice, an increase in the coefficient of variation 
of the uniform KM279 signals is only significant between 12- and 24-months and is on 
average 33%. Thus, the average variation of uniform KM279 detection signals in WT 
mice is significantly higher than in LKOs (Table 2.1 and Figure 2.30E). Further, the WT 
KM279 detection signal variation is the same in laforin heterozygote mice (Figure 
2.11C). In contrast to the PAS+ signals, the average diameters of the LKO 6-, 9-, 12-, and 
24-month-old uniform KM279 signals did not change with age, which is also seen in WT 
mice (Table 2.1). However, the average diameter of the uniform KM279 signals in LKOs 
is larger than in WT, averaging 3.7 μm versus 2.9 μm (Table 2.1). These collective 
findings indicate that the average diameter of the LKO uniform KM279 signals is larger 




Further, in both WT and LKO mice, the average diameter of the uniform KM279 signals 
is larger on average than PAS+ signals (Figure 2.1D, 2.30E, and Table 2.1). Thus, analysis 
of PAS+ and KM279 detection signals indicate diverging characteristics between the LKO 
and aging PGB. Furthermore, PAS+ and KM279 detection signals exhibit a divergence in 









































2.3.4 Longitudinal analysis of Gfap and Iba1 inflammatory markers 
Astrocytes and microglia play complementary roles in building and maintaining the 
brain, especially with respect to their proinflammatory reactions to 
neurodegeneration246. These glial cells also have an emerging relationship to glycogen 
and aberrant PGBs. Astrocytes are the main cells that accumulate glycogen in the brain 
and two recent independent studies demonstrated that glycogen inclusions within LKO 
or malin knockout (MKO) mouse brains were found in 99% of astrocytes and only 4% of 
neurons96. Glycogen inclusions were also found within microglia, suggesting a role for 
both astrocytes and microglia in LD96. Further, some recent studies have pointed to the 
possibility that the glycogen inclusions that accumulate in glia may promote irregular 
functionality of their inflammatory responses, which may be an important biomarker of 
LD96,97. Gfap-immunoreactive astrocytes and Iba1-immunoreactive microglia have 
previously been quantified at 3-4-months and 12-months in LKO and MKO mice showing 
increased cell count or activation at the latter time point25,28,221,247,248. For a more 
complete assessment of the inflammatory response in LD we performed a longitudinal 
analysis of Gfap expressing astrocyte and Iba1 expressing microglia activation in the LKO 
mouse brains and compared them to WT and laforin heterozygous aging mouse brains.  
Using “Multiplex IHC” analysis of Gfap reactive astrocytes, we first quantitated the 
number of these glial cells over time. Whole brain quantitation indicates that the 
number of Gfap positive astrocytes in LKO mice is the same as WT animals until 12-
months (Figure 2.31A). A similar trend is observed in the brainstem and cerebellum 
(Figure 2.31C, D). In the hippocampus, Gfap positive astrocytes increase in quantity 
from 6- to 24-months (Figure 2.31B). Since reactive astrocytes are scored by quantifying 
the area of hypertrophy and elongated protractions, we next measured reactive 
astrocytes by Gfap “Area Quantitation”. No difference in astrocyte activation is detected 
between WT and LKO mice in any region before 12-months (Figures 2.18A, 2.19, 2.20, 
2.21, and 2.22). Since no change in astrocyte number or activation is seen for the first 
year of life in the LKO mice, the late stage or “middle-aged” emergence of astrocyte 
activation may be more related to aging than LD pathology. Interestingly, at 6-months 
and after, the laforin heterozygote mice exhibit an increase in Gfap expressing astrocyte 
count and area quantitation comparted to WT (Figure 2.32). Why laforin heterozygotes 
have increased number and activation of Gfap astrocytes is unclear, however this 
finding is in opposition to what is seen in LKO mice, further supporting the hypothesis 
that astrocyte reactivity in LKO mice is defective. 
Performing a similar analysis on Iba1-immunoreactive microglia, we used “Multiplex 
IHC” analysis to measure any change in the number of these cells over time. We find 
that the quantity of Iba1 reactive microglia significantly increases in the hippocampus of 
LKO mice between 6- and 24-months (Figure 2.31F and Figure 2.23). No difference is 
seen in whole brain analysis or in the other ROIs (Figure 2.31E, G-H, 2.24, 2.25, and 
2.26). To perform a microglia activation analysis, we used the HALO tissue analysis 
software “Microglial Activation” quantification method in which Iba1 positive cells 
completely lacking protractions are scored as active. Unlike astrocyte activation, the 




protractions. Using this specified method, we find that LKO microglia activation is 2 
times higher than WT within the whole brain, brainstem, and cerebellum and less 
prominent in the hippocampus (Figure 2.18B). Importantly, no difference in whole brain 
or any ROI is observed in microglia cell count or activation between WT and laforin 
heterozygotes (Figure 2.33). These analyses show that microglia, not astrocytes, are 



































Figure 2.1 Whole brain PAS stain and GCMS analysis of glucose polymers on WT and 
LKO mice aged 1-, 3-, 6-, 9-, 12-, and 24-months.  
IHC analysis was performed using Indica labs software (HALO) "Area Quantification". A) 
Representative IHC images of PAS staining. B) Quantitation of PAS positive inclusions. C) 
Quantitation of acid-hydrolyzed glucose polymers by GCMS analysis. D) Quantitation of 
PAS+ signal diameters within the hippocampi of 6-, 9-, 12-, and 24-month-old WT and 
LKO mice. Black = WT, red = LKO. Pop-out column graphs are WT data. **** = (p < 








































Figure 2.3 Whole brain KM279 and IV58B6 IHC analysis of WT and LKO mice aged 1-, 3-
, 6-, 9-, 12-, and 24-months. 
IHC analysis was performed using Indica labs software (HALO) "Area Quantification". A) 
Schematic illustration of IV58B6 and KM279 antibody affinity to healthy and diseased 
glycogen. B, D) Representative IHC images of KM279 and IV58B6 quantitated in C and E, 
respectively. C, E) Quantitation of KM279 and IV58B6 IHC analysis, respectively. Black = 




































































Figure 2.6 Skeletal muscle and heart PAS stain and KM279 IHC analysis of WT and LKO 
mice aged 1-, 3-, 6-, 9-, 12-, 24-months. 
IHC analysis was performed using Indica labs tissue analysis software (HALO) "Area 
Quantification". A, D) Representative KM279 IHC analysis on skeletal muscle and heart 
quantified in B, E, respectively. B, C) Quantitation of KM279 IHC and PAS stain analysis 
on skeletal muscle, respectively. E, F) Quantitation of KM279 IHC and PAS stain analysis 





























































































































Figure 2.11 Brain region-of-interest KM279 and IV58B6 IHC analysis of WT and LKO 
mice aged 1-, 3-, 6-, 9-, 12-, 24-months. 
IHC regional analysis on hippocampus (top row), brainstem (middle row), and 
cerebellum (bottom row) was performed using Indica labs software (HALO) "Area 
Quantification". A-C) Representative region-of-interest IHC analysis of KM279 (mainly 
diseased glycogen) (left) and quantitation (right). D-F) Representative region-of-interest 
IHC analysis of IV58B6 (total glycogen, diseased and non-diseased) (left) and 








































































































































































Table 2.1 Descriptive statistics of PGB diameters. 
PGB diameter measurements were taken from 200 PGBs per hippocampus using Indica 
labs software (HALO). Average diameter, 25% percentile, 75% percentile, range, and 
coefficient of variation were calculated using Prism 9. Color gradients were produced 













Age (months) 6 9 12 24 6 9 12 24 6 9
PAS 1.4 1.7 2.3 3.2 1.6 1.5 1.4 1.5
KM279 3.5 3.7 3.6 4.0 2.7 2.7 3.2 3.0
PAS 1.1 1.3 1.7 2.3 1.0 1.0 0.9 1.0
KM279 2.7 3.0 2.8 3.0 1.8 1.6 2.2 2.1 2.3 2.1
PAS 1.7 2.3 3.0 4.9 2.0 1.8 1.7 2.0
KM279 4.2 4.3 4.3 4.8 3.7 3.8 4.2 3.9
PAS 4.5 6.0 7.5 14.6 4.4 4.0 4.0 3.5
KM279 7.4 5.8 6.0 11.1 52.2 56.6 53.6 47.7 5.1 7.2
PAS 42 48 49 61 49 25 51 47

































Figure 18. Whole brain activated astrocyte (GFAP) and microglia (Iba1) analysis of 
WT and LKO mice aged 1-, 3-, 6-, 9-, 12-, 24-months. IHC analysis was performed 
using the Indica labs tissue analysis software (HALO) "Area Quantification" of GFAP 
IHC and “Microglia” activation of Iba1 IHC. A) Representative GFAP IHC (left) and area 
quantitation (right). B) Representative Iba1 IHC (left) and area quantitation (right). 






































































































































































































































Figure 2.27 Whole brain and region-of-interest KM279 IHC analysis of WT and laforin 
heterozygote brains aged 1, 3, 6, 9, 12-months. 
IHC analysis was performed using Indica labs software (HALO) "Area Quantification" and 
ruler tool. A) Representative IHC images quantitated in B. B) Whole brain quantitation of 
KM279 IHC. C) ROI quantitation of KM279 IHC. D) Violin plots of dense dark brown 
circular aggregate diameters. E) "Area Quantification" of WT and heterozygote dense 
dark brown circular aggregates and light brown uncondensed material. Black = WT, gray 
= laforin heterozygotes. Squares and solid line = dense dark brown circular aggregates, 


















Figure 2.28 Whole brain IV58B6 IHC and GCMS analysis of glucose polymers on WT 
and laforin heterozygote mice aged 1, 3, 6, 9, 12-months. 
IHC analysis was performed using Indica labs software (HALO) “Area Quantification”.  
A) Representative IHC images quantitated in D. B) Quantitation of acid hydrolyzed 
glucose polymers by GCMS. C) Whole brain quantitation of IV58B6. D, E, F) ROI 
quantitation of IV58B6 in hippocampus, brainstem, and cerebellum, respectively. Black = 










Figure 2.29 Skeletal muscle and heart GCMS analysis of glucose polymers of WT and 
LKO mice aged 1-, 3-, 6-, 9-, 12-, and 24-months.   
A) Quantitation of GCMS analysis of glucose polymers from skeletal muscle B) 



















Figure 2.26  Quantitative and qualitative analysis of KM279 IHC on WT and LKO 
hippocampus of 6, 9, 12, 24-month-old mice. IHC analysis was performed using the 
Indica labs tissue analysis software (HALO) "Area Quantification" and ruler tool.  
A, B) Qualitative representation of uniform dark brown circular aggregates and 
uncondensed light brown material detected by KM279 on WT and LKO brains, 
respectively. C) Hippocampus quantitation of WT and LKO uniform and uncondensed 
material. Pop-out column graph is WT data. WT = black, LKO = red. Squares and solid 
line/bar = uniform material, triangles and broken line/bar = uncondensed material. D) 
Representation of "Area Quantification" analysis in C. Red = “uniform” material, yellow 
= “uncondensed” material. E) Violin plots of “uniform” material diameters. WT = black, 
LKO = red. *** = (p = 0.0002), ** = (p = 0.0021), * = (p = 0.0209) 
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Figure 2.27 Whole brain and region-of-interest cell count analysis of GFAP expressing 
astrocytes and Iba1 expressing microglia of 1, 3, 6, 9, 12-month-old-mice.  
IHC analysis was performed using the Indica labs tissue analysis software (HALO) 
”Multiplex IHC". A-D) Quantitation of whole brain and region-of-interest analysis of 
GFAP. E-H) Quantitation of whole brain and region-of-interest analysis of Iba1. Black = 
WT, red = LKO 
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Figure 2.28 Whole brain GFAP IHC analysis on WT and laforin heterozygote brains 
aged 1, 3, 6, 9, 12-months. IHC analysis was performed using the Indica labs tissue 
analysis software (HALO) ”Multiplex IHC” and “Area Quantification”.  
A) Representative GFAP IHC quantitated in B and C. B) Astrocyte cell count. C) GFAP 
"Area Quantification". Black = WT, gray = laforin heterozygotes. Black = WT, gray = 









Figure 2.29 Whole brain Iba1 IHC analysis on WT and laforin heterozygote brains aged 
1, 3, 6, 9, 12-months. IHC analysis was performed using the Indica labs tissue analysis 
software (HALO) ”Multiplex IHC” and “Area Quantification”.  
A) Representative Iba1 IHC quantitated in B and C. B) Microglia cell count. C) Iba1 "Area 
Quantification". Black = WT, gray = laforin heterozygotes. Black = WT, gray = laforin 









This study uses four complementary methods and a longitudinal analysis approach 
to fill in knowledge gaps regarding normal and diseased glycogen dynamics. This 
longitudinal analysis was performed using C57BL/6J WT, LKO, laforin heterozygous mice, 
and a digital pathology workflow to produce rigorous and reproducible data that is 
supported by GCMS. Our results form a more complete characterization of the LKO 
mouse that models LD pathophysiology. These characterizations lead to a model of LD 
pathophysiology in which LB accumulation begins in the cerebellum, then the 
brainstem, and last the hippocampus, increasing in number to a height that is most 
egregious in the hippocampus. Current therapeutic approaches that aim to limit the 
production of glycogen or degrade LBs will benefit from the discovery that brain LBs 
stop accumulating and begin to form aggregations at 6-months of age. Furthermore, LD 
inflammation rescue is widely assessed by reversing the quantity of Gfap expressing 
astrocytes in older mice95,215,247,249–252. Our results indicate that microglia, but not 
astrocytes, are activated over the entire lifespan of the LKO mouse. Therefore, 
microgliosis is the more likely driver of inflammation in LD. These findings among others 
discussed below will be highly informative guides for current and future pre-clinical 
therapeutic development.  
 
2.4.1 Soluble versus insoluble glycogen in the LKO mouse  
The water-soluble quality of glycogen provides cells with carbon and energy105. 
Pathogenic buildup of insoluble glycogen defines glycogen storage diseases253. Previous 
reports have measured the ratio of soluble to insoluble glycogen in LKO, MKO, and WT 
age matched mice. One study on 10-13-month LKO and 15-month MKO mice indicated 
that skeletal muscle total glycogen (soluble and insoluble) is 2-times higher in both 
genotypes compared to WT106. To uncouple the quantities of soluble glycogen to PGBs, 
they used centrifugation to separate the soluble from insoluble glycogen fractions. WT 
soluble glycogen levels were the same as in the LKOs and the WT insoluble fraction was 
nominal. Since the soluble and insoluble fractions of the LKO mice were approximately 
equal, the 2-fold increase in total glycogen in the LKO mice was a result of the insoluble 
fraction. The same analysis has been published on the brain tissue from 11-month-old 
MKO mice51. These data indicated that total WT glycogen is equal parts soluble and 
insoluble. WT and MKO soluble glycogen levels are the same, but MKO insoluble 
glycogen is 3-times higher than WT, bringing the total increase in glycogen to ~2.5-times 
higher than WT. In both LD models using skeletal muscle or brain tissues, the increase in 
total glycogen is driven by LBs while soluble glycogen is unchanged from normal 
conditions. These reported findings fall in line with our total glycogen and LB analysis 
using IHC. 
Using both KM279 IHC and IV58B6 IHC on adjacent tissue sections we were also able 
to separate LB accumulation from total glycogen load. Total LKO brain glycogen 




brain LBs measured by KM279 IHC is half the amount of total glycogen detected by 
IV58B6 IHC. Given the preceding studies quantifying soluble and insoluble glycogen in 
these mouse models we may infer that the 2-fold increase in IV58B6 detection 
compared to WT or laforin heterozygotes is driven by LBs. Importantly, our GCMS 
analysis measures total LKO glucose polymers to be 5-fold higher that WT, and 3-times 
higher than analyzed by IV58B6 IHC. This result is likely explained by more sugars being 
broken down by acid hydrolysis required for GCMS analysis than are detected by the 
anti-glycogen antibody IV58B6.  
 
2.4.2 LB aggregation and diverging characteristics of corpora amylacea 
Varied sizes of LBs have been previously categorized as type I and II/III80. Type I 
refers to smaller dust-like inclusions that are most abundant and type II/III refers to 
larger and more rare inclusions254. These characteristics are captured by our 
measurements and statistical analyses of PAS+ signal size and variation. The LBs we 
categorized in the 25th and 75th percentile represent type I and II/III respectively. Recent 
studies have indicated that type I inclusions are exclusive to astrocytes and type II/III to 
neurons, even in old age96. Our results show that type I and type II/III, both increase in 
size after 6-months of age while total PAS+ signal “Area Quantification” is rises quickly 
between 1- and 6-months and is unchanged thereafter. Furthermore, the increased 
variation of LB sizes is driven by the appearance of type II/III. Collectively, these analyses 
suggest that LBs accumulate and then aggregate. Furthermore, neuronal LBs, not 
astrocytic, have been recently suggested to be the main contributors of increased 
susceptibility to kainate-induced epilepsy in LD mice98. If so, neuron specific LB (type 
II/III) aggregation may be driving epilepsy in LD. 
Our diameter measurements and statistical analysis of WT PAS+ signals indicate that 
average LB average size and range is larger than corpora amylacea. Furthermore, 
corpora amylacea size variation is unchanged with time while LB variation increases and 
is driven by the increasing size of type II/III LBs. Thus, these statistics describe innate 
differences between corpora amylacea and type II LBs. The same analysis performed on 
the uniform material detected by KM279 reveal the opposite, LKO uniform KM279 
signals do not increase in variation and the variation of WT uniform KM279 signals is 
larger than in LKOs. Collectively, these results suggest innate differences between 
corpora amylacea and any type of LB. This is an important distinction considering recent 
published data that showcased a common epitope of type I inclusions and corpora 
amylacea not shared by type II/III, thus naming the type I inclusions corpora amylacea-
like bodies (CAL)96. Indeed, CAL and corpora amylacea have structural similarities and 
our results contribute to this comparative analysis indicating that corpora amylacea and 
CAL are not exactly the same.  
KM279 IHC analysis further led to differentiating characterizations between the 
detection specificities of KM279 IHC and PAS+ staining. Unlike PAS staining, the anti-PGB 
antibody detection signals reveal an uncondensed material encircling a uniform 




and LBs contains a dense core surrounded by an uncondensed network of particles 
made of the same material. These findings are intriguing considering a recently 
published model of spontaneous in vitro LB aggregation. In this model, polyglucosan 
particles spontaneously aggregate to form networks and active cellular sequestration of 
these polyglucosan networks creates tissue specific morphologies20. The uncondensed 
material detected by KM279 may be the physiological representation of polyglucosan 
networks.  
Characterizing the aggregation behavior of LBs is important for informing the 
efficacy of the therapeutics in development that aim to decrease LB load by either 
reducing and/or breaking down LBs. According to our finding that LBs aggregate in the 
brain in combination with the in vitro model of spontaneous LB aggregation, incomplete 
destruction or removal of LBs in late-stage LD represented after the 6-month mark in 
LKO mice may result in re-aggregation and unsuccessful therapeutic intervention. 
 
2.4.3 Inflammation markers of LD 
To assess inflammatory brain damage in LD, two histological markers are widely 
used. Gfap for astrogliosis and Iba1 for microgliosis. Previous studies have quantified 
Gfap expressing astrocytes in LKO mice at 12-months and 20- to 26-months25,28,221,247,248. 
Our longitudinal analysis indicates that before 12-months the number or “Area 
Quantification” of reactive Gfap expressing astrocytes does not increase above normal 
levels. Therefore, astrogliosis occurs well after the PGBs have infiltrated. Conversely, we 
show that activated microglia, the synergistic inflammatory signaling companion of 
astrocytes, are significantly higher throughout the lifespan of LKO mice compared to WT 
and laforin heterozygotes.  
Compared to LKOs, the laforin heterozygote mice show a reverse inflammatory 
response in terms of astrocyte and microglia reactivity despite regional increases in 
reactive astrocyte levels. This may be accounted for by increased soluble glycogen in the 
hippocampus as laforin heterozygotes do not have LBs. Further study is needed to 
determine the reason for laforin heterozygous hippocampal glycogen. It may be possible 
that there are regional differences in the ability to compensate for laforin expression 
that is not accounted for in our whole brain analysis.  
Why astrocyte activation is delayed in the LKO mouse model is unclear. One aspect 
to consider is that since Gfap is an intermediate filament protein that outlines the 
cytoskeletal profile of astrocytes’ somata and main branches, the entire astrocytic 
morphology cannot be evaluated by Gfap staining, and thus astrocytic activation may 
not be properly captured by “Area Quantification” of Gfap density. On the other hand, 
considering the damage inflicted to the brain in LD, the unresponsiveness of astrocytes 
may simply be a consequence of their inundation with LBs. CAL is demonstrated to 
accumulate in astrocytes and makes up the majority of brain LBs, while only minor 
quantities exist in microglia97. Therefore, the possibility that CAL accumulation affects 
astrocyte health and compromises the astrocyte’s ability to become activated in LD is 




a delayed response or more related to aging than LD pathology. Taken together, 
activated microglia are more likely important to the driving mechanism of inflammation 
in LD than activated astrocytes and should be more heavily considered as an important 
biomarker for therapeutic development.  
 
2.5 Final conclusions 
In this study we confirm and expand on previously published data describing 
pathological LD biomarkers. Our analysis of astrogliosis and microgliosis challenges 
assumptions about inflammatory drivers. These results redirect the focus of 
inflammatory biomarkers and putative therapeutic targets from astrocytes to microglia. 
Our longitudinal analysis illustrates the progressive pathology of both LD and WT aging 
mice. This thorough analysis will be a highly beneficial benchmark reference for all pre-






















Aging is a universal human condition that is harmful and likened to disease and the 
main risk factor for neurodegenerative disease3. The progressive nature of 
neurodegeneration further intertwines neurodegenerative disease with an age-
dependent dimension5. Central nervous system (CNS) metabolic defects have been 
proposed to be an important underlying feature of both aging and neurodegenerative 
disease1,3. Thus, it is not only important to understand the metabolism of aging for the 
potential to enhance quality of life, but to also establish a metabolic baseline for 
studying neurodegenerative disorders. In fact, many aging metabolism studies have 
emerged as a consequence of the problem of subtracting the influence of age from 
metabolism studies of neurodegenerative diseases144. In aging and neurodegenerative 
diseases, a progression of glucose hypometabolism emerges by Fluorodeoxyglucose 18F 
Positron Emission Tomography (18F-FDG-PET)10,255. Targeting brain glucose metabolism 
has been proposed as one of five ‘brain energy rescue’ strategies to provide significant 
symptom relief and disease modification in neurodegenerative disorders7.  
Mammalian brain energy consumes 20% of total body energy, and glucose is the 
major substrate of brain energy metabolism256. Glycogen can store ~50,000 glucose 
molecules that when released can fuel the TCA cycle, making glycogen an important 
energy cache257. To form this macromolecule, linear glucose polymers are synthesized 
by glycogen synthase (GS) and branched every ~13 residues by glycogen branching 
enzyme258. Breakdown is achieved by glycogen debranching enzyme and glycogen 
phosphorylase17. Glycogen is well-studied in the liver and muscle where liver glycogen is 
catabolized to provide systemic glucose, and muscle glycogen is catabolized to meet 
local energy demands during exercise13. The role of glycogen in the heart is suggested to 
be an ‘energy buffer’ where glycogen catabolism is titrated relative to glucose uptake 
and liberated only during times of ‘anoxaemic emergencies’259.  
The role of glycogen in the brain is an emerging field. Historically, glycogen was not 
detected in the brain due to issues with euthanasia that triggered glycogen degradation 
and lack of sensitivity260,261. Brain glycogen is critical for long-term potentiation and 
memory formation, and impairments to these processes characterize neurocognitive 
aging45,55. Further, brain glycogen metabolism has been recently linked to proteostasis, 
a common feature of aging and neurodegenerative disease262. Additionally, 25% of brain 
glycogen is comprised of the sugar monomer glucosamine, which is incorporated into 
and released from glycogen by the same enzymes that incorporate and release 
glucose16. In two GSD mouse models, brain regions affected by PGBs have impaired 
protein N-glycosylation16. If glucosamine sequestration is driven by the formation of 
PGBs, thereby limiting the production of UDP-GlcNAc, the fundamental building block of 
N-glycans, this would lead to dire consequences of proteostasis and cellular function. 




age and extends lifespan in mice99. With reduction in glycogen synthase, an age-related 
aberrant glycogen-aggregate known as corpora amylacea is also reduced in mice and 
flies99. These data are strong evidence that the development of corpora amylacea 
depends on the synthesis of glycogen and that their formation is an evolutionarily 
conserved process. The underlying cause of corpora amylacea formation and whether 
corpora amylacea is protective, pathological, or both is still under investigation.  
Similar cellular origins and morphological characteristics of corpora amylacea have 
been reported in the highly pathological glycogen-like aggregates called Lafora bodies 
(LBs), found in the childhood dementia Lafora disease (LD)96. LD is a neurodegenerative 
glycogen storage disorder, as well as a fatal myoclonic epilepsy and childhood dementia 
where seizures and cognitive symptoms emerge around the age of ten and patients 
typically die in their early to mid-twenties (OMIM: 254780). LBs are the result of a 
molecular deficit in glycogen metabolism and drive the severe clinical course by 
depriving the brain of access to its normal glycogen derived glucose cache118. LD is 
caused by autosomal recessive mutations in the epilepsy progressive myoclonus type 2a 
or 2b (Epm2a or Epm2b) gene46. The proteins encoded by Epm2a and Epm2b are the 
glucan phosphatase laforin, and the E3 ubiquitin ligase malin respectively, and each 
account for ~50% of cases46. Loss of function of either protein promotes the generation 
of the pathogenic, cytoplasmic, LBs throughout the body and most extensively in 
skeletal muscle, the heart, and the brain where they are neurotoxic20. Multiple 
laboratories utilizing different pre-clinical models have demonstrated that LBs drive 
neurodegeneration, synaptic dysfunction, susceptibility to seizure activity, and changes 
to long-term potentiation (the process required for memory storage)51,55,92,216,217,263. 
To explore the relationship between brain glycogen metabolism and aging, we 
utilized the power of metabolomics. Metabolomics has emerged as the latest ‘omics’ 
technology that is powerful in creating a comprehensive profile of global or systemic 
metabolite changes in biological systems at a specific time and condition264. Though the 
metabolomics field is new compared to other ‘omics’ fields like, genomics, 
transcriptomics, and proteomics, metabolomics has already shown significant potential 
for novel biomarker discovery and enhancing our understanding of underlying biological 
mechanisms264. Over the last decade, a few global-untargeted metabolomics studies of 
the aging murine brain have emerged145,146,265,266. As cross-sectional studies, they are 
limited in capturing the real age-related phenomenon. Therefore, there is a need to 
incorporate longitudinal measures in aging studies to fill in significant gaps in our 
knowledge about metabolite stability over time. This research is important for accurate 
identification of age-related biomarkers and biologically relevant metabolic targets.  
We designed a unique opportunity to study the effects of aberrant glycogen 
metabolism in aging and disease by performing a longitudinal metabolomics analysis on 
laforin KO (LKO) and WT mice. The LKO mouse is a monogenetic model of aggressive 
neurodegeneration, inflammation, decreased proteostasis, cellular stress response, and 
mitochondrial dysregulation caused by aberrant glycogen metabolism267. These 
pathologies are also well-established symptoms of aging and aging mice147. An 
important common feature of LD and the LKO mouse to aging is the accumulation of 




depend on glycogen synthase99. One differing characteristic is that LB accumulation is 
rapid in comparison to the slowly accumulating corpora amylacea99. To study the 
longitudinal metabolic relationship between age and glycogen utilization, we focused 
our investigations on central carbon metabolism, hypothesizing that aberrant glycogen 
metabolism in the LKO mouse causes changes to TCA cycle metabolism. We performed 
this study using LKO and WT C57BL/6J mice aged to be 1-, 3-, 6-, 9-, 12-, and 24-months. 
We examined the brain, skeletal muscle, and heart tissues and used an additional 
genotype, Epm2a-/+ (laforin heterozygotes), to represent healthy carriers of an LD locus.  
We report the TCA metabolite signature of the aging WT mouse and show relative 
differences in the metabolic signature in the LKO mouse that are met by the aging WT 
mouse in older age. Our data show that defective glycogen metabolism is correlated 
with changes to cellular respiration and that with normal aging, similar changes to 
cellular respiration are seen. Using a statistical biomarker detection tool, we confirm 
recent findings that glucosamine depletion is a likely driving feature of feature of LD and 
show a similar pattern in WT aging. Collectively, our findings begin to uncover the 
impact of glycogen metabolism on neural energetics and suggest an underlying 
metabolic signature common to aging and a mouse model of childhood dementia. These 
results have allowed us to form a new hypothesis that glucosamine is depleted by the 
























3.2.1 Mouse models and tissue preparation 
Laforin KO (LKO) mice have been described previously and were generated 
by removing the DSPD exon of Epm2a, producing an Epm2a-null mutant217. Male 
C57BL/6J WT, and LKO mice were bred to birth laforin heterozygotes. All mice were 
housed in a climate-controlled environment with a 14/10 h light/dark cycle (lights on at 
0600 h) with water and solid diet provided ad libitum throughout the study. The 
Institutional Animal Care and Use Committee (IACUC) at the University of Kentucky 
approved the animal procedures used in this study as specified by the 1985 revision of 
the Animal Welfare Act. WT, LKO, or laforin heterozygous mice were aged to be 1-, 3-, 6-
, 9-, 12-months. WT and LKO mice were also aged to be 24-months old. Mice were 
sacrificed by cervical dislocation and tissues were rapidly dissected. One half of the 
heart, half the quantity of dissected skeletal muscle, and one hemisphere of the brain 
was flash-frozen in liquid nitrogen and pulverized into powder (5 m particles) using a 
liquid nitrogen Freezer/Mill Cryogenic Grinder (SPEX SamplePrep) for glycogen 
quantification using gas-chromatography mass spectrometry analysis40. The remaining 
halves were formalin fixed and set aside for other experiments. 
 
3.2.2 Gas Chromatography-Mass Spectrometry (GC-MS) analysis  
3.2.2.1 Extraction 
20 mg of each pulverized tissue was extracted in 1mL of 50% methanol. 250 μL of 
the polar fraction was transferred to another eppi-tube and dried at 10-3 mBar using 
SpeedVac (Thermo), derivatized, and analyzed by GCMS. The remaining 750 μL was 
stored at -80oC for experimental replicates. Derivatization of dried polar samples began 
with the addition of 70 μL of 20 mg/mL methoxylamine hydrochloride in pyridine 
followed by a 30oC incubation for 1.5 hr. Then, 50 μL was transferred to a V-shaped 
amber glass chromatography vial and 80 μL of trimethylsilylating agent N-methyl-N-
trimethylsilyl-trifluoroacetamide (MSTFA) was added. This step was followed by a 30 
min incubation at 37oC. After cooling, the derivatized mixture was analyzed by a Triple 
Quadrupole GCMS (TQMS) (Agilent 7010). GCMS protocols were similar to those 
described previously except for a modified source temperature of 280°C209. Data 
processing was performed using MassHunter Unknowns Analysis (B.09.00, Agilent 
Technologies, Santa Clara, CA, USA) software matched to the FiehnLib metabolomics 
library. Mass spectra were translated to relative metabolite abundance using 
MassHunter Quantitative Analysis (TOF) (B08, Agilent Technologies, Santa Clara, CA, 





3.2.2.2 Quantification and statistical analysis 
Statistical analysis was carried out using GraphPad Prism9. All data are presented as 
means ± S.E. One-way ANOVA was used to compare each set of age groups or two 
genotypes from the same age group. Up to 5 biological replicates were used for each 
age group. Protein normalized metabolites were uploaded to MetaboAnalyst and run 






























Glucose derived from glycogen catabolism is used for cellular respiration in a tissue 
dependent manner. Thus, we hypothesized that LKO glycogen dysmetabolism promotes 
changes to the TCA cycle that are tissue dependent. To test this hypothesis, we 
compared the longitudinal TCA signatures of WT mice to LKO mice and laforin 
heterozygote mice, which represent a healthy model of a LD caring locus. All mice were 
aged 1-, 3-, 6-, 9-, and 12-months, and WT and LKO mice were aged an additional year 
to model old-age. These age intervals represent young (1-month), mature adult (3-6-
months), middle age (9-12-months), and old age (24-months) of the mouse lifespan. We 
focused our comparisons on brain, skeletal muscle, and heart, as LBs dominate these 
tissues in LKOs. Tissues were rapidly dissected, submerged into liquid nitrogen. Using a 
magnetic assisted tissue-grinding mill, tissues were ground into 5 μm while remaining 
submerged in liquid nitrogen. Free polar metabolites were removed by the addition of 
50% methanol. Each sample set containing 210 polar fractions each and up to 5 
biological replicates per age group was derivatized and analyzed by TQMS in a randomly 
generated order (Figure 3.1A-B). The 210 pellet fractions containing protein/DNA/RNA 
were analyzed simultaneously using GCMS and quantitated protein input was used to 
normalize the polar metabolite quantitation (Figure 3.1A, C). Each tissue sample set was 
analyzed by the TQMS or GCMS in a single sequence and metabolites were assigned 
blindly to decrease the possibility of instrument drift.  
 
3.3.1 TCA metabolite signatures of the aging WT and LKO brain 
To establish a TCA cycle signature of the aging brain, we first analyzed WT brain TCA 
cycle metabolites that included glucose, fructose, lactate, pyruvate, citrate, glutamate, 
succinate, fumarate, and malate. Consistent among each of these metabolites in WT 
mice is an increase in metabolite load observed after 1-month that decreases after 6-
months and increases again between 9- and 24-months (Figure 3.2). Therefore, the 
aging brain TCA cycle metabolite load appears dynamic, despite no observable 
difference between adult and old-aged mice (3- and 24-months) for glucose, fructose, 
lactate, citrate, glutamate, or malate. 
We then compared the LKO TCA cycle metabolite signatures to WT. The WT aging 
TCA cycle metabolite signature among 1-, 9-, 12-, and 24-month-olds is similar to the 
brain TCA cycle signature of LKO mice (Figure 3.3). However, mature adult LKO mice, 3-
6-months, showed a decreased metabolite load for glucose, fructose, lactate, citrate, 
glutamate, succinate, fumarate, and malate. The decrease is statistically significant in 6-
month-olds, where fructose is 3-fold lower than WT, lactate is 2-fold lower than WT, 
malate is 2-fold lower than WT, and glutamate is 2-fold lower than WT. Thus, for all 




was lower than WT at 3- and 6-months. These results indicate a glycogen metabolism 
dependent effect on TCA cycle metabolism in the brain. 
 
3.3.2 TCA metabolite signatures of the aging WT and LKO skeletal muscle and heart 
To establish the TCA signature of aging in skeletal muscle, we analyzed TCA cycle 
metabolites that included lactate, pyruvate, citrate, succinate, fumarate, and malate. No 
change over time is observed in lactate, pyruvate, or citrate levels with WT skeletal 
muscle aging (Figure 3.4). A non-significant age dependent trend in WT mice skeletal 
muscle can be seen in succinate, fumarate, and malate, where metabolite load 
decreases after 1-month, increases after 6-months and decreases again between 9- and 
24-months. These results are consistent with previous reports indicating that old age 
does not impose significant changes to skeletal muscle TCA cycle metabolite load146,266. 
Quantitation of TCA cycle intermediates in LKO skeletal muscle indicates no trend or 
significant differences between WT and LKO metabolite load at any age (Figure 3.5). 
Therefore, unlike in brain, accumulation of LBs in the skeletal muscle does not appear to 
impose changes to TCA cycle metabolite load.  
Lastly, we defined the TCA cycle signature of the aging heart. WT heart TCA 
metabolite spectra included glucose, lactate, pyruvate, citrate, glutamine, succinate, 
fumarate, and malate. Except for glucose, no difference is measured between heart TCA 
cycle metabolites of different age groups (Figure 3.6). These data support previous 
findings suggesting that unlike glucose, glycogen load in the heart is stable259. 
Quantitation of TCA cycle intermediates in LKO heart tissue indicates no trend or 
significant differences between WT and LKO metabolite load at any age (Figure 3.7). 
Thus, like skeletal muscle, accumulation of LBs in the heart does not appear to create 
changes to TCA cycle metabolite load. Our analysis of longitudinal WT and LKO TCA cycle 
metabolite loads support our hypothesis that the influence of aberrant glycogen 
metabolism on TCA cycle metabolite loads is tissue dependent. 
 
3.3.3  TCA metabolite signatures of laforin heterozygote aging mice  
To further determine the influence of LB accumulation on TCA cycle metabolite 
signatures, we analyzed these signatures in the laforin heterozygote mice. Using laforin 
heterozygote mice to model healthy carriers of an LD locus, we see that no trend or 
significant change exists between laforin heterozygotes and WT mice in the brain, 
skeletal muscle, or heart (Figures 3.8, 3.9, and 3.10). Thus, the aging trends between WT 
are supported by the parallel longitudinal TCA metabolite signatures of the laforin 
heterozygotes in all three tissues. These data further suggest that brain TCA metabolism 
defects seen in the LKO mice at 3- and 6-months can be corrected with one functional 





3.3.4 Statistical analysis of TCA metabolite profile variation in aging WT, LKO, and 
laforin heterozygotes and biomarker prediction of LD and aging   
To examine why TCA metabolite load differs between LKO and WT mice at 3- and 6-
months but not at older ages, we used principal component analysis (PCA) to describe 
metabolite variation at each age interval. Through PCA we see that the brain TCA 
metabolite profile of LKO mice increasingly separates from WT and laforin 
heterozygotes during 1-, 3- and 6-months of age (Figure 3.11A-C). At 9-months, the 
metabolite profile of all three genotypes begins to overlap and by 12-months little 
variance exists between any of the metabolite profiles until 24-months (Figure 3.11D-F). 
No separation occurs in skeletal muscle or heart except at 24-months (Figure 3.12A-F, 
and 3.13A-F). This suggests that natural aging results in similar metabolic pathway 
changes as LD. Therefore, we predicted that similar predicted biomarkers of aging and 
LD should be observed using a receiver operating characteristic (ROC) curve-based 
approach for biomarker prediction. As expected, we identified glucosamine and its 
derivative galactosamine as molecular drivers of the LKO metabolic signature in 6-, 9-, 
and 12-month-olds (Figure 3.14A-D). Using the same approach to identify biomarkers of 
aging, glucosamine also emerged as a metabolite that differentiates young mice from 
aging mice (Figure 3.14E-H). These results suggest that glucosamine may be a driver of 




















Cognitive decline and neurodegeneration, as well as metabolic changes related to 
mitochondrial activity, reactive oxidative stress, proteolytic stress, and hypoxia, are 
known phenotypes of normal aging and neurodegenerative diseases of aging3. Glycogen 
metabolism has been shown or proposed to underly all of these features, which are 
exasperated in the glycogen storage disease and childhood dementia LD267. To explore 
our hypothesis that aberrant glycogen metabolism impacts TCA cycle cellular respiration 
in LD, we first analyzed a longitudinal model of WT aging TCA cycle metabolism of brain, 
skeletal muscle, and heart tissues. We then compared the WT aging signature to LKO 
and laforin heterozygote aging to define the age dependent influence progressive LB 
accumulation on the TCA cycle.  
In the brain of WT mice, there is evidence of a consistent time-dependent trend in 
metabolite load that increases after 1-month, decreases after 6-months, and increases 
again between 9-and 24-months, such that no observable difference is seen between 
the metabolite load of 24- and 3-month-olds. These trends are supported by the laforin 
heterozygote mice, as no difference is observed between the laforin heterozygote and 
WT mice in any tissue. Our WT aging data is consistent with previously published cross-
sectional analyses on brain, skeletal muscle, and heart indicating that no TCA cycle 
dysregulation is seen in old-aged (24-month-old) mice compared to young adult mice (3-
month-olds)145,146,266. Consistent with our hypothesis, TCA cycle metabolite load is 
decreased in LKOs as adults (3-6-months) which correlates with the time frame in which 
significant emergence of LBs is seen. Further, by PCA the LKO brain TCA metabolite 
variation diverges from WT, increasing in separation from 1 to 6 months of age. 
Interestingly, the TCA metabolome divergence is not seen in older ages, instead the 
aged-matched WT TCA metabolome signature increasingly overlaps between 9 and 12-
months of age. One interpretation of this finding is that the aging TCA metabolome may 
be shifting with age such that it progressively resembles the TCA signature of LKO mice. 
A similar phenomenon was recently reported in an Alzheimer’s mouse model, wherein 
the WT brain metabolome begins to overlap with the AD metabolome at 24-months268. 
In support of this interpretation is our predicted biomarker analysis in which we found 
that a known biomarker of LD, glucosamine sequestration, is also predicted to be 
implicated in WT aging16.  
Sequestration of glucosamine in PGBs is a recently published LD phenomenon, which 
has been shown to create major downstream infarctions to cellular function largely 
involving glycosylation16. Thus, considering the well documented aging and glycogen 
dependent progressive accumulation of corpora amylacea, glucosamine sequestration 
may be a reasonable target of investigation for the downstream neural dysfunctions of 
aging19,138. Further, the lesser degree of glucosamine sequestration by corpora amylacea 
may explain the lesser degree of neurocognitive and molecular insults in aging 
compared to LD. The overlapping brain cellular respiration signatures between the WT 
an LKO mouse models in older age may be further explained by the fact that the LKO 




model lives until old-age, where LD patients typically die just as they reach adulthood in 
their early 20’s215,217–219. As no differences at any age are observed between the LKO 
and WT genotype in skeletal muscle or heart tissues, these collective findings contribute 
to a growing body of data characterizing unique roles for glycogen that are specific to 
the brain. These results suggest that LBs and their metabolic consequences are more 
detrimental to the CNS than in the skeletal muscle or heart where they also heavily 
accumulate, further supporting previous indications that LBs are neurotoxic78,222. 
The extent to which glycogen supports brain energy metabolism requires continued 
investigation. Glycogen is required for a healthy cognitive functioning and its 
accessibility is critical, as demonstrated in LD118. Glycogen-like aggregations and/or 
corpora amylacea hyper-accumulation have been documented in other 
neurodegenerative diseases e.g., Alzheimer’s disease, amyotrophic lateral sclerosis 
(ALS), temporal lobe epilepsy (TLE), Parkinson’s disease, diabetic neuropathy, peripheral 
neuropathy, and motor neuron disease19,138. As compromised energy metabolism is a 
known underlying factor of neurodegenerative disease and aging, glycogen 
dysmetabolism may be an underlying cause in not only LD and aging, but of many other 
neurodegenerative diseases not currently classified as glycogen storage disorders. A 
similar analysis of the influence of glycogen on these diseases may be modeled by the 
present study. Further, flux analysis on TCA cycle metabolites and glucosamine should 
be considered in aging, LD, and other dementias where aberrant glycogen-like 
























Figure 3.1 Metabolomics workflow.  
A) Polar metabolites from brain, skeletal muscle, and heart tissue were extracted and 
separated from the tissue pellet containing protein/DNA/RNA. B) (Top) Polar 
metabolites from each tissue were derivatized and analyzed by TQMS. C) (Bottom) 











Figure 3.2 WT brain TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 









Figure 3.3 WT versus LKO brain TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 

















Figure 3.4 WT skeletal muscle TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 







Figure 3.5 WT versus LKO skeletal muscle TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 






Figure 3.6 WT heart TCA metabolites 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 








Figure 3.7 WT versus LKO heart TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 














Figure 3.8 WT versus laforin heterozygote brain TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 












Figure 3.9 WT versus laforin heterozygote skeletal muscle TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 






Figure 3.10 WT versus laforin heterozygote heart TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 













Figure 3.11 PCA plots of brain TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 
S.E. In each ager group, up to 5 biological replicates were used. Protein normalized 
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Figure 3.12 PCA plots of skeletal muscle TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 
S.E. In each ager group, up to 5 biological replicates were used. Protein normalized 
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Figure 3.13 PCA plots of heart TCA metabolites. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 
S.E. In each ager group, up to 5 biological replicates were used. Protein normalized 
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Figure 3.14 Biomarkers of LD and aging. 
Mass spectra were translated to relative metabolite abundance normalized to protein 
input. Statistical analysis using one-way ANOVA comparing each set of age groups or 
genotypes was performed using GraphPad Prism9. All data are presented as means ± 
S.E. In each ager group, up to 5 biological replicates were used. Protein normalized 
metabolites were uploaded to MetaboAnalyst and run through receiver operating 






 Generation and characterization of a laforin nanobody inhibitor 
4.1 Introduction 
 
Glycogen is the storage form of glucose and a highly important substrate for cellular 
metabolism271. Nearly all tissues metabolize glycogen and recent work has focused on 
the importance of glycogen metabolism in the brain14. Characterization of the enzymes 
and mechanisms of glycogen metabolism began over 70 years ago and include: 
synthesis by glycogen synthase, branching via glycogen branching enzyme, hydrolysis by 
glycogen phosphorylase, and debranching via glycogen debranching enzyme13. Over the 
last 20 years, a previously unknown protein called laforin has emerged as an important 
contributor to glycogen metabolism homeostasis.  
Multiple labs demonstrated that laforin is a glycogen phosphatase and mutations in 
the gene encoding laforin cause the formation of aberrant glycogen-like aggregates 
called Lafora bodies (LBs)86,89,272. LBs are cytoplasmic, water-insoluble aggregates more 
similar to plant starch than human glycogen20,103,104,273. The LBs form in cells from nearly 
all tissues and are the pathological agent driving neurodegeneration and death in Lafora 
disease (LD) patients25–28. LD is autosomal recessive and classified as both a progressive 
myoclonus epilepsy and glycogen storage disease. The direct relationship between 
mutated laforin, LB formation, and LB neurotoxicity highlights the importance of 
glycogen metabolism in the brain. While laforin removes phosphate from glycogen, how 
phosphate impacts normal glycogen homeostasis or how hyper-phosphorylation is 
detrimental to glycogen homeostasis and LB formation remains under investigation.  
Based on sequence and structural conservation, laforin is classified in the protein 
tyrosine phosphatase superfamily and the dual specificity phosphatase clade274. Laforin 
is the only known human glycogen phosphatase and is comprised of a dual-specificity 
phosphatase (DSP) domain and a carbohydrate binding module (CBM). Like all DSPs, 
laforin contains a protein-tyrosine phosphatase catalytic loop that includes a CX5R motif 
(CNAGVGR, residues 266–272) at the base of the active site115. The architecture and 
depth of this active site allow laforin to dephosphorylate glycogen274–276. The laforin 
CBM belongs to CBM family 20 and allows laforin to bind glycogen as well as other 
complex carbohydrates in vitro and in vivo, like LBs, amylopectin, and 
maltodextrins20,222,276. Key structural aspects of laforin that promote glucan-specific 
phosphatase activity are: closely integrated CBM-DSP domains, an anti-parallel 
dimerization, and a signature DSP sequence within the active site channel274. 
In addition to being a glycogen phosphatase, laforin interacts with several proteins 
involved in glycogen metabolism, including the E3 ubiquitin ligase malin84. 
Approximately 50% of LD patients have mutations in the gene encoding malin and ~50% 
have mutations in the gene encoding laforin. Malin polyubiquitinates a number of 
proteins involved in glycogen metabolism, including both laforin and glycogen 
phosphorylase84,114,277. The consequences of malin-directed ubiquitination are still being 




LBs and display neurodegeneration88,89. However, the relationship between 
phosphorylation and LD progression remains an unresolved and critical issue78,107,278.  
Recombinant antigen-specific, single-domain antibodies, often referred to as 
nanobodies (Nb), are increasingly used for modulating protein properties for the 
purpose of elucidating function279. While canonical antibodies are comprised of two 
heavy chains and two light chains, nanobodies are derived from the antigen binding 
domain of heavy-chain antibodies, produced in camelids and select other organisms. 
Thus, nanobodies are monomers with a dedicated variable domain, also referred to as 
VHH, and are ten times smaller than a canonical IgG, i.e. ~15 kDa. Their small size 
promotes their high propensity for binding unique structural features of proteins, 
otherwise unreachable by conventional immunoglobulins and capable of manipulating 
protein conformation linked to function279–281. Nanobodies contain three 
complementary determining regions (CDRs) that are primary determinants of specific 
antigen binding. Similar affinities between VHHs and conventional antibodies are 
generally attributed to elongated CDR3 loops in VHH domains, which provide a paratope 
formed by a single entity282. 
In this study, we present the characterization of six laforin nanobodies, consisting of 
five unique CDR3 regions. Two llamas were immunized with recombinant human laforin, 
74 potential VHH anti-laforin candidates were screened, and six stably binding anti-
laforin nanobodies were characterized. Epitope mapping of the six laforin nanobodies 
established three general epitopes, one that spans both the CBM and DSP on the 
opposite side of the DSP active site, one that lies on the CBM, partially covering regions 
that bind glycogen, and one that covers the DSP active site. Secondary structure epitope 
mapping established that nanobody Nb72 binds the PTP-loop of the laforin DSP domain. 
Utilizing three in vitro assays, we demonstrate that Nb72 inhibits the phosphatase 
activity of laforin. These laforin nanobodies are a novel set of molecular tools for 

















4.2.1 VHH library generation 
4.2.1.1 Purification of Laforin 
H. sapiens (Hs) Laforin residues 1-328 was expressed from pET28b (Novagen) as an 
N-terminal His6 tagged protein, as previously described283. Briefly, laforin was expressed 
in BL21 (DE3) (Novagen) E. coli cells grown in 2xYT media at 37oC until OD600 = 0.6, 
culture flasks were placed on ice for 20 min, induced with 1 mM (final) isopropyl thio-β -
D-galactopyranoside (IPTG), grown for an additional 14h at 20oC, and harvested by 
centrifugation. Cells were resuspended and lysed in buffer A (20 mM Tris-HCl, 100 mM 
NaCl, 10% glycerol, 2 mM DTT, pH 7.5), centrifuged, and the proteins were purified 
using a Profinia immobilized metal affinity chromatography (IMAC) column with Ni2+ 
beads (Bio-Rad) and a Profinia protein purification system (Bio-Rad) using wash (buffer 
A) and elution buffer (300mM imidazole, 20 mM Tris-HCl, 100 mM NaCl, 10% glycerol, 2 
mM DTT, pH 7.5). The desalted elution fraction was further purified using fast protein 
liquid chromatography (FPLC) with a HiLoad 16/60 Superdex 200 size exclusion column 
(GE Healthcare). The buffer used for laforin purification for the small-scale pulldowns 
described in methods 2.3.2 was (50 mM HEPES, 100 mM NaCl, 10% glycerol, 2 mM DTT, 
pH 7.5. For all other experiments, laforin was purified in 20 mM Tris-HCl, 100 mM NaCl, 
10% glycerol, 2 mM DTT, pH 7.5. 
 
4.2.1.2 Immunizations 
Inoculation, construction of the VHH libraries, panning, and cloning was performed 
by the VIB Nanobody Core (Vrije Universiteit Brussel, Brussels). Two llamas were 
subcutaneously injected on days 0, 7, 14, 21, 28 and 35 with 250 g/animal of 
recombinant laforin emulsified with Gerbu adjuvant P. On day 40, anticoagulated blood 
was collected for lymphocyte preparation.  
 
4.2.1.3 Construction of the VHH libraries 
A VHH library was constructed from each llama to screen for the presence of laforin 
specific nanobodies. First strand cDNA synthesis was achieved using an oligo(dT) primer 
and total RNA from peripheral blood lymphocytes as a template. The VHH encoding 
cDNA sequences were amplified by PCR, digested with PstI and NotI, and cloned into the 





4.2.2 Isolation of laforin specific nanobodies 
Each library was panned individually for three rounds on solid-phase coated antigen 
(200 µg/mL in 100 mM NaHCO3, pH 9.3). After each round of panning, the enrichment 
for laforin-specific phages was assessed by comparing the number of phagemid particles 
eluted from antigen-coated wells with the number of phagemid particles eluted from 
negative control (uncoated blocked) wells. In total, 950 colonies (475 colonies for each 
library: 95 from panning round one, 285 from round two, and 95 from round three) 
were randomly selected and analyzed by ELISA for the presence of laforin specific 
nanobodies in their periplasmic extracts. The antigen used for panning and ELISA 
screening was the same as the one used for immunization, using uncoated blocked wells 
as negative control. Out of these 950 colonies, 138 colonies scored positive in this assay. 
Based on sequence data of the positive colonies, 74 different full-length nanobody 
candidates were distinguished based on complementary determining regions.  
 
4.2.3 Sequence verification, alignment, and evolutionary analysis 
Nanobody sequences were verified using the primer: 5’ TTA TGC TTC CGG CTC GTA 
TG 3’ and the six direct laforin binding nanobody plasmids will be deposited to 
https://www.addgene.org/. All sequence alignments were performed using Clustal-
Omega available on the European Bioinformatics Institute’s 
server(http://www.ebi.ac.uk/.)The evolutionary tree was calculated from the alignment 
using neighbor-joining clustering implemented in the Clustal-Omega package284. The 
guide tree was displayed with the program iTOL (http://itol.embl.de/)285. 
 
4.2.4 Screening for VHH expression 
74 potential VHH candidates were transformed into BL21 (DE3) E. coli cells 
(MilliporeSigma) and expression levels were analyzed by Western analysis. Nanobodies 
were expressed from pMECS as a C-terminal HA and His6 fusion in 10 mL cultures grown 
in 2xYT until OD600 = 0.6. 100 µL of each culture was aliquoted, centrifuged, air dried, 
and stored at -20oC while protein expression was induced in the remaining cultures 
using 1 mM IPTG (final concentration). Induced cultures grew for 3.5h, 80 µL of the 
induced cultures were pelleted, air dried and stored at -20oC. The 100 µL uninduced and 
80 µL induced culture pellets were lysed with 75 µL of 50 mM TRIS, 8M urea by 
vortexing. Total proteins from the bacteria culture lysate were resolved by stain-free gel 
SDS-PAGE (Bio-Rad). Nanobody expression was visualized by Western analysis using an 
anti-6xHis antibody (1:1000) (NeuroMab #75-169) and goat anti-mouse secondary 





4.2.5 Small scale pulldowns 
4.2.5.1 Small scale nanobody purification 
Nanobodies screened for expression were purified using the remaining 9.82 mL of 
induced culture, which was pelleted and frozen at -20oC. Nanobodies were purified from 
the E. coli pellets with Ni-NTA resin. E. coli cell lysates were centrifuged to separate 
soluble protein which was incubated with Ni-NTA agarose beads for 1 h at 4oC in 1 mL 
bind buffer (20 mM Tris-HCL, 100 mM NaCl, 15 mM Imidazole, pH 8.0). The samples 
were washed three times in bind buffer and eluted in 100 µL of 300 mM imidazole, 100 
mM NaCl, pH 8.0 and used for small scale pulldowns. 
 
4.2.5.2 Antigen affinity pulldown 
Primary screening for nanobody binding was achieved by a small-scale pulldown 
method in which Affi-gel 10 affinity resin (Bio-Rad) was bound to laforin and 
subsequently to each purified VHH clone286. Expression and purification of laforin was 
performed as described above in 50 mM HEPES, 100 mM NaCl, 10% glycerol, 2 mM DTT, 
pH 7.5. 50 µL Affi-gel (100 µL slurry) per pulldown was washed and resuspended in cold 
PBS per manufacturer’s directions. The washed Affi-gel was saturated with laforin in 50 
mM HEPES, 100 mM NaCl, 10% glycerol, 2 mM DTT, (final volume 500 µL) and incubated 
with rocking for 1 h at 4o C. The laforin bound Affi-gel resin was spun down at 300 rpm 
for 2 min and washed with cold PBS two times. Affi-gel alone was used as a control. 
Then, the laforin bound or unbound Affi-gel was blocked with cold 1X TBS for 1 h at 4oC. 
The samples were spun down, supernatant was removed, and 75 µL (~4-12 µg) of small 
batch Ni2+ purified nanobodies were added. Pulldowns were washed three times with 
1X PBS, and the supernatant was removed. Bound proteins were denatured in 
Laemmli’s buffer, and ~12 µL of each sample was loaded per well of a stain free SDS-
PAGE gel and imaged.  
 
4.2.6 Nanobody purification 
Larger concentrations of purified nanobodies were achieved by scaling up methods 
described in 2.2 and 2.3.1. Nanobodies were expressed in BL21 (DE3) E. coli cells grown 
in 2xYT at 37oC to OD600 = 0.9. 15 mL of pre-culture was used per L culture. Cultures 
were induced with 1 mM IPTG (final) and incubated for ~16-18 h at 25oC after which, 
pellets were harvested by centrifugation. Nanobodies were purified from the E. coli 
pellets with Ni-NTA resin. E. coli cell lysates were centrifuged to separate soluble protein 
which was incubated with Ni-NTA agarose beads for 1 h at 4oC in 30 mL bind buffer (20 
mM Tris-HCL, 100 mM NaCl, 15 mM Imidazole, pH 8.0). The samples were washed three 




samples were separated from the Ni-NTA beads by filtering through a 25 mM syringe 
filter and then buffer exchanged with 20 mM Tris-Hcl pH 7.5, 100 mM NaCl using FPLC 
with a HiLoad 16/60 Superdex 75 column (GE Healthcare).   
 
4.2.7 Size exclusion analysis of VHH-laforin complexes 
Laforin and VHH were combined in molar ratio (1:1.1) and resolved by size 
exclusion chromatography (SEC) using a HiLoad 10/300 Superdex 200 size exclusion 
column and 100 mM NaCl, 20 mM Tris, 10% glycerol, 0.35 mM β-mercaptoethanol 
(BME), pH 7.5. WT laforin alone was utilized as a control. Fractions were collected in 500 
µL volumes and visualized by loading 20 µL of each fraction onto a stain-free gel SDS-
PAGE (Bio-Rad) and imaged. 
 
4.2.8 Hydrogen Deuterium Exchange Mass Spectrometry (HDX) 
HDX experiments were performed as previously described276,287. The optimal 
peptide coverage map of laforin was obtained using a quench solution containing 0.08 
M GuHCl, 0.1 M Glycine, 16.6% glycerol, pH 2.4. To initiate HDX experiments, 3 µL of 
stock solution (laforin or laforin-nanobody complex at 1 mg/mL) was mixed with 9 µL of 
D2O buffer (8.3 mM Tris, 50 mM NaCl, pDREAD 7.2) and incubated at 0oC for 10, 100, 1000 
and 10,000 sec. The exchange reaction was quenched by adding 18 µL of the above 
quench solution, and the quenched samples were flash frozen with dry ice. All frozen 
samples, including un-deuterated and equilibrium-deuterated control samples, were 
passed over an immobilized pepsin column (16 µL) at a flow rate of 25 µL/min and 
digested peptides were collected on a C18 trap column (Optimize Tech, Opti-trap, 0.2x2 
mm) for desalting. The peptide separation was performed on a C18 reverse phase 
column (Agilent, Poroshell 120, 0.3x35 mm, 2.7 µL) with a linear gradient of 8-48% B 
over 30 min (A: 0.05% TFA in H2O; B: 80% acetonitrile, 0.01% TFA, and 20% (H2O)). Mass 
spectrometry (MS) analysis was performed on the Orbitrap Elite mass spectrometer 
(Thermo Fisher Sci), which was adjusted for HDX experiments288. The resolution of the 
instrument was set at 120,000 at m/z 400. Proteome Discoverer software (v1.3, Thermo 
Scientific) was used to identify the sequence of the digested peptide ions from their 
MS/MS data. HDXaminer (Sierra Analytics, Modesto, CA) was utilized to confirm the 
peptide identification and calculate the centroids of isotopic envelopes of all the 
peptides. The level of deuterium incorporation of each peptide was calculated by 
applying back-exchange correction289. The ribbon maps were generated from 





4.2.9 Phosphatase assays 
4.2.9.1 Para-Nitrophenyl Phosphate (pNPP) assay 
Generic phosphatase activity assays were performed using para-Nitrophenyl 
Phosphate (pNPP) as previously described86,290. Assays were performed using 96 well 
plates in 50 µL reactions containing 1X phosphatase buffer (0.1 M sodium acetate, 0.05 
M Bis-Tris, 0.05 M Tris-HCl, pH 5.0), 2 mM dithiothreitol (DTT), and 50 mM pNPP. To 
maintain reactions in the linear phase, 250, 500, or 1000 ng of laforin pre-bound to an 
equal molar quantity of nanobody were added to the reaction in triplicates and 
incubated in a 37˚C water bath for 10 minutes. The reaction was terminated by the 
addition of 200 µL of 0.25 M NaOH and absorbance was measured at 410 nm. 
 
4.2.9.2 Glucan dephosphorylation assays 
Glucan phosphatase activity assays were performed as previously described86,290. 
Assays were performed using 96 well plates in 100 µL reactions containing 1X 
phosphatase buffer (100 mM sodium acetate, 50 mM bis-Tris, 50 mM Tris-HCl, pH 7.0) 
and 2 mM DTT, and 10mg/mL rabbit skeletal muscle glycogen or 1 mg/mL potato 
amylopectin (MilliporeSigma). To maintain enzymatic activity in the linear phase, every 
10 seconds, 250, 500, or 1000 ng of laforin pre-bound to an equal molar quantity of 
nanobody were added to the reaction mixture in quadruplicates and incubated for 30 
min at RT. The reaction was stopped by the addition of 25 µL of malachite gold reagent 
mix added every 10 sec. Once each well was given the malachite gold reagent mix, 
stabilizer was added to each well in intervals of 10 seconds. Absorbance was measured 
at 635 nm.  
 
4.2.9.3 Statistical analysis 
Two-way ANOVA was performed using GraphPad Prism version 9.0.0 for Mac, 











4.3.1 Anti-laforin nanobody primary screen 
Two llamas were immunized with purified recombinant human laforin. Lymphocytes 
were isolated, and the VHH coding sequences were cloned into a phagemid vector. After 
three rounds of panning and ELISA screens using recombinant laforin protein, a total of 
74 clones scored positive and were sequenced, revealing 37 different CDR3 groups 
(Figure 4.6). A sequence similarity tree reveals the presence of two nanobody groups in 
which 35 clones are found in one and 39 are found in the other (Figure 4.1). All 74 
clones were transformed into BL21 E. coli cells and VHH expression was determined by 
western analysis using an anti-HIS antibody. Approximately 50% of the clones were 
eliminated due to lack of expression in BL21 cells (data not shown). The expressing 
clones were each purified on a small scale and screened for their capacity to bind laforin 
by a pulldown method using affinity resin. 
To identify nanobodies that form a stable complex with laforin, the ability of purified 
nanobodies to be precipitated by laforin affinity resin was assessed. Laforin coupled 
resin was incubated individually with each of the purified VHH clones, the resin was 
washed, and bound proteins were eluted and analyzed by SDS-PAGE. This primary 
screen identified six clones as having direct antigen binding (Figure 4.2A).  
The six identified anti-laforin nanobodies are: Nb40, Nb41, Nb50, Nb57, Nb72, and 
Nb73. Based on phylogenetic analysis and sequence alignment (Figures 4.1 and Figure 
4.2B), the six identified nanobodies that bind laforin exhibit sequence diversity and 
contain five different CDR3 regions. Complete DNA sequences of the six laforin 
nanobodies are provided in Table 4.1. 
 
4.3.2 Size-exclusion analysis of anti-laforin nanobodies complexed to laforin 
Size-exclusion chromatography (SEC) was utilized to detect and characterize the 
laforin-nanobody complexes. Each nanobody was incubated with laforin in ~10% molar 
excess, samples were subjected to SEC, fractions were collected, and analyzed by SDS-
PAGE (Figure 4.3). The laforin-nanobody complexes eluted between 12.11-14.51 mL, 
laforin alone eluted at 15.40 mL, and the nanobodies alone eluted between 18.08-19.53 
mL. All six laforin-nanobody complexes eluted prior to laforin or the nanobody alone, 
indicating a higher molecular weight and supporting the results of the primary screen. 
Similarly, SDS-PAGE analyses of the fractions demonstrate co-elution of the laforin-
nanobody complexes. Nb40 and Nb73 complexed with laforin eluted earlier than others 
(Figure 4.3). These supershifted complexes may indicate an increase in nanobody to 
laforin stoichiometry. Alternatively, Nb40 and Nb73 may interfere with the laforin CBM 
binding to the carbohydrate-based resin. Laforin CBM mutations have been shown to 





4.3.3 Nanobody epitope mapping via Hydrogen-Deuterium Exchange Mass 
Spectrometry (HDX) 
 Epitope mapping can be accomplished using hydrogen-deuterium exchange (HDX) 
mass spectrometry. HDX quantifies protein surfaces that are solvent accessible. When a 
nanobody binds a protein, the surface of the protein becomes less solvent accessible. 
This decrease in solvent accessibility can be quantified by HDX.  
Each laforin-nanobody complex and laforin alone were incubated in deuterated 
buffer for 10, 100, 1,000, and 10,000 seconds (Figures 4.4 and 4.7). A decrease in laforin 
deuteration (≥15% decrease in deuteration compared to WT) emerged with Nb40 and 
Nb41 (Figures 4.4A and 4.7A), Nb50 and Nb57 (Figures 4.4B and 4.7B), and Nb72 and 
Nb73 (Figures 4.4C and 4.7C). Nb40 and Nb41 differ by only one amino acid within 
CDR2, with an alanine in Nb40 replaced with a valine in Nb41. Given this high degree of 
sequence similarity, their shared epitope was expected. Their epitope partially maps 
across the CBM (residues 60-66, 120-124, and 126-129) with the majority spanning 
across the recognition domain of the DSP (residues 139-145, 148-161, 163-169, and 171-
186). The epitope of Nb41 extends further on the DSP (residues 193-197). Sequence 
homology between Nb40 and Nb41 is 99.2% (Figure 4.8). Nb50 and Nb57 share a similar 
epitope that encompasses most of the CBM (residues 30-33, 35-41, 43-52, 60-66, 120-
124) and partially across the DSP (residues 287-291). Nb57 extends further on the CBM 
(residues 43-56, 58-66, and 126-129). Sequence homology between Nb50 and Nb57 is 
66.2% (Figure 4.8). Nb50 and Nb57 share a partial CBM epitope with Nb40 and Nb41. 
The DSP epitope of Nb40 and Nb41 partially overlaps with Nb72 and Nb73. The epitopes 
of Nb72 and Nb73 are mapped solely on the DSP and overlap with the recognition 
domain (residues 139-145, 148-155, 193-197, 236-242). Importantly, Nb72 includes the 
PTP-loop (residues 267-275). Intriguingly, the sequence homology between Nb72 and 
Nb73 is 70.6% and no sequence homology exists between their CDR3 regions (Figure 
4.8). 
These results indicate that three general binding regions exist among the six laforin 
nanobodies. Nb40 and Nb41 span both the CBM and DSP on the opposite side of the 
DSP active site (Figures 4.4D and 4.7D). Nb50 and Nb57 span the CBM, partially covering 
regions that bind glycogen (Figures 4.4E and 4.7E). Nb72 and Nb73 bind a region near 
the DSP active site and Nb72, but not Nb73, overlaps with the PTP-loop (Figures 4.4F 
and 4.7F).  
 
4.3.4 Nb72 inhibits the general phosphatase activity of laforin 
Given the binding site of Nb72, we predicted that this nanobody would decrease or 
inhibit the phosphatase activity of laforin. To assess laforin’s general phosphatase 
activity, we utilized the phosphatase substrate para-nitrophenyl phosphate (pNPP). 




(pNP) that results in a colorimetric change that can be quantified at OD410. Three 
concentrations of recombinant laforin were incubated with a respective and ~1:1 molar 
ratio of nanobody Nb72 or Nb23, a nanobody that did not co-precipitate with laforin 
(Figure 4.2A) As controls, recombinant laforin was also pre-incubated in buffer lacking a 
nanobody, and nanobodies were tested in the absence of laforin. The pNPP substrate 
was added to each combination using previously defined optimal conditions, reactions 
were quenched with sodium hydroxide, and dephosphorylation levels were quantified 
at OD410. Laforin incubated with Nb23 yielded similar levels of pNPP dephosphorylation 
as laforin alone, indicating that Nb23 did not inhibit laforin phosphatase activity (Figure 
4.5A). Conversely, laforin incubated with Nb72 displayed a dramatic 85% reduction in 
pNPP phosphatase activity (Figure 4.5A).  
 
4.3.5 Nb72 inhibits the glycogen phosphatase activity of laforin 
The small molecule pNPP is a readout for general phosphatase activity. However, 
pNPP can integrate into the DSP active site independent of the laforin CBM to be 
converted into pNP. In cells, laforin binds glycogen via its CBM and engages the 
phospho-glucose substrate with its DSP active site to dephosphorylate the substrate. 
Therefore, we sought to determine if Nb72 binding to laforin inhibits its specific glucan 
phosphatase activity.  
Glycogen dephosphorylation can be assessed by quantifying phosphate release using 
a malachite gold colorimetric assay. Three concentrations of recombinant laforin were 
incubated with nanobody Nb72 or the negative control nanobody Nb23 in a respective 
and ~1:1 molar ratio. As a control, recombinant laforin was also pre-incubated in buffer 
lacking a nanobody. Then, rabbit skeletal muscle glycogen was added as the substrate 
using previously defined optimal conditions. Reactions were incubated at 20˚ C for 30 
min and then quenched with the phosphatase inhibitor N-ethylmaleimide. Malachite 
gold solutions were added, and dephosphorylation levels were quantified at OD635. 
Laforin incubated with Nb72 yielded a dramatic 95% reduction in laforin’s glycogen 
phosphatase activity while Nb23 did not reduce the activity (Figure 4.5B). No other 
nanobody showed a robust inhibitory effect on laforin’s phosphatase activity towards 
amylopectin (Figure 4.9).  
Laforin’s endogenous substrate is glycogen86,272,292. However, laforin has a higher 
binding affinity for LBs222,293. While glycogen is water-soluble, the glucose chains of LBs 
are longer and predicted to form helical structures making LBs more water-
insoluble20,104,273. Plant amylopectin is also a water-insoluble glucan that has covalently 
attached phosphate and has been utilized as a LB proxy20,86,292,294. Therefore, we 
performed a similar assay as above utilizing malachite gold, laforin, and the nanobodies 
with amylopectin as the substrate. Overall, laforin released ~10-fold more phosphate 
from amylopectin than glycogen, which is as expected given the higher level of 
phosphate in amylopectin105,295. Nb72 was observed to significantly inhibit laforin 




strengthen a growing body of results suggesting that laforin has a higher degree of 































The glycogen phosphatase laforin is critical for brain glycogen metabolism. 
Mutations in the laforin gene promote the formation of cytoplasmic, insoluble glycogen-
like aggregates that are the pathological agent of LD46,49,118,272 . The mechanism by 
which laforin influences the solubility of glycogen is still unknown, and progress in this 
discovery could be accelerated with additional tools. The current study showcases the 
generation of six laforin nanobodies, mapping of the nanobody epitopes by HDX, and 
three in vitro assays demonstrating that nanobody Nb72 inhibits laforin’s phosphatase 
activity.  
HDX nanobody epitope mapping revealed that one nanobody, Nb72, decreased 
deuterium exchange within the laforin PTP-loop, implying that Nb72 could inhibit the 
laforin phosphatase activity. Three in vitro phosphatase activity assays established that 
binding Nb72 to laforin markedly reduces the phosphatase activity of laforin. The first 
assay employed a non-specific substrate, para-nitrophenyl phosphate (pNPP), to assess 
the inhibitory activity of Nb72. The pNPP assay quantifies laforin phosphatase activity 
independent of glycogen binding. Nb72 decreased laforin phosphatase activity by 85%. 
Using more biologically relevant substrates, we discovered that Nb72 diminishes laforin 
phosphatase activity against skeletal muscle glycogen by 95%, and amylopectin by 55%. 
Thus, Nb72 is more effective at inhibiting laforin’s phosphatase activity directed towards 
glycogen. These data are consistent with published reports demonstrating that laforin 
preferentially binds more water-insoluble substrates like amylopectin and LBs222,296. The 
reason for this preference has been proposed to be that the CBM domain has an 
enhanced contribution to phosphatase activity as the carbohydrate increases in 
complexity and/or insolubility294. Laforin is dramatically stabilized in the presence of a 
longer chain length oligosaccharide compared to a shorter chain length oligosaccharide. 
Further, the presence of the longer chain length oligosaccharide promotes cooperativity 
in binding between the dimers of laforin that is not observed with a shorter chain length 
sugar substrate276. These data are further supported by our findings that more 
phosphate is released from amylopectin than glycogen in the presence of laforin. The 
~10-fold difference in phosphate release can be accounted for by the ~10-fold 
difference in total phosphate contained in amylopectin versus glycogen. Glycogen 
contains 1 phosphate per 1,000-10,000 glucose residues and amylopectin contains 1 
phosphate per ~300 glucose residues89,106,258,294,297,298. 
Nanobodies are a rapidly growing technology that are being utilized in novel ways to 
refine a wide variety of traditional techniques such as crystallization chaperoning, 
affinity purification, immunoprecipitation, super-resolution microscopy, confocal 
microscopy, flow cytometry, cell delivery, radiolabeling, and modulating protein 
function and interactions in cells299,300. An immediate opportunity to utilize the laforin 
nanobodies is with respect to modulating laforin’s phosphatase activity, glycogen 
binding, and interactions. Nb72 clearly inhibits the glycogen phosphatase activity of 




catalytic activity (Figure 4.9) by altering carbohydrate binding in cell culture. These 
nanobodies could be expressed in cells as intrabodies to probe the relationship between 
glycogen phosphate with glycogen metabolism, central carbon metabolism, and 
metabolic signaling events without imposing structural mutations to laforin.  
Another opportunity to use the laforin nanobodies is protein crystallography. The 
only full-length laforin structure to date is the catalytically inactive human Laforin-
C266S276. While this structure has provided key insights, as described above, a structure 
of the wildtype and patient mutations is needed to fully define the catalytic cycle and 
resolve why laforin mutations cause LD. This work has been hampered due to the 
extensive conformational dynamics of laforin. Crystallizing laforin with the nanobodies 
could permit capturing additional conformational states299 that are important for its 
biological function. Additional panning of the nanobody library using either laforin 
mutants with distinct conformational states or laforin bound to substrate or partner 
protein could allow identification of additional unique conformation-specific 
nanobodies. 
Multiple groups have demonstrated that laforin and malin physically interact and 
form a complex301. Additionally, the in vivo function of laforin likely includes a 
sophisticated scaffolding and/or signaling role because multiple studies have found that 
laforin interacts with several glycogen metabolism related proteins86,116,117. In fact, many 
laforin protein interactions are both involved in glycogen metabolism and are putative 
substrates of malin, including the protein phosphatase 1 regulatory subunits GL, R5 and 
R6/PTG; glycogen synthase, the pyruvate kinase isoforms PKM1 and PKM2; and AMP-
activated protein kinase  subunits49,111,301,302. Due to these interactions, the laforin-
malin complex has been suggested to participate in protein degradation, oxidative 
stress, and the unfolded protein response117. Therefore, LD pathology could arise from 
mutations that affect the specific activity of laforin and/or malin, and also from 
mutations that impair the interaction of both proteins to form a complex.  
Moreover, laforin has potentially pleiotropic roles associated with dynamic cellular 
localization changes303,304. Laforin has been shown to translocate to the nucleus under 
nutrient or heat stress and can return to the cytoplasm once the stress conditions 
cease50. Interestingly, malin has recently been shown to ubiquitinate glycogen 
phosphorylase and translocate it to the nucleus thereby promoting nuclear glycogen 
catabolism. The released glucose 1-phosphate is utilized for histone acetylation to 
regulate transcriptional profiles114. Therefore, the nuclear localization of malin and, 
under certain conditions, of laforin suggests a regulatory function of both proteins in the 
nucleus. Furthermore, a natural mutation in laforin causes it to lose ER localization303. 
Fluorescent nanobody fusions, sometimes called chromobodies, are useful markers to 
track and visualize dynamic changes without disturbing other cellular functions279,305–307. 
To date, most assays detecting laforin localization have probed for a tagged version of 
laforin that is often over-expressed50. Anti-laforin nanobodies as intrabodies and/or 
chromobodies could be useful tools for defining both laforin dynamic localization and 
physical interactions. Overall, these nanobodies represent an important set of tools that 
will open new avenues to illuminate the mechanism of laforin’s role in normal glycogen 







Figure 4.1 Anti-laforin nanobody guide tree. 
A binary tree was generated from a sequence alignment and subsequent tree 





Figure 4.2 Direct antigen binding nanobodies and comparison of their sequences. 
(A) Primary screening for nanobody binding was achieved by incubating laforin with 
affinity resin, washing the resin, blocking the resin with TBS, incubating the laforin 
bound affinity resin with a nanobody, and washing the resin before the laforin-
nanobody complex was eluted. Free (wash) and bead bound laforin and/or nanobody 
was loaded onto an SDS-PAGE stain-free gel and imaged (top). As a control, affinity resin 
without bound laforin was blocked and then incubated with nanobody (bottom). (B) 
Sequence alignment of nanobodies in A. Sequence homology is 55.9% identical. 
Complementary determining regions are highlighted in red and framework regions are 






Figure 4.3 Size-exclusion (SEC) analysis of anti-laforin nanobodies complexed to 
laforin. 
For each SEC analysis of the laforin-nanobody complex, the respective fractions are 
visualized by an SDS-PAGE stain-free gel shown to the right. A-F) SEC analysis of the 
laforin dimer alone is shown in black (15.4mL). A) Nb40 (18.45mL) complexed to laforin 
in light teal (12.65mL). B) Nb41 (18.58mL) complexed to laforin in dark teal 
(14.51mL).  C) Nb50 (18.08mL) complexed to laforin in light orange (14.28mL). D) Nb57 
(18.19mL) complexed to laforin in dark orange (14.3mL). E) Nb72 (18.89mL) complexed 













Figure 4.4 HDX analysis of anti-laforin nanobody binding of Nb41, Nb57, and Nb72.  
Fractions of each nanobody bound to laforin (Figure 4.3) were analyzed by hydrogen 
deuterium exchange mass-spectrometry (HDX) and the deuteration level was compared 
to laforin alone. The percent difference in deuteration between the nanobody complex 
versus laforin alone is represented with a negative percent change in blue to a positive 
percent change in red. Each colored bar below the primary sequence represents percent 
change in deuteration at one of four time points. Secondary structure elements are 
depicted above the primary sequence with the CBM and DSP motifs labeled. Regions 
where the nanobody caused a ≥15% change in deuteration are highlighted with a 
colored line. A) The Nb41 epitope on laforin spans β3, β7 and β8 sheets, ⍺4, ⍺5, and 
partially ⍺6 helices. Highlighted with a dark teal line. B) The Nb57 epitope on laforin 
includes the β3 sheet and partially covers the ⍺10 helix. Highlighted with a dark orange 
line. C) The Nb72 epitope on laforin covers the ⍺4 helix, and partially spans the ⍺6, ⍺8, 
and ⍺9 helices. Highlighted with a light green line. D-F) The identified epitope for each 
nanobody was modeled onto the surface map of the laforin structure (PDB: 4RKK). Nb41 
(dark teal), Nb57 (dark orange), and Nb72 (light green) respectively mapped on laforin. 










Figure 4.5 Laforin activity in the presence of Nb72. 
A) The specific activity of laforin against pNPP in the presence and absence of 
nanobodies. B) The specific activity of laforin against rabbit skeletal muscle glycogen in 
the presence and absence of nanobodies. C) The specific activity of laforin against 
potato amylopectin in the presence and absence of nanobodies. Each bar is the mean 




































































Figure 4.6 Nanobody sequence alignment. 
37 CDR3 groups are represented among the 74 generated laforin nanobodies 















Figure 4.7 HDX analysis of anti-laforin nanobody binding of Nb40, Nb50, and Nb73.  
Fractions of each nanobody bound to laforin (Figure 4.3) were analyzed by hydrogen 
deuterium exchange mass-spectrometry (HDX) and the deuteration level was compared 
to laforin alone. The percent difference in deuteration between the nanobody complex 
versus laforin alone is represented with a negative percent change in blue to a positive 
percent change in red. Each colored bar below the primary sequence represents percent 
change in deuteration at one of four time points. Secondary structure elements are 
depicted above the primary sequence with the CBM and DSP motifs labeled. Regions 
where the nanobody caused a ≥15% change in deuteration are highlighted with a 
colored line. A) Laforin-Nb40 epitope spans β3, β7 and β8 pleated sheets and ⍺4 and ⍺5 
helices. Highlighted with a light teal line. B) Laforin-Nb50 epitope includes the β3 
pleated sheet and partially covers the ⍺10 helix. Highlighted with a light orange line. C) 
Laforin-Nb73 epitope covers the ⍺4 helix, and partially covers the ⍺6 and ⍺8 helices. 
Highlighted with a dark green line. D-F) The identified epitope for each nanobody was 
modeled onto the surface map of the laforin structure (PDB: 4RKK). Nb40 (light teal), 
Nb50 (light orange), and Nb73 (dark green) respectively mapped on laforin. The CBM 


























Figure 4.8 Anti-laforin nanobody sequence alignments. 
Sequence homology between Nb40 and Nb41 is 99.2%, Nb50 and Nb57 is 66.2%, and 
Nb72 and Nb73 is 70.6% (Clustal-Omega). CDRs highlighted in red, framework 

















Figure 4.9 Laforin-nanobody activity assays.  
The specific activity of laforin against potato amylopectin in the presence and absence 
of nanobodies. Only Nb72 inhibits laforin’s phosphatase activity. Each bar is the mean 





















 A nanobody-based ELISA screen for PTC readthrough of Epm2a 
5.1 Introduction 
 
Over 8,000 rare genetic diseases have been described and most are without 
therapeutic options308. Underlying ~12% of rare genetic disease mutations are nonsense 
mutations/STOP mutations/premature termination codons (PTCs)309. PTC mutations 
transcribed in frame into mRNA result in truncated protein translation310. Excitingly, 
repurposed small molecules have shown promising results in correcting PTC mutations 
to generate full-length proteins311,312. 
The first pharmaceutical agents tested to suppress PTC mutations therapeutically 
were aminoglycosides (AGs)313. AGs are primarily used as antibacterial agents that 
inhibit bacterial protein synthesis314. Translational inhibition occurs because AGs 
prevent ribosome mRNA translocation by binding the 50S ribosomal subunit and the 
bacterial aminoacyl site of the 16S ribosomal mRNA. In eukaryote cells, AGs do not 
inhibit translation and can promote misincorporation of near-cognate aminoacyl-tRNA 
at the site of the PTC mutation310,315. Therefore, AGs can promote full length translation 
of PTC mutated mRNA. The precise mechanism of PTC readthrough is not yet well 
understood. However, a recent study indicated that geneticin (G418), the best 
characterized PTC readthrough AG, may interfere with tRNA due to tight binding of the 
ribosome’s decoding center, like that observed for bacterial ribosomes316.  
AGs have been tested for their ability to promote readthrough in over 100 tissue-
culture and mouse models for multiple diseases, including Duchenne Muscular 
Dystrophy (DMD) and Cystic Fibrosis (CF)317. These studies demonstrated that AGs like 
G418 and gentamicin can promote readthrough of the PTC mutations, however, their 
clinical application is limited due to ototoxicity and contribution to superbug evolution. 
Therefore, the application of AGs is better suited for proof-of-concept experiments in 
vitro.  
The search for non-toxic, well-characterized compounds that safely confer 
readthrough activity in humans led to the first bench to bedside translation of a PTC 
readthrough therapy. The non-aminoglycoside molecule ataluren (PTC124) produced 
full readthrough of the most common PTC mutation found in patients with DMD and is 
approved for clinical use by the European Commission318. However, The Food and Drug 
Administration denied approval for PTC124 in the United States because the provided 
data, including a safety evaluation, was inadequate319. Interestingly, the mechanism of 
action for PTC124 is suggested to diverge from G418 and is derived exclusively from its 
ability to inhibit release factor activity316. Unfortunately, a recent meta-analysis of 
PTC124 clinical trials in DMD patients determined that PTC124 provided only a mild 
slowing of DMD disease progression compared with placebo320. Furthermore, PTC124 




These outcomes have been attributed to the repeated finding that nucleotide 
sequence regulates suppression of PTCs and no one drug suppresses two PTCs to the 
same extent321. Further, no algorithms can predict how the genetic context influences 
the readthrough ability of a given PTC. The CF field recently discovered the readthrough 
properties of escin, a non-toxic herbal supplement, by using an enzymatic assay to 
screen 1600 small molecules311. Therefore, the development of a high throughput drug 
screening approach designed for discovering PTC specific readthrough compounds 
among clinically approved drug libraries may be required to achieve therapeutic and 
translational potential.  
An ideal disease to develop a PTC readthrough high throughput screening assay is 
one that is monogenetic where mutations result in aberrant protein function that drive 
disease. Lafora disease (LD) is an autosomal recessive childhood dementia resulting 
from mutations in the Epm2a gene322,323. Epm2a mutations, of which 15% are PTCs, 
result in the loss-of-function of laforin, the glycogen phosphatase324. Sequence and 
structural conservation classifies laforin in the protein tyrosine phosphatase superfamily 
and the dual specificity phosphatase clade274. Laforin is the only known human glycogen 
phosphatase and is comprised of a dual-specificity phosphatase (DSP) domain and a 
carbohydrate binding module (CBM)274. Laforin loss-of-function results in the production 
of aberrant glycogen-like aggregates in the cytoplasm called Lafora bodies (LBs)81,324. 
The LBs are found in the cytoplasm of cells from most tissues, including patient skin 
biopsies and post-mortem brain tissue80. Using multiple mouse and fly models, 
independent investigators have determined that LBs drive pathophysiology25,26,28,81. No 
treatment exists for this fatal disease, but recent pre-clinical work suggests that rescuing 
normal laforin expression leads to the ablation of LBs325,326. Thus, rescuing laforin 
expression may be an attractive avenue for therapeutic development.  
In this study, we explored three cell culture approaches for screening the 
readthrough efficiencies of small molecules against the 12 clinically known Epm2a PTC 
mutations. We generated a Western blot assay, an enzymatic assay, and a laforin 
nanobody-based ELISA to test readthrough. Using these assays, we tested gentamicin, 
G418, and escin for readthrough. PTC124 was excluded from this study as prior work 
determined that it was unsuccessful at promoting readthrough of Epm2a PTC 
mutations. The Western blot and enzymatic assay are widely used low-throughput 
approaches for PTC readthrough screening that we modified for Epm2a309–312,322,323. The 
results of these screens proved that gentamicin and G418 can induce readthrough of 
Epm2a PTC mutations in vitro. However, they are limited in their potential to be 
adapted for high throughput screening due to demanding technical requirements.  
For a third screening approach with potential for scale, we designed a novel 
nanobody based sandwich ELISA. Nanobodies are antibodies naturally produced the 
camelid family327. Nanobodies consist of a single monomeric variable domain (VHH) 
with a complete antigen binding site. Nanobodies can be readily selected and 
produced in E. coli, ensuring their supply and consistent quality328. In contrast to 
conventional antibodies, nanobodies are exceptionally stable, withstanding 
fluctuations in temperature and pH281,282. These advantages make nanobodies ideal 




generated nanobodies raised against human recombinant laforin, we developed 
highly specific monoclonal antibodies to replace the polyclonal anti-laforin 
antibodies currently used to isolate laforin329. Our nanobody based ELISA system is a 
unique readthrough screening system in which full-length laforin, but not truncated 
laforin, can be detected by a CBM binding anti-laforin nanobody. This same system can 
be used to determine phosphatase activity by interchanging the addition of the 
CBM binding detection nanobody with the phosphorylated substrate para-nitryl 
phenyl phosphate. Therefore, the nanobody based ELISA readthrough screening 
system has two possible outputs, quantitation of laforin full length translation and 
resulting phosphatase activity. The laforin nanobody ELISA may be a scalable option 































5.2.1 cDNA generation and sequencing 
Primary fibroblasts were grown using Fibrolife S2 Cell Culture Medium 
supplemented with Fibrolife S2 Lifefactors LS-1038 (Lifeline Cell Technology). 1% 
Penstrep was substituted for gentamicin for suppression of bacterial growth. To extract 
genomic DNA, 20 μl of ThermoPol Buffer (New England Biolabs) was added to the 
samples, boiled for 5 min and digested with Proteinase K (10 mg/mL) for 2 h at 55°C. 
Then, Proteinase K was inactivated by boiling for 10 min. Total RNA was isolated using 
PureZOL/Aurum Total RNA Isolation Kit (Bio-Rad) according to the manufacturer’s 
instructions. The RNA quality for RNA-seq was tested using an Agilent Bioanalyzer 2100. 
Quantitative RT-PCR was performed using SoAdvanced SYBR® Green supermix. The 
cDNA and a 207 bp sequence of the genomic DNA was amplified using PCR. PCR was 
carried out in a 25 μl reaction solution containing 1 μl of 10 mm dNTP, 1 μl of 10 mm 
forward and reverse primer, 2.5 μl of 1× ThermoPol Buffer (New England Biolabs), and 
0.5 units of Pfu Polymerase (New England Biolabs).  Amplicons were purified and 
subcloned into a pJET1.2/blunt vector using the CloneJET PCR Cloning Kit (ThermoFisher 
Scientific). Plasmids were transformed into E. coli and the DNA was sequenced.  
 
5.2.2 Reporter plasmid cloning 
Three sets of reporter plasmids were generated for this study. For the enzyme 
assays, complementary oligonucleotides were generated, annealed, and ligated into a 
pAC99 reporter plasmid, as previously described323. This plasmid contains a unique 
Msc1 cloning site between lacZ and luc genes coding for β-galactosidase and luciferase, 
respectively. β-galactosidase and luciferase coding sequences are separated by an in-
frame stop codon corresponding to the mutation found in a patient, flanked by four 
codons in 5’ and 3’, respectively.  
The reporter plasmids generated for the Western blots were generated using site 
directed mutagenesis to insert an Epm2a PTC mutation into WT laforin cDNA flanked by 
a 5’ Flag tag and 3’ Myc tag. Each mutated amplicon was inserted into a pcDNA 3.1+ 
Amp/Zeocin cloning plasmid (ThermoFisher Scientific) using the BamHI and NotI 
restriction sites. Because the Flag and Myc tags could interfere with laforin nanobody 
capture and detection in the ELISA screening system, a similar set of plasmids without 
tags was created. PCR amplification of the previously generated PTC mutated laforin 
cDNA was inserted into a pcDNA 3.1+ Amp/Zeocin (ThermoFisher Scientific) cloning 




5.2.3 Cell culture transfections and drug treatments 
HEK293 cells were grown in DMEM (ThermoFisher Scientific) containing 10% fetal 
bovine serum. Reporter plasmids were transfected for 24 h using FuGene according to 
the manufacturer’s instructions. For drug treatments, 2 mL of multiple concentrations of 
Geneticin (G418), Gentamicin, or 0.04% DMSO in media was added per well of a 6-well 
plate and left to incubate overnight (~24 h). Cells were harvested using trypsin, 
prepared for Western blots or ELISAs, and flash frozen. Cells harvested for Western blots 
were lysed in RIPA buffer (0.5% deoxycholate, 1% IGEPAL-CA630, 0.1% sodium dodecyl 
sulfate, 150 mM NaCl, 50 mM Tris-8.1). Cells harvested for ELISAs were lysed in PLC-lysis 
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 10% (v/v) glycerol, 1% (v/v) NP-40, 1 mM 
EGTA, 10 mM NaPPi, 100 mM NaFl, supplemented with protease inhibitor cocktail). 
For the enzymatic assays, HeLa cells were seeded in the wells of 6 well plates and 
left to grow overnight (~24 h). Then, 3 h before transfection, the cell medium was 
removed, and 2 mL of fresh medium was added. During the 3 h incubation, the 
transfections were prepared using 18 μL at 1 μg/μL of DNA in 600 μL of NaCl and 
vortexed. In a separate tube, 36 μL of JetPei in 600 μL of NaCl was mixed by vortexing. 
Then, the JetPei mixture was added to the DNA mixture and incubated for 30 min at RT. 
Next, 200 μL of the transfection mixture was added to each well of the 6-well plate. 
Because the precipitate can be toxic to these cells, transfections were performed close 
to the end of the day and cell treatment was performed in the morning ~16 h later. Drug 
treatment consisted of aspirating the media from the 6-well plates and adding 2 mL of 
either 2.5 mM Gentamicin, 2.5 mM Geneticin, 10 μM Escin, or 0.4% DMSO in media and 
incubating overnight (~24 h). Finally, the cells were harvested by trypsin and added to 
respective epi-tubes for enzyme assay preparation. 
 
5.2.4 SDS-PAGE and Western Blot 
Protein concentrations were determined using the Pierce BCA Protein Assay Kit 
(Thermo Scientific 2327) according to the manufacturer’s protocol. Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blots were run using 
TGX stain free pre-case 12% gels (Bio-Rad). Western transfers were performed using a 
semidry turbo-transfer system onto PVDF membranes (Bio-Rad). The membranes were 
blocked with 5% nonfat milk and probed with primary antibodies [mouse anti-FLAG M2 
(Sigma-Aldrich) and rabbit anti-MYC (Origene)] at a 1:1000 dilution. The membranes 
were incubated with the secondary antibodies [goat anti-rabbit IgG, HRP-linked 
antibody and goat anti-mouse IgG, HRP-linked antibody (Invitrogen)] at a 1:3000 
dilution. The membranes were developed using chemiluminescence followed by 







5.2.5 Enzyme assays 
Luciferase was assayed by following the protocol of Nguyen, with a Berthold LUMAT 
LB 95501 luminometer for light detection330. Chloramphenicol acetyltransferase (CAT) 
activity was determined in accordance with the two-phase partition method331. β-
galactosidase was assayed in accordance with the classical method of Miller332. 
 
5.2.6 Laforin purification 
H. sapiens (Hs) laforin residues 1–328 was expressed from pET28b (Novagen) as an 
N-terminal His6 tagged protein, as previously described329. Briefly, laforin was expressed 
in BL21 (DE3) (Novagen) E. coli cells grown in 2xYT media at 37oC until OD600 = 0.6, 
culture flasks were placed on ice for 20 min, induced with 1 mM (final) isopropyl thio-ß-
D-galactopyranoside (IPTG), grown for an additional 14 h at 20oC, and harvested by 
centrifugation. Cells were resuspended and lysed in buffer A (20 mM Tris-HCl, 100 mM 
NaCl, 10% glycerol, 2 mM DTT, pH 7.5), centrifuged, and the proteins were purified 
using a Profinia immobilized metal affinity chromatography (IMAC) column with Ni2+ 
beads (Bio- Rad) and a Profinia protein purification system (Bio-Rad) using wash (buffer 
A) and elution buffer (300 mM imidazole, 20 mM Tris-HCl, 100 mM NaCl, 10% glycerol, 2 
mM DTT, pH 7.5). The desalted elution fraction was further purified using fast protein 
liquid chromatography (FPLC) with a HiLoad 16/60 Superdex 200 size exclusion column 
(GE Healthcare). Laforin was purified in 20 mM Tris-HCl, 100 mM NaCl, 10% glycerol, 2 
mM DTT, pH 7.5). 
 
5.2.7 Nanobody purification and HRP-conjugation 
Nanobodies were purified as previously described329. Nanobodies were expressed in 
BL21 (DE3) E. coli cells grown in 2xYT at 37oC to OD600 = 0.9. 15 mL of pre-culture was 
used per L culture. Cultures were induced with 1 mM IPTG (final) and incubated for ~16–
18 h at 25oC after which, pellets were harvested by centrifugation. Nanobodies were 
purified from the E. coli pellets with Ni-NTA resin. E. coli cell lysates were centrifuged to 
separate soluble protein which was incubated with Ni- NTA agarose beads for 1 h at 4oC 
in 30 mL bind buffer (20 mM Tris- Hcl, 100 mM NaCl, 15 mM imidazole, pH 8.0). The 
samples were washed three times in bind buffer and eluted in 300 mM imidazole, 100 
mM NaCl, pH 8.0. Eluted samples were separated from the Ni-NTA beads by filtering 
through a 25 mM syringe filter and then buffer exchanged with 20 mM Tris-Hcl pH 7.5, 
100 mM NaCl using FPLC with a HiLoad 16/60 Superdex 75 column (GE Healthcare). 
Nanobodies being screened for their use as detection nanobodies were conjugated to 





5.2.8 Enzyme-Linked Immunosorbent Assay (ELISA) 
Wells of a Corning 9018 96-well plate were incubated with 100 μL of capture 
nanobody (Nb41) overnight (~16 h) at a final concentration of 0.18 μL/mL in 1X Tris-
buffered saline (TBS) at 4 oC with a plate cover. Wells were then rinsed three times with 
200 μL 1X TBS followed by incubation for 1 h with 200 μL of blocking solution (1% BSA in 
1X TBS) at RT followed by wells being rinsed three times with 200 μL 1X TBS. The sample 
(100 μL; recombinant H. sapiens (Hs) laforin 329X or whole cell lysate diluted to 100 μL 
in 1X TBS, 1mM DTT) was added and incubated for 1 h a RT, the wells were rinsed three 
times with 200 μL of 1X TBS, and 100 μL of primary HRP-conjugated nanobody was 
added in 1X PBS in 1% BSA, 1mM DTT and incubated for 1 h at RT. The wells were then 
washed three times with 200 μL TBS and 100 of TMB substrate (Thermo Fisher) was 
added and developed according to the manufacturer’s instructions. The reaction was 
terminated by adding 100 of stopping solution (0.18 M H2SO4). Absorbance was 
quantified at 450 nm using a BioTek Ephoch2 microplate reader. To quantify the 
saturation curves for putative capture nanobodies bound to the plate, the anti-Camelid 
IgG, HRP-linked antibody was used at a 1:5000 dilution and developed using TMB 
substrate (Thermo Fisher).  
 
5.2.9 para-Nitrophenyl phosphate (pNPP) assay 
Generic phosphatase activity assays were performed using para-nitrophenyl 
phosphatase (pNPP) as previously described329. Assays were performed using 96 well 
plates in 50 μL containing 1X phosphatase buffer (0.1 M sodium acetate, 0.05 M Bis-Tris, 
0.05 M Tris- HCl, pH 5.0), 2 mM dithiothreitol (DTT), and 50 mM pNPP). Wells of a 96-
well plate were incubated capture nanobody (Nb41) overnight (~16 h), rinsed three 
times with 1X TBS, by incubating with blocking solution (1% BSA in 1X TBS) at RT, 
followed by wells being rinsed three times with 200 μL 1X TBS. 100 μL recombinant 
laforin in 1X TBS, 1mM DTT was added and incubated for 1 h at RT, the wells were 
rinsed three times with 200 μL of 1X TBS, and 100 μL of 1X phosphatase buffer 
containing 50mM pNPP was added to the wells and incubated in a 30oC water bath for 













5.3.1  PTC mutations in Epm2a 
An important consideration before developing PTC readthrough screening assays is 
whether the PTC in question is transcribed in frame into mRNA. PTC mutations located 
near splice sites may not be transcribed in frame and instead result in alternatively 
spliced mRNA or trigger nonsense mediated decay of the pre-mRNA transcript333. These 
PTC mutations are not candidates for readthrough therapy.  
Twelve Epm2a LD PTC mutations have been reported with R241X being the most 
common mutation in LD (Figure 5.1A and Table 5.1)81,296,334–339. The point mutation 
underlying R241X is a g.113165 C>T mutation that results in a premature TGA stop 
codon (Figure 5.1A and Table 5.1). The C>T point mutation is located three nucleotides 
from the 5’ end of the fourth exon and not predicted to trigger nonsense mediated 
decay, which typically requires a PTC to be at least 50-55 nucleotides upstream of an 
exon-exon junction (Figure 5.1A)333. However, the C>T placement could induce variance 
in pre-mRNA splicing. To assess whether the g.113165 C>T mutation is transcribed in 
frame, we obtained primary skin fibroblasts from a patient homozygous for g.113165 
C>T. After confirming the genetic mutation by gene sequencing, we performed an RNA 
prep from the same primary fibroblasts followed by RT-PCR to determine in frame 
transcription (Figure 5.1B-C). The cDNA was isolated and sequenced to determine that 
the R241X mutation is not alternatively spliced and results in the c.721 C>T point 
mutation (Figure 5.1C). This result implies that the resulting translated protein will be 
truncated at R241 and the R241X Epm2a PTC mutation is a candidate for readthrough 
therapy.  
 
5.3.2 A Western blot assay for screening PTCs 
A traditional approach for determining readthrough expression involves 
overexpressing PTC mutated cDNA in HEK293 cells, incubating the cells with a 
readthrough drug, and determining total expression levels via Western blot analysis. To 
adapt this system for Epm2a R241X, we utilized the MeCP2 R294X PTC mutation 
implicated in Rett syndrome as an experimental control. Readthrough expression of 
MeCP2 R294X has been previously shown using gentamicin340. Thus, two similar 
plasmids were made, one containing MeCP2 R294X cDNA and the other containing 
Epm2a R241X cDNA, each joined to a 5’ Flag-tag sequence. A third construct was made 
in the same way, except it contained the WT Epm2a cDNA. The WT cDNA allowed us to 
control for change in translation levels independent of readthrough. After incubating 
the HEK293 cells with increasing concentrations of gentamicin (0-3.5 mM), cells were 
harvested, total protein extracts were generated, and WBs were performed to detect 




increases in concentration, while WT laforin levels do not change (Figure 5.2A). These 
are encouraging results, but not definitive results of readthrough as they do not 
normalize for basal levels of readthrough. Additionally, aminoglycosides have been 
shown to stabilize PTC mutated mRNA, potentially promoting variation in mRNA stability 
between the WT and PTC targets analyzed310.  
Therefore, we generated a dual reporter system also detectable by Western blot. 
The benefit of a dual gene reporter system is that both reporter proteins are expressed 
from the same mRNA, eliminating potential variation in mRNA stability between the 
different targets. We developed this system by flanking the PTC mutated Epm2a cDNA 
by a 5’ Flag-tag and a 3’ Myc-tag. HEK293 cells were transfected with 2 μg/mL of DNA 
and incubated with 0-2 mM G418 for 24 hr. Cells were harvested, total protein extracts 
were generated, and WBs were performed to detect the Flag- or Myc-tag. After 
overexpression of the test plasmid in HEK293 cells and incubation with G418, we ran a 
Western blot and detected the Flag-tag with a fluorescent secondary antibody, and the 
Myc-tag with a chemiluminescent secondary antibody (Figure 5.2B). Thus, translation 
levels of the truncated laforin peptide are detected by the anti-Flag antibody and 
readthrough is measured by the anti-Myc antibody on the same blot. As expected, 
Western blot analysis indicated that WT expression levels as detected by either anti-Flag 
or anti-Myc are not changed with increasing concentrations of G418. Conversely, 
increased expression of the R241X mutated cDNA is detected by the anti-Myc antibody 
at 1 mM G418 indicating readthrough. Using the anti-Flag antibody, we also observed 
increased expression of laforin at 1 mM G418. Furthermore, we detected a protein with 
at 29 kD upon G418 addition. This protein may be the result of expression of the 
truncated form of laforin R241X, which is calculated to have a molecular weight of 29 
kD. Interestingly, higher concentrations of G418 did not result in readthrough. This 
result is likely explained by the fact that G418 is often used as a cell selection reagent 
and high concentrations of G418 can compromise cell vitality. This result supports the 
notion that the toxicity of G418 limits its use to preliminary pre-clinical studies in low 
doses. These data suggest that the Flag/Myc reporter system is useful as a readthrough 
screening system. However, due to Western blot limitations, like technical demand, 
time, and off-target antibody detection, this screening assay is not practical for a quick 
and streamlined analysis of readthrough compound libraries. 
 
5.3.3 An enzymatic assay for screening PTCs 
To examine readthrough across the 12 Epm2a PTC mutations, we employed a widely 
cited cell culture-based assay optimized for higher throughput compared to Western 
blot analysis309–312,322,323. The basic mechanics of this assay involve the overexpression of 
a plasmid containing two enzyme reporter genes, LacZ and Luc, that flank a 9-codon 
sequence containing a PTC mutation at codon 5 (Figure 5.3). This plasmid is transfected 
into HeLa cells, optimal for their fast growth, that are then incubated with a 
readthrough drug. When partial protein expression is generated in the cells, the 5’ 




sequence. If readthrough of the PTC mutation occurs, then the full dual reporter fusion 
protein will be expressed containing an N-terminal β-galactosidase and the C-terminal 
luciferase (expressed from luc), linked together by the 9 amino acid protein sequence. 
Therefore, readthrough efficiency is estimated by normalizing luciferase activity to β-
galactosidase activity.  
HeLa cells were transfected with 1 μg/μL of DNA and incubated with each 0.04% 
DMSO, 2.5 mM gentamicin, 2.5 mM G418, or 10 μM escin for 24 hours. Cells were 
harvested and added to respective epi-tubes for enzyme assay preparation. Using the 
enzymatic assay, we first determined the readthrough expression of each of the 12 
Epm2a PTC mutations, grouped by PTC codon, using 2.5 mM gentamicin versus DMSO. 
There was an increase in expression for all of the mutants with W165X, R241X, and 
E158X expression being statistically significant with gentamicin versus DMSO. These 
results indicated that gentamicin could produce readthrough of each Epm2a PTC 
mutations to varying degrees above the DMSO control with a 2-6-fold increase observed 
(Figure 5.4A-B). Interestingly, there was some level of readthrough for each of the 
mutants in the presence of DMSO, indicating basal readthrough, with R241X exhibiting 
the highest level of basal readthrough in this system (Figure 5.4A). This result is 
encouraging because basal readthrough levels are suggested in the literature to be an 
indicator of best responders to drug induced readthrough323. Additionally, R241X is the 
most common LD mutation. Next, we tested G418 to establish its usefulness as a 
positive control, and escin as a possible clinically relevant drug candidate. G418 typically 
produced readthrough expression levels higher than that of gentamicin (Figure 5.5A). 
Like gentamicin, G418 yielded statistically significant readthrough in W165X, R241X, and 
E158X as well as two additional PTCs, W287X, E138X. These results demonstrate that 
G418 is a more potent readthrough compound than gentamicin for the Epm2a 
mutations and align with published reports testing G418 on other genes316. For both 
AGs, Epm2a TAG mutations yielded the highest level of readthrough and TGA the lowest 
(Figure 5.4A, 5.5A). In contrast, escin did not produce readthrough expression above 
basal DMSO-treated levels (Figure 5.5B). Therefore, gentamicin and G418, but not escin, 
can be used to promote readthrough of Epm2a PTCs in cell culture.  
Commercial gentamicin is not a pure compound and is majorly composed of 
gentamicins C1, C1a, C2, and C2a constituting 92–99% of the mixture. Of the minor 
components, gentamicin B constitutes 0.8–5.3%, and C2b between 1.3–2.1%. 
Occasionally, sisomisin is found, comprising only 0.4–0.6%. Additionally, gentamicin A 
and X2 (also known as gentamicin X) together comprise between 1.1–7.8%. Other 
components in the complex include gentamicin B1 and garamine. Recent work showed 
that despite gentamicin X2 and B1 being minor components they are potent 
readthrough inducers341,342. Since their levels can vary by lot, this variation may impact 
readthrough expression. To determine the effect of drug batch on readthrough 
variability we tested 9 batches of gentamicin on the R241X mutation. HeLa cells were 
transfected with 1 μg/μL of DNA and incubated with each 0.04% DMSO, 2.5 mM G418, 
or 2.5 mM gentamicin from 9 different batches for 24 hours. Cells were harvested and 
added to respective epi-tubes for enzyme assay preparation. While there was some 




readthrough between batches (Figure 5.6). Thus, despite some variability, lot should not 
greatly affect the accuracy of readthrough measurements.  
Lastly, we considered the role of cell type on readthrough expression variability. 
While HeLa cells are more optimal for higher throughput screening than slower growing 
cells like NIH3T3 or HEK293, HeLa cells may not necessarily be optimal for highest 
expression of readthrough. HeLa, NIH3T3, or HEK293 cells were transfected with 1 
μg/μL of DNA and incubated with each 0.04% DMSO, or 2.5 mM gentamicin. Cells were 
harvested and added to respective epi-tubes for enzyme assay preparation. 
Interestingly, gentamicin promoted statistically significant readthrough of R241X in HeLa 
and NIH3T3 cells but the increased readthrough in HEK293 cells was not statistically 
significant (Figure 5.7A-C). These results suggest that HeLa cells in comparison to 
NIH3T3 or HEK293 are an optimal cell line because they grow faster and can yield 
statistically significant effects of readthrough. The enzymatic assay established in vitro 
proof that readthrough of all 12 Epm2a PTC mutations is possible. However, the 
technical requirements, though easier than Western blot analysis, are still too time 
consuming and prone to human error for efficient screening of large drug libraries.  
 
5.3.4 A nanobody based ELISA screening approach 
We recently developed six laforin nanobodies and characterized their binding 
affinity and the laforin epitope. The six laforin nanobodies were categorized into three 
groups that shared epitopes. One epitope spans both the CBM and DSP on the opposite 
side of the DSP active site and is bound by nanobodies 40 and 41 (Nb40 and Nb41). The 
second epitope spans the CBM, partially covering regions that bind glycogen and is 
bound by nanobodies 50 and 57 (Nb50 and Nb57). The third epitope overlaps with a 
region near the laforin DSP active site, and is bound by nanobodies 72 and 73 (Nb72 and 
Nb73), but only Nb72 inhibits laforin phosphatase activity329. Based on these known 
epitopes, we hypothesized that a pair of nanobodies could be used to generate a 
sandwich ELISA for detecting and quantifying laforin readthrough.  
We first determined the optimal plate saturation concentrations of the nanobodies 
that primarily bind the DSP. We excluded the use of Nb72 since it inhibits laforin 
enzymatic activity and we wanted to use phosphatase activity as a potential readout. 
Therefore, we examined Nb40, Nb41, and Nb73. We first plated 100 μL per well of 
increasing concentrations of Nb40 (0–30 μg/mL), Nb41 (0–70 μg/mL), and Nb73 (0–150 
μg/mL) and detected the saturation curves with an HRP conjugated anti-Camelid 
antibody, developed using TMB substrate and read at OD450 using a microplate reader. 
The results indicated that Nb40, Nb41, and Nb73 each displayed a different pre-
saturating concentration of 3 μg/mL, 8 μg/mL, and 11 μg/mL, respectively (Figure 5.8A-
C). To determine which of these nanobodies was useful as a capture nanobody, we 
tested each nanobody by plating the respective pre-saturating concentration and 
subsequently binding 100 μL of increasing concentrations (0–20 μg/mL) of purified 
recombinant human laforin. As a readout of laforin phosphatase activity, we incubated 




performed pNPP assays. Protein tyrosine phosphatases, including laforin, can covert 
pNPP to para-nitrophenyl (pNP) and the colorimetric change is quantified at OD410. By 
performing pNPP assays, Nb41 was identified as a useful capture antibody that allows 
the DSP of laforin to remain active (Figure 5.8D, data not shown for Nb40, and Nb73)). 
The linear range of captured laforin was within the known linear range of detection by 
the pNPP assay. Based on the pNPP assay results, the saturation concentration of 
recombinant laforin is 20 μg/mL. 
We then determined which CBM binding nanobody was most optimal for laforin 
detection. In each well, we plated 100 μL of Nb41 at 8 μg/mL and bound 100 μL purified 
recombinant human laforin at 20 μg/mL. After washing, capture nanobody saturation 
curves were generated using increasing concentrations of Nb50, or Nb57, at 0–2 μg/mL 
each conjugated to HRP (Figure 5.8E-F). Wells were then washed and developed using 
TMB substrate and read at OD450 using a microplate reader. Nb57-HRP exhibited a 
robust saturation curve with a higher specificity than Nb50-HRP (Figure 5.8E-F). Pre-
saturating concentrations were indicated to be 0.18 μg/mL for Nb57-HRP and 1 μg/mL 
for #113. 
Currently, the polyclonal anti-laforin antibody #113 is utilized to immunoprecipitate 
laforin as it demonstrated the most robust ability to capture laforin from cell lysate290. 
We sought to determine whether Nb57-HRP provided higher specificity than polyclonal 
anti-laforin antibody #113. To generate and compare the saturation curves using Nb57-
HRP and #113, we plated 100 μL of Nb41 at 8 μg/mL and bound 100 μL purified 
recombinant human laforin at 20 μg/mL. After washing, we bound of 100 μL of Nb57-
HRP at 0.18 μg/mL, or 100 μL of #113 at 1 μg/mL (Figure 5.9A-B)343. Bound #113 was 
subsequently washed and bound with a secondary antibody. A 
After washing the Nb57-HRP bound and #113 and secondary bound plates, the 
assays were developed using TMB substrate and read at OD450 using a microplate 
reader. Comparing the standard curves generated by Nb57-HRP or #113, Nb-57-HRP 
signals appeared in closer alignment with the four-parameter logistic (FPL) model. Thus, 
the monoclonal Nb57-HRP detected laforin with higher specificity than the polyclonal 
anti-laforin antibody.  
To determine the assay efficiency, the percent recovery of Nb57-HRP was 
determined by generating a 22-point standard curve of recombinant laforin and 
analyzing the linear range using a four-parameter logistic (FPL) model (Figure 5.10A-B). 
100 μL of Nb41 at 8 μg/mL was plated and bound 100 μL purified recombinant human 
laforin at 20 μg/mL. After washing, 100 μL of Nb57-HRP at 0.18 μg/mL was bound. A 
second wash performed before the assays was developed using TMB substrate and read 
at OD450 using a microplate reader. The FPL model was selected because it provides a 
better fit (percent recovery) to all of the data compared to linear models, even under 
circumstances where the linear model lack-of-fit value (R2) is equal or greater than 
0.99344.  












In the FPL mode, Y is the output value, absorbance in this case, which is 450 nm for 
the pNPP assay. “Top” is the upper asymptote and “bottom” is the lower asymptote. X is 
the concentration of recombinant laforin in the well, EC50 is the concentration with 50% 
maximum response, and slope is the Hill coefficient. Evaluation of the percent recovery 
of each point with the concentration calculated by the FPL curve established that the 
lowest concentration measured within 20% of the FPL curve and that is significantly 
higher than background, which is 2 μg/mL recombinant laforin (Figure 5.10A-B). The 
upper limit is 10 μg/mL, indicating that the range for accurate quantification of laforin is 
between 20-1000 ng (Figure 5.10A).  
A final experiment concluded preliminary development of the nanobody-based 
laforin ELISA for the purpose of screening laforin PTC readthrough. Plasmids containing 
WT Epm2a, R241X Epm2a or an empty vector were transfected into HEK293 cells. After 
transfection, whole cell lysates were then prepared using native PLC-lysis buffer. 
Increasing concentrations of whole cell lysates were incubated in the wells of a 96-well 
plate saturated with Nb41. Subsequent detection of laforin was performed using 0.18 
μg/mL of Nb57-HRP (Figure 5.11). The signal of WT laforin detection exceeded the signal 
produced in the wells containing laforin R241X or empty vector by 10-fold. Therefore, 
these data indicate that this nanobody based ELISA may be used to screen readthrough 



























To date, more than 100 studies have shown that the stimulation of PTC readthrough 
may result in the partial restoration of the expression of deficient proteins that underlie 
~40 different genetic diseases317. However, no study has demonstrated a remarkable 
improvement in patient health or a significant alleviation of the disease phenotype. The 
establishment of a truly efficient PTC readthrough based therapy requires new, more 
potent compounds with less toxicity. This goal may be achieved by scanning drug 
libraries to repurpose and/or modify compounds to achieve efficient nonsense 
suppression. To effectively implement this strategy, high throughput testing is needed 
to screen drugs against specific PTC mutations.  
LD is an ideal disease to model a high throughput screening approach for PTC 
readthrough as PTC mutations in a single gene result in loss-of-function at the protein 
level that directly causes LD pathophysiology25,26,28,81. Furthermore, a simple and cost-
effective in vitro assay has been previously developed to establish the presence or 
absence of glucan phosphatase activity290. To explore high throughput assay 
development for Epm2a PTCs we first adapted two traditional low-throughput screening 
approaches, a Western blot assay and an enzymatic assay, to test two AGs and the non-
toxic herbal anti-inflammatory compound escin, that had been reported to promote 
readthrough in some systems, to establish a proof-of-concept for Epm2a readthrough. 
Using these dual gene reporter assays we determined that readthrough is possible for 
all 12 Epm2a PTC mutations using gentamicin. Gentamicin and G418 are the most 
commonly used pre-clinical aminoglycosides in PTC readthrough studies, with G418 
promoting readthrough at lower concentrations and higher efficiencies than gentamicin 
and other aminoglycosides such as amikacin, paromomycin, and tobramycin321. As 
expected, G418 proved to be a more potent readthrough compound for Epm2a PTCs 
than gentamicin and may serve as a robust positive control for future studies.  
A known factor of readthrough efficiency variation is the PTC mutation and 
surrounding nucleotide sequence321. Though there is no absolute rule to predict PTC 
mutation readthrough efficiencies, TAA are often reported as the PTC mutations most 
recalcitrant to readthrough, followed by TGA with TAG exhibiting the highest level of 
readthrough315,323. For the Epm2a PTC mutations, TAG mutations yielded the highest 
level of readthrough and TAA the lowest. Interestingly, Epm2a PTC readthrough in TGA 
and TAA PTCs using either gentamicin or G418 was more frequent. Therefore, the 
surrounding Epm2a nucleotide context may be uniquely modulating ease of 
readthrough. TGA and TAA PTC mutations exhibited higher readthrough by gentamicin 
than TAG. These results are inconsistent with other disease models and suggest that the 
surrounding nucleotides may be a more important factor in modulating PTC 
readthrough. Encouragingly, the TGA mutation R241X, the most common mutation in 
LD, shows a significant amount of basal readthrough, which has predive value for its 




Using the dual reporter enzymatic assay, all 12 PTC mutations were screened for 
readthrough with three compounds and a control and analyzed within the span of 15 
days. Therefore, this enzymatic assay proved to be higher throughput than the Western 
blot assay. As a dual reporter assay, the enzymatic assay provides similar benefits as the 
Western blot but is a much more quantitative approach. The fluorescent nature of the 
internal control (β-galactosidase) permits accurate calibration of individual experiments 
for the overall expression level of each construct (vector stability, transfection 
efficiency, transcriptional and translation rates). However, limitations still exist in this 
assay as luciferase was shown to have off-target interactions with small molecules. 
Thus, the possibility of readthrough drug interaction and attenuation of excitation or 
emission light is an important consideration with this assay. A more ideal screening 
method would include the benefits of a fast-growing cell culture system, a dual reporter 
system, and an absence of off target drug interaction. 
To generate the proof-of-concept for a such an approach, we generated a novel 
nanobody based ELISA. We used previously generated anti-laforin nanobodies to 
construct an ELISA that can capture laforin without inhibiting its phosphatase activity 
and subsequently detect the full-length product. With nanobody epitopes previously 
defined, we chose a pair of nanobodies with different binding sites, such that the 
capture nanobody (Nb41) binds the DSP, and the detection nanobody (Nb57) binds the 
CBM329. We first developed a recombinant laforin standard curve by capturing with 
Nb41 and detecting with Nb57-HRP. We also determined that the generic phosphatase 
activity of recombinant laforin captured by Nb41 can be tested using para-nitrophenyl 
phosphate in a pNPP assay. These results provided the proof-of-concept that laforin 
recovered from cell lysate or human tissue may be quantified and assessed for 
phosphatase activity in parallel assays. To test the laforin nanobody ELISA using whole 
cell lysate, we used Nb41 to capture laforin from cell culture previously overexpressed 
with WT laforin, laforin R241X, or EV. We discovered the encouraging results that Nb57-
HRP can detect WT laforin at 10-times the concentration found in the cell lysates 
compared to empty vector. Importantly, Nb57-HRP does not detect the truncated 
laforin peptide generated from transcribing laforin R241X in the absence of readthrough 
compounds. These data suggest that the overexpressed truncated form has competed 
for binding to Nb41 but is not subsequently detected by Nb57-HRP because it lacks a 
CBM. These results suggest that the nanobody based ELISA using Nb41 and Nb57-HRP 
can be used to detect readthrough of R241X. 
Continued development of our nanobody based ELISA screening strategy is needed 
to verify this hypothesis. Theoretically, the combination of Nb41 and Nb57-HRP should 
be able to detect the full readthrough products of any laforin PTC mutation. However, 
detection of basal readthrough for internal control may be limited depending on the 
PTC mutation or require different sets of nanobodies. Of note, the pre-clinical 
development for therapy aiming to recover laforin protein expression, like adeno-
associated viral vector (AAV) therapy, may use the laforin nanobody ELISA to quantitate 
and assess the quality of laforin phosphatase activity326. Moreover, the long shelf life of 
nanobodies, low technical requirements, and ease of reproducibility when performing 




Further development of the nanobody based ELISA for PTC readthrough may act as a 
blue-print for creating similar assays for screening PTCs specific to other diseases, 










































Figure 5.1 12 PTC mutations in Epm2a cause Lafora disease. 
A) Location of LD PTCs mapped to Epm2a. Blue = Carbohydrate Binding Module, Green = 
Dual Specificity Phosphatase Domain. Arrow is pointing to R241X, the most common 
mutation in LD. B) Gene sequencing of patient fibroblasts C) cDNA was generated from 
patient fibroblasts and sequenced. The g.113165 C > T and corresponding c.721 C > T 
C>T point mutation is found, indicating that the R241X PTC mutation is transcribed in 







Table 5.1 Epm2a PTC mutations and corresponding nucleotide changes at the mRNA 
and gene level. 
Underscored nucleotides indicate the position in the gene codon that is mutated and 










Protein mRNA Gene 
p.Q55X c.163 C > T g.5520 C > T; CAG 
p.W60X c.179 G > A g.5536 G > A; TGG 
p.Y86X c.258 C > G g.5615 C > G; TAC 
p.Y87X c.259 A > T g.5616 A > T; AAG 
p.Y112X c.336 C > A g.54594 C > A; TAC 
p.E138X c.412 G > T g.54670 G > T; GAA 
p.S158X c.473 C > G g.54731 C > G; TCA 
p.W165X c.495 G > A g.105388 G > A; TGG 
p.R241X c.721 C > T g.113165 C > T; CGA 
p.Q247X c.739 C > T g.113183 C > T; CAG 
p.C278X c.834 C > A g.113278 C > A; TGC 









Figure 5.2 Western blot screening of aminoglycoside induced readthrough of R241X. 
A) HEK293 cells were transfected with MeCP2 R241X, R241X, or WT NT-Flag construct 
and treated with increasing concentrations of gentamicin for 48 h. Laforin or MeCP2 
levels were assessed by western analysis with anti-Flag antibody. B) HEK293 cells were 
transfected with R241X, or WT NT-Flag and CT-Myc construct, treated with increasing 
concentrations of G418 for 48h. Laforin levels were assessed by western analysis using 
















Figure 5.3 Description of the dual gene reporter system.  
For quantification in HeLa cells, β-galactosidase and firefly luciferase coding sequences, 
flanked an oligonucleotide that included a PTC mutation. Their expression is driven by 
the SV40 promoter (pAC99 vectors). The construction of the oligonucleotides was 
performed by surrounding the PTC mutation of interest by four codons and cloned in-
frame between β-galactosidase and firefly luciferase coding sequences. Readthrough 
was determined by normalizing the expression of firefly luciferase to the expression of 





















Figure 5.4. Enzymatic screening for identifying nonsense mutations responsive to 
aminoglycoside treatment. 
A) Readthrough of 12 PTC mutations in Epm2a was measured in HeLa cells with and 
without gentamicin (2.5 mM) treatment for 24 h. B) Foldchange of readthrough from 
gentamicin treatment compared to DMSO. Mean values are presented together with 




















Figure 5.5 Enzymatic screening for identifying nonsense mutations responsive to G418 
or escin treatment. 
A) Readthrough of 8 PTC mutations in Epm2a was measured in HeLa cells with and 
without G418 (2.5 mM) compared to gentamicin (2.5 mM) treatment for 24 h. 
Gentamicin and DMSO data is previously shown. B) Readthrough efficiencies of 10 PTC 
mutations in Epm2a were measured in HeLa cells with and without escin (10 μM) for 24 
h. DMSO data is previously shown. Mean values are presented together with the 



















Figure 5.6 Enzymatic screening for variability in gentamicin induced readthrough. 
A) Readthrough of the R241X PTC mutations in Epm2a was measured in HeLa cells with 
and without gentamicin (2.5 mM) or G418 (2.5 mM) treatment for 24 h. A different lot 


















Figure 5.7 Enzymatic screening of Epm2a R241X readthrough in NIH3T3 and HEK293 
cells.  
Readthrough of the R241X PTC mutation in Epm2a was measured in A) HeLa (data is 
previously shown) B) NIH3T3, and C) HEK293 cells with and without gentamicin (lot 3) 






















Figure 5.8 Optimizing capture and detection nanobodies. 
A-C) Each putative capture nanobody was plated in a 96-well plate at increasing 
concentrations overnight. Saturation curves were determined by detecting each 
nanobody with an HRP-conjugated anti-camelid antibody. A) Nb40 B) Nb41 C) Nb73  
D) To determine the working range of recombinant laforin, a standard curve using a 
pNPP assay was performed to detect laforin phosphatase activity. Nb41 was plated at 8 
μg/mL overnight. Increasing concentrations of recombinant laforin were incubated with 
pre-bound Nb41. E-F) To determine the saturation curves of putative detection 
nanobodies, Nb41 was plated at 8 μg/mL overnight. 2000 ng per well of recombinant 
laforin was captured by Nb41. E) Increasing concentrations of Nb50-HRP detected 






Figure 5.9 Saturation curves of laforin detection antibodies, Nb57-HRP and polyclonal 
anti-laforin antibody #113. 
Nb41 was plated at 8 μg/mL overnight. Increasing concentrations of recombinant laforin 
was captured by Nb41. A) Nb57-HRP at 0.18 μg/mL was used to detect laforin. B) 



















Figure 5.10 Working range of recombinant laforin at optimized antibody 
concentrations. 
A) An absorbance versus concentration curve was generated for multiple concentrations 
to determine the working range of the laforin ELISA. The minimum detection is 2 μg/mL 
and signal saturation is reached above 10 μg/mL. The curve is fit with an FPL best fit 
curve and R2 = 0.9153. The experiment uses n = 3 replicates. B) Using the FPL model, 
percent recovery was determined by comparing concentration loaded vs the 




















Figure 5.11 Laforin nanobody ELISA detection from whole cell lysates. 
WT laforin, empty vector (EV), or R241X was overexpressed in HEK293 cells. Whole cell 
lysates were prepared using PLC-lysis buffer and flash frozen. 8 μg/mL Nb41 was plated 
in a 96-well plate overnight, increasing concentrations of whole cell lysate were 



















 Concluding remarks 
6.1.1 Summary and future directions 
 
The pathophysiology of Lafora disease (LD) is centered around the overaccumulation 
of aberrantly structured glycogen called polyglucosan bodies (PGBs)81,324. Aberrant 
metabolism is a cause and consequence of LD PGBs resulting in early onset, rapid 
progression, and exacerbated symptomology common to many neurodegenerative 
diseases (Chapter 1)322,323. LD is one of 17 glycogen storage diseases (GSDs) that are 
defined by aberrant accumulation of glycogen/PGBs, where the contribution of PGBs to 
neuropathology is the most well studied in LD models17. From the atomic to pathological 
levels, the fundamentals of LD are understood. Several in vitro biochemical and 
structural techniques, in situ cell culture models, and in vivo mouse models have been 
generated to determine: 1. Mutations in laforin or malin result in LD PGBs that are 
hyperphosphorylated and aberrantly branched compared to normal glycogen78,222. 2. 
Laforin binds and dephosphorylates glycogen115. 3. The accumulation of LD PGBs causes 
disruptions to neuronal energetics resulting in defects in memory and cognition, and 
neurodegeneration25,26,28,81.  
As the field tests putative therapeutics for LD in pre-clinical settings, our cellular, 
structural, biochemical, and physiological understanding of LD is being put to the 
ultimate test of translatability. In this work, we have scrutinized assumptions of the 
laforin knockout (LKO) model. We have confirmed and expanded on time dependent 
physiological aspects and challenged assumptions about the relationship of PGB 
accumulation to inflammation, a widely used marker of LD recovery (Chapter 2). Now 
that we have clarified benchmarks of pre-clinical therapeutic testing for LD, these 
references may act as guides for future studies. Additionally, the finding that microglia 
(not astrocytes) are activated throughout the lifespan of the LKO mouse indicate that 
they are possible therapeutic targets for neuroinflammation and should be examined 
further. The absence of astrocyte activation during the most acute time frame of LD PGB 
accumulation is curious, and future studies should explore whether astrocytic PGB 
accumulation is driving deleterious metabolic defects that influence their expected 
neuroinflammatory behavior. Furthermore, the coordination of activity between 
astrocytes and microglia may be disrupted and investigation of this matter in the LKO 
mouse model may reveal clues about the pathological cascade effect that is initiated by 
LD PGBs.  
In the LKO mouse we utilized cutting edge metabolomics techniques to begin to 
understand the consequences of aberrant glycogen metabolism to cellular respiration 
(Chapter 3). This study opened an avenue for discovering metabolic therapeutic targets 
in LD and proposed a direct link between PGB accumulation and downstream metabolic 
defects in LD and normal aging. Although our insights into citric acid cycle metabolite 




accumulation, their biological impact should be thoroughly investigated (Chapter 3). 
This area of investigation will also lead to filling in the ripple effect events that link PGBs 
to downstream brain dysmetabolism.  Moreover, our methods for characterizing LD 
pathophysiology should be used as a model for similar investigations of other 
neurodegenerative diseases that are also affected by aberrant glycogen/PGB 
accumulation. Of the 17 GSDs, only a handful have been discovered to have 
glycogen/PGB accumulation that is neurotoxic. Most GSDs are clinically classified as 
myopathies or cardiopathies. However, in several GSDs, secondary CNS symptomology 
has been documented but understudied, for example, patients with GSD0 are often 
afflicted by seizures. Furthermore, the contribution of peripheral and/or motor neuron 
glycogen/PGB accumulation to GSDs should be re-examined as its contribution to 
defects in muscular and cardiac failure may be significant.  
One major gap in our understanding of biochemical aspects of LD is the mechanism 
of laforin’s phosphatase activity on glycogen, and moreover, the biological relevance of 
glycogen phosphate. To tackle these important questions about glycogen metabolism, 
we have made significant advancements in generating tools. The generation of six anti-
laforin nanobodies and their defined epitopes opens the doors for discovering the role 
of laforin interactions and mechanisms (Chapter 4). 
Although LD is a very rare disease, this body of work has shown that studying LD 
offers a unique window into understanding issues that are universal among mammals 
including glycogen metabolism, neurodegenerative disease, and aging. Our last study 
again aimed to use the in-depth genetic and biochemical understanding of LD to 
generate a translatable drug screening system for all other genetic diseases (Chapter 5). 
Though more work is required to realize the potential of these assays, these 
explorations have set up the tools and framework for pre-clinical testing of laforin 
rescue. The laforin nanobody enzyme linked immunosorbent assay (ELISA) can be 
immediately useful for current efforts to development an AAV therapy for LD. 
Although this work and the hypotheses generated herein are directly applicable to 
LD, future findings may impact other neurodegenerative diseases and epilepsies. LD 
shares key cellular processes with many diseases and developments in our 
understanding of their translation to treatments will provide similar valuable insight for 
others. Additionally, these findings may assist in resolving some of the questions and 
controversies surrounding the significance of glycogen to brain energy metabolism. 
 
6.1.2 Final conclusions 
 
This work has contributed to the advancements of biomarkers, tools, and 
therapeutics for LD. These studies have also laid a model for the investigation of 
aberrant glycogen and aberrant glycogen metabolism in other neurodegenerative 
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